Abstract Funding Sources*

AGA Oral and Poster Presentations at DDW® 2020

* Information contained in this report is current as of April 22, 2020.
1. IMPROVING LYNCH SYNDROME IDENTIFICATION THROUGH THE... (4*)

2. PLACENTAL-DERIVED STEM CELLS AMELIORATE INTESTINAL DAMAGE... (2*)[4]

3. INTESTINAL EPITHELIAL RECEPTOR LRRC19 DEPLETION PROTECTS... (2*)

4. CROHN'S DISEASE PATHOBIONT ENTEROBACTERIACEAE GROWTH... [6*]

5. USE OF A TARGETED BACTERIOPHAGE COCKTAIL... (3*)[BionX Inc.]

6. PATHOETIOLOGY OF LEVATOR ANI SYNDROME: EVALUATION... (5*)

7. IMPROVING THE UTILITY OF HIGH RESOLUTION... (2*)

8. REDUCTIONS IN ALL-CAUSE MORTALITY ASSOCIATED WITH... [3*][This work was supported by Salix Pharmaceuticals, a division of Bausch Health US, LLC, Bridgewater, NJ, USA, which has licensed the rights to develop and commercialize Relistor® from Progenics Pharmaceuticals, Inc, New York, NY, USA.]

9. NEW INSIGHTS INTO THE ROLE OF... (2*)

10. A RANDOMIZED PILOT STUDY TO COMPARE... (7*)[4]

11. *FLIP* FROM INCONTINENCE TO CONTINENCE WITH... (2*)

12. NORMALIZATION OF NUMBER OF REFLUX... (5*)[The original study was conducted by Torax, Inc, from which this post hoc analysis was extracted]

13. CLINICAL UTILITY OF NARROW BAND IMAGING... (5*)

14. CLINICAL-PHYSIOLOGIC PHENTYPES OF LARYNGOPHARYNGEAL REFLUX: EXPLORATORY... (7*)

15. IMPAIRED PROXIMAL ESOPHAGEAL CONTRACTILITY IS INDEPENDENTLY... (5*)

16. TALIN-1 IS A NOVEL REGULATOR OF... (2*)

17. IRON DEFICIENCY PROMOTES HELICOBACTER PYLORI-INDUCED CARCINOGENESIS... (2*)

18. OVEREXPRESSION OF CD44V9/SIALYL-LEWIS X METAPLASIA DURING... (2*)

19. BUTYRATE PRODUCING GASTRIC NON-HELCOBACTER COMMENSAL BACTERIA... (4*)[2]

20. CIRCULAR RNA PABPN1 INHIBITS AUTOPHAGY IN... (2*)

21. NOXIOUS LUMINAL STIMULI TREATED ESOPHAGEAL MYOFIBROBLASTS... (2*)[4]

22. QUALITY OF CARE INITIATIVE IMPROVES OUTCOMES... (6*)

23. PSYCHIATRIC COMORBIDITY IN IBD INCREASES HEALTH... (2*)

24. ASSOCIATION OF ADDED DIETARY SUGAR AND... (2*)

25. SOCIAL DETERMINANTS OF OUTCOMES IN IBD... (6*)

26. IDENTIFICATION OF RISK FACTORS ASSOCIATED WITH... (5*)

27. TROP2 IS UPREGULATED IN THE TRANSITION... (2*)[4]

28. HELICOBACTER PYLORI-MEDIATED ACTIVATION OF NF-κB STAT3 NETWORK... (2*)[4]

29. IN VIVO ADMINISTRATION OF ANTISENSE MIR130B... (2*)

30. DOWNREGULATION OF IL-33 PREVENTS THE... (2*)[Korean NTIS]

31. SER-287, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC, INHIBITS COLONIC INFLAMMATION... (3*)[Seres Therapeutics]

32. THE SULFUR MICROBIAL DIET AND RISK... (2*)[6]

33. DISRUPTION OR DISCONNECTION OF THE PANCREATIC... (5*)

34. ALTERED DISTRIBUTION OF THE INTESTINAL NA-BILE... (2*)

35. ENTERAL NUTRITION AND RISK... (5*)

36. THE SULFUR MICROBIAL DIET AND RISK... (2*)[6]

37. DIETARY INTERVENTION INHIBITS COLONIC INFLAMMATION... (6*)

38. VE303, A RATIONALLY DESIGNED BACTERIAL CONSORTIUM... (3*)[2][CARB-X]

39. EFFECT OF MICROBIAL Ecosystem THERAPEUTICS (MET-2)... (3*)[NuBiota]

40. THE SUSTAINED INCREASE IN TGFB PRODUCTION... (2*)

41. PREDICTING GASTROINTESTINAL (GI) HEMORRHAGE USING A... (5*)

42. BUILDING AN AI SYSTEM ON HIGH-RESOLUTION... (2*)

43. PROSPECTIVE COMPARISON STUDY OF EUS-FNA ONSITE... (4*)

44. TOWARDS COMPUTER-AIDED DIAGNOSIS (CAD) FOR COLONOSCOPY... (2*)

45. PREVALENCE AND PREDICTORS OF ADVANCED NEOPLASIA... (6*)

46. OPPORTUNISTIC INFECTIONS ARE MORE PREVALENT IN... (5*)

47. DISRUPTION OR DISCONNECTION OF THE PANCREATIC... (5*)

48. ALTERED DISTRIBUTION OF THE INTESTINAL NA-BILE... (2*)

49. ENTERAL NUTRITION AND RISK... (5*)

50. THE SULFUR MICROBIAL DIET AND RISK... (2*)[6]

51. DIETARY INTERVENTION INHIBITS COLONIC INFLAMMATION... (6*)

52. ESTIMATING THE ENVIRONMENTAL IMPACT OF DISPOSABLE... (5*)

53. PATIENT AND PHYSICIAN PERSPECTIVES ON THE... (3*)[Celgene Corporation]

Abstract Funding Source Key
* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
124. CANADIAN ASSOCIATION OF GASTROENTEROLOGY CLINICAL PRACTICE... (7*)
125. SUNSHINE ACT: SHEDDING LIGHT ON DISCLOSURES... (5*)
126. IMPACT OF AN ONLINE NIH PROMIS-BASED... (7*)
127. THE VOLUME-OUTCOME EFFECT CALLS FOR CENTRALIZATION... (4*)
128. MAJOR GASTROINTESTINAL BLEEDING RISK WITH DIRECT... (5*)
129. MORTALITY AFTER CHOLECYSTECTOMY IN A NATIONWIDE... (2*)
130. A MURINE MODEL OF OBSTRUCTIVE SLEEP... (2*)[(7]
131. NORMAL WEIGHT TYPE 2 DIABETES IS... (6*)
132. GUT DYSBIOSIS INDUCED BY CIRCADIAN RHYTHM... (2*)
133. INFLUENCE OF EARLY LIFE FACTORS ON... (6*)[(The International Organization for the Study of Inflammatory Bowel Disease (IOIBD), The Crohn's and Colitis Foundation, and the Kenneth Rainin Foundation.)
134. ALTERATIONS OF INTESTINAL MICROBIOTA BY HIGH-FAT... (2*)
135. THE GEM PROJECT: DIETARY PATTERNS ARE... (6*)[(2]
136. NORMAL FUNCTIONAL LUMINAL IMAGING PROBE PANOMETRY... (2*)
137. IMPAIRED ESOPHAGOgastric JUNCTION OPENING ON REAL-TIME... (5*)
138. ACHALASIA SUBTYPES CAN BE IDENTIFIED WITH... (2*)
139. PREVALENCE OF MAJOR AND MINOR MOTOR... (5*)
140. MULTIPLE RAPID SWALLOWS AND RAPID DRINK... (2*)
141. CLASSIFICATION OF ESOPHAGEAL SWALLOWS BY A... (5*)
142. A NOVEL ROLE FOR DOUBLE-STRANDED RNA... (2*)[(7]
143. COLITIS-INDUCED GLYCOLYSIS DRIVES YAP-DEPENDENT REPROGRAMMING OF... (2*)
144. NRF2 REGulates A NOVEL PROLIFERATIVE CHECKPOINT... (2*)
145. CONSTITUTIVE BINDING OF βPAK-INTERACTING EXCHANGE FACTOR... (2*)
146. TRANSCRIPTION OF MITCHondRIA-TRANSCRIBED GENES DIFFERENTIATES NORMAL... (2*)[(4)
147. PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY UNDERGOING... (5*)
148. ARTIFICIAL INTELLIGENCE AUTOMATES EVALUATION OF BASELINE... (5*)
149. NATIONAL TRENDS IN MEDICARE PRESCRIPTIONS OF... (5*)
150. ANTI-REFLUX SURGERY REDUCES MORTALITY IN LUNG... (5*)
151. IS CHRONIC USE OF RANITIDINE... (5*)
152. EXPOSURE OF BARRETT’S AND ESOPHAGEAL ADENOCARCINOMA... (2*)
153. ROLE OF TRANSIENT RECEPTOR POTENTIAL VANILLOID... (2*)
154. PRODUCTS OF MATURE ADIPOCYTES IN VISCERAL... (4*)
155. THE MICROBIOME OF BARRETT’S ESOPHAGUS WITH... (2*)[(4)
156. THE MICROBIOME OF BARRETT’S ESOPHAGUS... (2*)[(4)
157. THE ACTIVATION OF MACrophages PLAYS A... (4*)
158. LOW DIETARY FIBER-INDUCED MUCOSAL EROSION... (2*)
159. METABOLOMICS ANALYSIS IDENTIFIED NOVEL ORALLY ACTIVE... (2*)
160. CHROMOSOME TOPOLOGY ANALYSIS REVEALS REMOTE SUPER-ENHANCERS... (2*)[(4)
161. A NOVEL SYSTEM FOR COMPARTMENTALIZED ANALYSIS... (4*)[(6]
162. FERMENTABLE VS NON-FERMENTABLE DIETARY FIBERS DIFFERENTIALLY... (6*)[(2)
163. THE EFFICACY AND SAFETY OF A... (5*)
164. INCIDENCE, RISK FACTORS AND OUTCOMES ASSOCIATED... (5*)
165. ASSOCIATION OF FASTING GASTRIC VOLUMES WITH... (5*)
166. NEW ONSET DIABETES: A POTENTIAL BIOMARKER... (5*)
167. QUANTIFICATION OF PANCREATIC FAT ON ABDOMINAL... (5*)
168. SERA ANTI-HUD ANTIBODIES FROM IRRETTABLE BOWEL... (1*)
169. ACTIVE VARICELLA ZOSTER IDENTIFIED BY NOVEL... (4*)
170. PREPERIPHERAL CGRP AS A CONVERGENT... (2*)[(3][(Teva Biologics)
171. LOSS OF CX3CR1+ - GASTRIC MUSCULARIS... (2*)[(7]
172. A NIGRO-VAGAL PATHWAY CONTROLS COLONIC MOTILITY... (2*)
173. EPigenetic upregulation of ACID-SENSING ION CHANNEL... (2*)
174. FOOD-INDUCED IMMEDIATE RESPONSE IN THE ESOPHAGUS... (5*)
175. BUDESONIDE ORAL SUSPENSION (BOS) IMPROVES ENDOSCOPIC... (3*)[(This study was funded by Shire ViroPharma, Inc., a member of the Takeda group of companies. Medical writing support was provided by Joanna L Donnelly of Pharmagenesis London, London, UK, funded by Shire Human Genetic Therapies Inc., a member of the Takeda)
176. INTERIM RESULTS OF AN OPEN-LABEL EXTENSION... (3*)[(2][(Allakos, Inc.)
177. RESULTS FROM THE ELEMENT STUDY: PROSPECTIVE... (2*)[(Nutritia)
178. PRIMARY AND PLURIPOTENT STEM CELL DERIVED... (2*)
179. MATERNAL SUCRALOSE INTAKE ALTERS GUT MICROBIOTA... (2*)[(4)
180. ALTERED BILE ACID HOMEOSTASIS AND PATHOLOGIC... (7*)[(2)
181. T CELL P38α PROMOTES NUTRITIONAL STEATOHEPATITIS... (2*)

Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
234. . . . PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) HAVE... (5*)
235. . . . LARGE EFFECTS OF SGLT2 INHIBITORS/GLP1 RECEPTOR... (5*)
236. . . . INFILXIMAB, ADALIMUMAB AND VEDOLIZUMAB LEVELS ARE... [6*][4]
237. . . . BASELINE DRUG CLEARANCE OF INFILXIMAB PREDICTS... (5*)
238. . . . VEDOLIZUMAB CONCENTRATIONS IN COLONIC MUCOSAL TISSUE... (5*)
239. . . . THE EARLY APPEARANCE OF ANTI-DRUG ANTIBODIES... (4*)
240. . . . REAL-WORLD APPLICATION OF AN ADAPTIVE DOSING... [4*][Prometheus Ran the drug levels]
241. . . . COMBINATION OF SERUM ENDOSCOPIC HEALING INDEX... [3*][7*][Prometheus Biosciences, San Diego, CA]
242. . . . COMPUTER- AIDED DETECTION OF ADVANCED NEOPLASIA IN... (7*][4]
243. . . . IMPAIRMENT OF THE EMBRYONIC MACROPHAGE COMPARTMENT... (2*)
244. . . . POLY (ADP-RIBOSE) POLYMERASE 1 (PARP1) PROMOTES... (2*)
245. . . . A NOVEL TNFSF13 VARIANT IN POLY (ADP-RIBOSE) POLYMERASE 1 (PARP1) PROMOTES... (4*)
246. . . . THE INCIDENCE OF PNEUMONIA AND IMPACT... (3*)[4](This study was supported by an unrestricted research grant from Pfizer Pharmaceuticals. Pfizer had no role in the study concept and design, acquisition of data and interpretation of results.)
247. . . . EFFECTIVENESS OF RECOMBINANT ZOSTER VACCINE (SHINGRIX)... (5*)
248. . . . EARLY LAPAROSCOPIC ILEOCECAL RESECTION DECREASES NEED... (5*)
249. . . . NON-INVASIVE BREATH TEST SCREENING FOR BARRETT’S... (2*)
250. . . . GLYCEMIC STATUS IN PATIENTS WITH CHRONIC... (7*)
251. . . . CYTOF ANALYSIS OF HUMAN COLON AND... (6*)
252. . . . SINGLE CELL DISSECTION OF THE TRANSCRIPTIOANL... (4*)[6]
253. . . . MAJOR GASTROINTESTINAL BLEEDING IN OLDER PERSONS... [2*][4](Bayer AG supplied the aspirin tablets and matching placebos but had no other role in trial conduct or reporting.)
254. . . . FEWER GASTROINTESTINAL BLEEDS WITH TICAGRELOR WHEN... (2*)
255. . . . WARFARIN IS ASSOCIATED WITH HIGHER RATES... (4*)
256. . . . PREDICTING TREND OF UPPER AND LOWER... (5*)
257. . . . ANTITHROMBOTIC CESSATION FOLLOWING HOSPITALIZATION FOR DIVERTICULAR... (5*)
258. . . . THE IMPACT OF NIGHT-TIME EMERGENCY DEPARTMENT... (5*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Abstract

Funding Source Key

* = Primary Source

(1) Clinical Practice Funds (2) Government (e.g. NIH, CDC, Health Ministry, etc.) (3) Industry or Commercial Entity (4) Institutional Funds
(5) No Study Funding (6) Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) Professional Organization (e.g. AGA, AASLD, etc.)
563. . . . INTESTINE-SPECIFIC DELETION OF RNA-BINDING MOTIF PROTEIN... (2*)
564. . . . AN INFLAMMATORY DIET AND RISK OF... (2*)
565. . . . TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF... (6*)[(3)](Taekda Pharmaceuticals)
566. . . . LARGE META GENOME WIDE ASSOCIATION STUDY... (4*)[(2)](Helmskey Charitable Trust)
567. . . . TL1A OVEREXPRESSION IN CD PATIENTS AND... (2*)
568. . . . FAMILIAL SMALL INTESTINAL (MIDGUT) NEUROENDOCRINE TUMOR... (2*)
569. . . . INVESTIGATION OF THE INTEGRIN SIGNALLING PATHWAY... (4*)
570. . . . PREVALENCE OF LYMPH NODE/ DISTANT METASTASIS... (5*)
571. . . . NOVEL DIGITAL SPATIAL PROFILING OF GASTROENTEROPANCREATIC... (2*)
572. . . . ASSOCIATION BETWEEN SOMATOSTATIN ANALOGUE TREATMENT AND... (5*)
573. . . . EGF-INDUCED NUCLEAR EXPORT OF MENIN STIMULATES... (2*)
574. . . . RECENT TRENDS IN COLORECTAL CANCER SCREENING... (3*)[(Exact Sciences)
575. . . . A HIGHLY SENSITIVE AND QUANTITATIVE MULTIMODAL... (3*)[(CellMax Life)
576. . . . EARLY COLORECTAL CANCER SCREENING IN AFRICAN... (5*)
577. . . . EFFECT OF ORGANIZED MAILED FECAL IMMUNOCHEMICAL... (2*)[(4)
578. . . . DELAY TO DIAGNOSTIC COLONOSCOPY AFTER ABNORMAL... (2*)
579. . . . PREVALENCE AND CHARACTERISTICS OF POST-COLONOSCOPY COLORECTAL... (2*)
580. . . . RACE, ETHNICITY, AND SOCIOECONOMIC STATUS PREDICT... (5*)
581. . . . DECREASED EXPRESSION AND FUNCTION OF INTESTINAL... (2*)
582. . . . TEDUGLUTIDE INHIBITS SODIUM CAPRATE-INDUCED CLATHRIN-MEDIATED LPS... (2*)[(3)](Shire/Takeda Pharmaceuticals)
583. . . . NPC1L1-DEPENDENT TRANSPORT OF 27-ALKYNE CHOLESTEROL TO... (2*)
584. . . . DYNAMIC INTERACTIONS AMONG CFTR, NHERF4 (NF4)... (2*)
585. . . . UNIQUE REGULATION OF CHLORIDE BICARBONATE EXCHANGERS... (2*)
586. . . . ER LUMINAL ERADE AS A NOVEL... (4*)[(2)
587. . . . INFLAMMATION CAN BE RE-INDUCED IN ORGANOID... (2*)
588. . . . GIL3 HUMAN NOROVIRUS REQUIRES BILE ACIDE... (2*)
589. . . . PEDIATRIC CROHN'S DISEASE PATIENT DERIVED ORGANOID... (4*)
590. . . . AN ORGANOID-IMMUNE CELL CO-CULTURE PREDICTIVE MODEL... (2*)[(4)
591. . . . HUMAN BIOPSY-DERIVED COLONOIDS ARE USEFUL TO... (3*)[(Merck IISP 53472)
592. . . . HUMAN INTESTINAL STEM CELL (ISC)- DERIVED ENTEROIDS/colonoids... (2*)
593. . . . CONFOCAL LASER ENDOMICROSCOPY FOR DETECTION OF... (2*)
594. . . . CLINICAL SIGNIFICANCE OF SURVEILLANCE-DETECTED DUCTAL ABNORMALITIES... (2*)[(6]
595. . . . SYNCHRONOUS OCCURRENCE OF PRENEOPLASTIC LESIONS IN... (5*)
596. . . . SURVEILLANCE BIOPSIES SHOULD BE DONE ON... (5*)
597. . . . OUTCOMES OF ENDOSCOPIC SURVEILLANCE AND FAMILY... (5*)
598. . . . POST-COLONOSCOPY COLORECTAL CANCER IN LYNCH SYNDROME... (5*)
611. . . . EFFICACY OF ENDOSCOPIC REVISION WITH COMBINATION... (5*)
613. . . . ANTIBODIES TO INFlixIMAB ACCELERATE DRUG CLEARANCE... (2*)[(6]
614. . . . RECTAL TISSUE DNA METHYLATION IN ULCERATIVE... (2*)
615. . . . PHARMACOKINETICS OF USTEKINUMAB IN CHILDREN AND... (3*)[(This study was funded by Janssen Research and Development, LLC.)
616. . . . RESULTS OF THE FIRST PAEDIATRIC RANDOMIZED-CONTROLLED... (4*)[(3)](Rebiotix Inc. supplied the fecal transplant product for this study.)
617. . . . TAXA4META: GENERATING PRECISE 16S TAXONOMIC PROFILES... (2*)
618. . . . THE SMALL INTESTINAL MICROBIOME VARIES WITH... (6*)
619. . . . A LOSS OF FUNCTION SNP IN... (2*)
620. . . . A MOLECULAR NETWORK SURVEY PREDICTS NICKEL... (4*)[(3)][(Janssen R & D)
621. . . . THE PREVALENCE OF PSYCHIATRIC COMORBIDITY IS... (5*)
622. . . . CURBING CHRONIC PANCREATITIS READMISSIONS: UTILIZING THE... (5*)
623. . . . EXCLUSION OF ATYPICAL FOOD ALLERGENS DETECTED... (4*)[(Rashid Hussain trust Kuala Lumpur, Malaysia)
624. . . . EXCLUSION OF ATYPICAL FOOD ALLERGENS DETECTED... (4*)[(Rashid Hussain trust Kuala Lumpur, Malaysia)
625. . . . THE IMPACT OF SCREENING LOWER ENDOSCOPY... (2*)[(4)
626. . . . THE FIRST PROSPECTIVE, MULTICENTER, RANDOMIZED CONTROLLED... (3*)[(Mitsubishi-Tanabe Pharma)
627. . . . THE FIRST PROSPECTIVE, MULTICENTER, RANDOMIZED CONTROLLED... (3*)[(Mitsubishi-Tanabe Pharma)
628. . . . THE FIRST PROSPECTIVE, MULTICENTER, RANDOMIZED CONTROLLED... (3*)[(Mitsubishi-Tanabe Pharma)
629. . . . THE IMPACT OF SCREENING LOWER ENDOSCOPY... (2*)[(4)
630. . . . TAK-101 (TIMP-GLIA) PREVENTS GLUTEN CHALLENGE INDUCED... (3*)[(The study was sponsored by COOR Pharmaceuticals Development Co., Inc.)
631. . . . THE IMPACT OF SCREENING LOWER ENDOSCOPY... (2*)[(4)
632. . . . CURBING CHRONIC PANCREATITIS READMISSIONS: UTILIZING THE... (5*)
633. . . . THE FIRST PROSPECTIVE, MULTICENTER, RANDOMIZED CONTROLLED... (3*)[(Mitsubishi-Tanabe Pharma)
634. . . . RESULTS FROM THE BARRETT'S OESOPHAGUS TRIAL... (6*)[(2)
635. . . . DIRECT ACTING ANTI-VIRAL PROPHYLAXIS TO PREVENT... (4*)[(Gilead provided DAA for some patients.)
636. . . . UNRAVELLING THE MOLECULAR MECHANISM RESPONSIBLE FOR... (2*)[(6]
637. . . . TUMOR NECROSIS FACTOR RECEPTOR 2 REGULATES... (2*)[(4)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds    (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)    (3) = Industry or Commercial Entity    (4) = Institutional Funds
(5) = No Study Funding    (6) = Philanthropic Organization (e.g. ALF, CFFA, etc.)    (7) = Professional Organization (e.g. AGA, AASLD, etc.)
638. COLONIC SPROUTY2 EXPRESSION IS DYSREGULATED IN... (2*)|(6) (NIH 1R01DK19694 (Frey); Crohn’s and Colitis Foundation CDA (Schumacher)

639. NEUROTENSIN (NT) SIGNALING-ASSOCIATED LONG NON-CODING RNA... (6*)

640. CIRCULAR RNA HIPK3 PROMOTES INTESTINAL EPITHELIAL... (2*)

641. DISRUPTION OF INTESTINAL EPITHELIUM DUE TO... (2*)

642. HIGH-THROUGHPUT SCREENING IDENTIFIED LORATADINE AND GENISTEIN... (2*)|(3)|(MERCK)

643. HOST-DIRECTED DRUG CANDIDATES TO COMBAT CLOSTRIDIODES... (2*)|(4)

644. IDENTIFICATION OF NOVEL CHANGES IN MICROBIALLY-DERIVED... (2*)|(4)

645. CLOSTRIDIODES DIFFICILE WHOLE GENOME SEQUENCING DIFFERENTIATES... (5*)

646. COLONIC MUCOSAL COLONIZATION OF CLOSTRIDIODES DIFFICILE... (4*)

647. FECAL MICRORNA ARE ASSOCIATED WITH TGF-BETA... (2*)

648. BRAIN-DERIVED NEUROTROPHIC FACTOR PLAYS A CRITICAL... (2*)

649. DE NOVO ENTERIC NEUROGENESIS IN POST-EMBRYONIC... (2*)|(4)

650. ENTERIC GLIAL ACTIVATION IS A PATHWAY-SPECIFIC... (2*)|(4)

651. ENTERIC GLIAL MHC II EXPRESSION MODULATES... (2*)

652. MIR-10B-5P RESCUES AND PREVENTS DIABETIC GASTROPARESIS... (2*)

653. EFFECTS OF SCFA ON HISTONE ACETYLATION... (2*)

654. DIETARY MONOSODIUM GLUTAMATE EXACERBATES VISCERAL HYPERSENSITIVITY... (2*)

655. EPIGENETIC MECHANISMS IN THE AMYGDALA UNDERLYING... (2*)

656. PGE2 PRODUCED BY MAST CELLS IS... (2*)

657. GUT DYSBIOSIS PROMOTES COLONIC M1 MACROPHAGE... (2*)

658. ENDOPLASMIC RETICULUM STRESS DRIVES INTESTINAL HYPERPERMEABILITY... (5*)

659. INCIDENCE OF VENOUS THROMBOEMBOLIC EVENTS IN... (3*)|(4)

660. VIRTUAL REALITY MINDFULNESS THERAPY VS. VIRTUAL... (5*)

661. TRANSLUMBOSACRAL NEUROMODULATION THERAPY (TNT): A NOVEL... (5*)

662. CHANGES IN AGED ENS INDUCES A... (2*)

663. CELL THERAPY USING ADULT NEURAL-PROGENITOR CELLS... (4*)

664. MACHINE LEARNING MODELS IN THE PREDICTION... (4*)

665. IS HELICOBACTER PYLORI CURE A LONG-LIFE... (2*)

666. COMPREHENSIVE PROFILING OF THE ANTIBIOTIC RESISTANCE... (4*)

667. IMMUNOGLOBULIN A COATING VIA GASTRIC... (5*)

668. TAILORED ANTIBIOTIC SUSCEPTIBILITY-GUIDED THERAPY VIA GASTRIC... (5*)

669. TREATMENT OF H PYLORI IS NOT... (2*)

670. NEUROMODULATION THERAPY (TNT): A NOVEL... (2*)

671. PAIRED IMMUNOGLOBULIN-LIKE RECEPTOR B REGULATES INFLAMMATION... (2*)

672. BLOCKADE OF ALPHA E BETA 7... (2*)|(6)

673. METABOLIC MODULATION OF CD4+ T CELLS... (4*)|(2)

674. NON-InVAsIVE eleCTRICAL sPLENIC nerve stIMUlation Ameliorates... (3*)|(Galvani Bioelectronics)

675. CONSISTENT ALTERATIONS OF SPECIFIC GUT MICROBIAL... (2*)

676. SACCHAROMYCES BOULARDII CNCM 1-745 IMPROVES GUT-BRAIN... (3*)|(Bionorm – Gentilly – France)

677. INCREASED RISK OF DEPRESSIVE DISORDER AFTR... (2*)

678. NOVEL ASSOCIATIONS OF BRAIN MORPHOMETRY WITH... (2*)

679. EFFECT OF EXCLUSION DIETS ON SYMPTOM... (5*)

680. HIGH STRESS REACTIVITY IS ASSOCIATED WITH... (2*)|(4)

681. MUTANT EPICAM MODEL OF CONGENITAL TUFTING... (2*)

682. MICROPHYSIOLOGICAL ENGINEERING OF INTESTINAL MORPHOGENESIS BY... (2*)|(4)

683. DIFFERENCES IN THE RISK OF PERSISTENT... (5*)

684. A FIVE BIOMARKER PANEL OUTPERFORMS EXISTING... (2*)

685. THE INTERPLAY BETWEEN GUT MICROBIOTA AND... (2*)

686. NOTCH INHIBITION PROMOTES PANCREATIC KRT5+ CELLS... (4*)

687. VARIABLE CELL-SPECIFIC SPINK1 EXPRESSION IN THE... (5*)

688. AN INDIVIDUAL-HOUSING BASED SOCIOECONOMIC STATUS MEASURE... (5*)

689. ASSOCIATION BETWEEN NEIGHBORHOOD INCOME AND PERSISTENT... (5*)

690. WHO’S OUT? RESULTS OF A SCREENING... (4*)

691. CHILDHOOD GROWTH IN SCREEN-DETECTED CELIAC DISEASE... (2*)

692. IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED CELIAC DISEASE ... (2*)|(7)

693. A NOVEL ORDINAL SEVERITY SCALE ALLOWS... (3*)|(This study was funded by Takeda Pharmaceutical Company Ltd. Medical writing support was provided by Steve Banner of Oxford PharmaGenesis, Oxford, UK and was funded by Takeda Pharmaceutical Company Ltd.)

694. NON-INVASIVE ELECTRICAL BRAIN MORPHOMETRY WITH... (2*)|(4)

695. SACCHAROMYCES BOULARDII CNCM 1-745 IMPROVES GUT-BRAIN... (3*)|(Bionorm – Gentilly – France)

696. INCREASED RISK OF DEPRESSIVE DISORDER AFTR... (2*)

697. NOVEL ASSOCIATIONS OF BRAIN MORPHOMETRY WITH... (2*)

698. EFFECT OF EXCLUSION DIETS ON SYMPTOM... (5*)

699. HIGH STRESS REACTIVITY IS ASSOCIATED WITH... (2*)|(4)

700. MUTANT EPICAM MODEL OF CONGENITAL TUFTING... (2*)

701. MICROPHYSIOLOGICAL ENGINEERING OF INTESTINAL MORPHOGENESIS BY... (2*)|(4)

702. DIFFERENCES IN THE RISK OF PERSISTENT... (5*)

703. THE INTERPLAY BETWEEN GUT MICROBIOTA AND... (2*)

704. NOTCH INHIBITION PROMOTES PANCREATIC KRT5+ CELLS... (4*)

705. VARIABLE CELL-SPECIFIC SPINK1 EXPRESSION IN THE... (5*)

706. AN INDIVIDUAL-HOUSING BASED SOCIOECONOMIC STATUS MEASURE... (5*)

707. ASSOCIATION BETWEEN NEIGHBORHOOD INCOME AND PERSISTENT... (5*)

708. WHO’S OUT? RESULTS OF A SCREENING... (4*)

709. CHILDHOOD GROWTH IN SCREEN-DETECTED CELIAC DISEASE... (2*)

710. IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED CELIAC DISEASE ... (2*)|(7)

711. A NOVEL ORDINAL SEVERITY SCALE ALLOWS... (3*)|(This study was funded by Takeda Pharmaceutical Company Ltd. Medical writing support was provided by Steve Banner of Oxford PharmaGenesis, Oxford, UK and was funded by Takeda Pharmaceutical Company Ltd.)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
761. . . . MEGA-ANALYSIS REVEALS NOVEL GENETIC ASSOCIATIONS WITH... (2*)[6]

762. . . . INCREASED RISK OF SMALL BOWEL CANCER... (4*)

763. . . . PREVALENCE AND EFFECT OF GENETIC RISK... (4*)[2](Helmley Charitable Trust)

764. . . . MACHINE LEARNING IDENTIFIES NOVEL BLOOD PROTEOMIC... (2*)[6]

765. . . . RISK OF AVOIDANT/RESTRICTIVE FOOD INTAKE DISORDER... (5*)

766. . . . SCATTERED INTESTINAL EPITHELIAL APOPTOSIS INDUCES MOUSE... (2*)

767. . . . ACTIVATION OF FXR SUPPRESSES TNFA AND... (3*)[Metacinere]

768. . . . THE ORIGIN AND FUNCTION OF CANCER-ASSOCIATED... (2*)

769. . . . DIETARY PROTEIN DEFICIENCY RECIPITATES KEY HISTOLOGIC... (4*)

770. . . . GENERATION OF A GASTRIC ADENOCARCINOMA AND... (2*)

771. . . . LYSOPHOSPHATIDIC ACID TREATMENT IMPROVES BRUSH BORDER... (2*)

814. . . . PLACEBO WITHOUT DECEPTION IS EFFECTIVE IN... [2*][6]

815. . . . IMPACT OF PARENTAL ILLNESS AND INJURY... (2*)

816. . . . OESOPHAGEAL MUCOSAL INTEGRITY AND INNERVATION IN... (4*)

817. . . . THE HUMAN GUT VIROME IS GEOGRAPHY... (2*)[4]

818. . . . IMBALANCE OF THE INTESTINAL VIROME CAUSED... (2*)[4]

825. . . . ONCOGENIC POTENTIAL OF DYSPLASTIC STEM CELLS... (2*)[4]

826. . . . THE ROLE OF THE HIPPO PATHWAY... (2*)[7]

827. . . . STROMAL CELLS STIMULATE BMI1-DEPENDENT SMALL INTESTINAL... (2*)

828. . . . SLC26A9 PROTECTS GASTRIC EPITHELIAL CELLS AGAINST... (2*)

829. . . . CONFIRMATION OF CHIEF CELLS AS THE... (2*)[4]

830. . . . TYPE II INNATE LYMPHOID CELLS (ILC2S)... (2*)

831. . . . CB1 MEDIATES THE ENERGY EFFECTS OF... (4*)

832. . . . EFFECT OF MODERATE ALCOHOL CONSUMPTION ON... (2*)

833. . . . DIETS HIGH IN OMEGA AND... (2*)

834. . . . EFFECT OF MATERNAL OBEITY INDUCED BY... (4*)

835. . . . LACTATED RINGER'S SOLUTION VERSUS NORMAL SALINE... (5*)

836. . . . EFFECT OF SYMBIOTICS IN REDUCING THE... (4*)

837. . . . RADIOMIC FEATURES DISTINGUISH PANCREATIC CANCER FROM... (2*)

838. . . . DISORDERING OF ACINAR CELL CHOLESTEROL HOMEOSTASIS... (2*)

840. . . . TOWARDS THE BIOCHEMICAL DIAGNOSIS OF BILE... (2*)[3][Sigma-tau Rare Disease Ltd. provided chenodeoxycholic acid (Xenbilox®) without restrictions as an independent grant.]

841. . . . EFFECT OF AMOXICILLIN-CLAVULANATE VERSUS METRONIDAZOLE AND... (2*)

842. . . . VALIDATION OF PERIPHERAL EISINOPENIA AS A... (5*)

844. . . . MEDICATION USE AND MICROSCOPIC COLITIS: A... (5*)

845. . . . CAN WE RELIABLY REPLACE THE SEHACAT... (3*)

846. . . . ANTIBIOTIC USE AND THE DEVELOPMENT OF... (6*)[2]

847. . . . DIETARY GLUTEN INTAKE AND RISK OF... (2*)[4]

848. . . . ASSOCIATION BETWEEN STATIN USE AND RISK... (4*)[6]

849. . . . CHOLECYSTECTOMY CONTRIBUTES TO FUNCTIONAL ABDOMINAL SYMPTOMS... (2*)

850. . . . ASSOCIATION OF LYMPHOMA WITH AGE AT... (6*)

851. . . . SQUALENE EPOXIDASE (SQLE) PROMOTES CRC VIA... (2*)

852. . . . BIOPHILA WADSWORTHIA SUPPLEMENTATION REDUCES ADENOMA BURDEN... (4*)[2]

853. . . . CIGARETTE SMOKE PROMOTES COLORECTAL CANCER THROUGH... (2*)

854. . . . EPITHELIAL TLR4-SHAPED MICROBIOTA INCREASES SUSCEPTIBILITY TO... (2*)[6]

855. . . . INVASIVE E. COLI SUPPRESS EPITHELIAL AUTOphagy... (2*)

856. . . . SPATIAL MICROBIAL SIGNATURES IN COLORECTAL NEOplasia... (1*)[4]

857. . . . RATES AND TIMECOURSE OF EXCESS SERIOUS... (5*)

858. . . . HOT OR COLD? PERSISTENCE OF HOT... (5*)

859. . . . COMPUTER-AIDED-DETECTION EMBEDDED COLONOSCOPY VERSUS ROUTINE COLONOSCOPY... (5*)

860. . . . DIGITAL NAVIGATION IMPROVES NO-SHOW RATES AND... (4*)

861. . . . THE BOWEL CLEANSING NATIONAL INITIATIVE (BCLEAN).... (5*)[This study was supported by Pendopharm, division of Pharmacience Inc.]

862. . . . MULTICOMPONENT INTERVENTION IMPROVES UPTAKE OF SURVEILLANCE... (4*)

863. . . . THE IL-33 RECEPTOR ST2 IS HIGHLY... (4*)[2]

864. . . . BARRIER DYSFUNCTION IN EOSINOPHILIC ESOPHAGITIS IS... (6*)[2]

865. . . . EOSINOPHILIC ESOPHAGITIS MAY FOSTER ESOPHAGEAL BASAL... (2*)

866. . . . CD252 (OX40L)+ ANTIGEN PRESENTING CELLS ARE... (4*)

867. . . . EGID BIOPSIES HAVE PRESENTING CELLS ARE... (3*)[4]

868. . . . HEPATOCELLULAR CARCINOMA INCIDENCE DECLINES AFTER WIDESPREAD... (2*)

869. . . . TELEMEDICINE HCV TREATMENT IN DEPARTMENT OF... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds

(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
870. . . RANDOMIZED CONTROLLED TRIAL OF IN-REACH WITH... [2*][3*](This study was conducted with support from CPRIT PP180091 and FOCUS.)

871. . . IMMUNOMODULATION OF AUTOIMMUNE HEPATITIS WITH A... (5*)

872. . . AUTOIMMUNE HEPATITIS PATIENTS ARE LESS LIKELY... (5*)

873. . . INCREASED RISK OF POST-TRANSPLANT MORTALITY IN... (5*)

911. . . LINACLITIDE SAFETY AND EFFICACY IN CHILDREN... (3*)[(This study was funded by Allergan plc and Ironwood Pharmaceuticals, Inc. Writing assistance by Complete HealthVizion, funded by Allergan plc and Ironwood Pharmaceuticals, Inc.)

913. . . QUANTITATIVE ANALYSIS OF TUG SIGN: AN... (1*)

914. . . NOVEL SUBTYPING OF EOSINOPHILIC ESOPHAGITIS BASED... (5*)

926. . . AN ELECTRONIC HEALTH RECORD-BASED MACHINE LEARNING... (2*)

929. . . INTERLEUKIN13-MEDIATED DISRUPTION OF MITOCHONDRIAL BIOLOGY CONTRIBUTES... (2*)[(4)]

930. . . HELICOBACTER PYLORI PROMOTES THE DIFFERENTIATION... OF... (2*)

931. . . INCIDENCE OF NONCARDIA GASTRIC ADENOCARCINOMA AFTER... (1*)

932. . . HISTOLOGIC AND SYMPTOMATIC IMPROVEMENT ACROSS MULTIPLE... (3*)[(2)](Allakos, Inc.)

933. . . INTERLEUKIN-23 RECEPTOR SIGNALING MODULATES THE STABILITY... (2*)[(4)]

934. . . STROMAL TNF RECEPTOR 1 (TNFR1) PRESERVES... (2*)

935. . . PRE-TREATMENT MUCOSAL INFLAMMATORY AND WOUND HEALING... (6*)

936. . . CADHERIN-11 IS UPREGULATED IN INFLAMMATORY BOWEL... (3*)[(Pliant Therapeutics)]

937. . . A POSITIVE FEEDBACK LOOP BETWEEN CREEPING... (4*)

938. . . ADIPOSE DERIVED MESENCHYMAL STEM CELLS ACELLULAR...[4*][(5)][MSC2018003 New Strategy to Improve MSC Based GVHD Therapy, Biological Industries USA (Li, PRIN CIPAL INVESTIGATOR)]

939. . . TRADIPITANT TREATMENT CAUSED CLINICALLY MEANINGFUL AND... (3*)[(Vanda Pharmaceuticals, Inc)]

940. . . GLOBAL KNOCKOUT OF MIR-10B IN MICE... (2*)

941. . . EPIGENETIC ALTERATIONS IN THE PERIPHERAL CIRCULATION... (2*)

942. . . SYSTEMIC EPIGENETIC ALTERATIONS ARE ASSOCIATED WITH... (2*)

943. . . ASSESSMENT OF SMALL BOWEL MOTEILITY IN... (4*)

944. . . MOLECULAR MECHANISM OF CINNAMALDEHYDE AND CURCUMIN... (2*)

945. . . HIGHER VERSUS STANDARD ADAIMMUB MAINTENANCE REGIMENS... (3*)[(AbbVie Inc.)

946. . . DEEP REMISSION AT 1 YEAR IS... (5*)

947. . . TOP-DOWN INFLIXIMAB SUPERIOR TO STEP-UP IN... (1*)[(3)](Pfizer)

948. . . A NOVEL SUBCUTANEOUS INFLIXIMAB (CT-P13) IN... (3*)[(Celltrion, Inc.)

949. . . EFFICACY AND SAFETY OF 2 VEDOLIZUMAB... (3*)[(Takeda)]

950. . . THE VISIBLE 2 PHASE 3 STUDY... (3*)[(Takeda)

951. . . DEXAMETHASONE PROPHYLAXIS OF POSTEMBOLIZATION SYNDROME AFTER... (5*)

952. . . INSUFFICIENT RADIOFREQUENCY ABLATION PROMOTES THE METASTASIS... (2*)

953. . . IN SITU VACCINE IMMUNOTHERAPY FOR GASTROINTESTINAL... (5*)

954. . . THE INFLUENCE OF IMMUNE HETEROGENEITY ON... (2*)

955. . . INHIBITION OF CYCLIN DEPENDENT KINASES OVERCOMES... (6*)

956. . . GENOMEWIDE TRANSCRIPTOMIC PROFILING IDENTIFIES A NOVEL... (5*)

957. . . VEGETARIAN DIET REDUCES HUMAN GUT MICROBIAL... (2*)

958. . . NEURAL NETWORK PREDICTS DROP IN HEMOGLOBIN... (2*)

959. . . ASSOCIATION OF METEOROLOGICAL PARAMETERS WITH INCIDENCES... (4*)

960. . . PHASE 3 STUDY EVALUATING THE EFFICACY... (3*)[(Funded by Takeda Development Center Asia Pte Ltd, Singapore.)

961. . . OUTCOMES IN PATIENTS ADMITTED WITH ACUTE... (5*)

962. . . SUPPRESSION OF LPS-INDUCED IL-6 PRODUCTION IN... (2*)[(6)]

963. . . LOCAL AND SYSTEMIC IMMUNE SIGNATURE DIFFERENCES... (2*)

964. . . FECAL MICROBIOTA TRANSPLANTATION AMELIORATES EXPERIMENTALLY INDUCED... (2*)

965. . . TWO TYPES OF HUMAN PANCREATIC ACINAR... (1*)[(2)]

966. . . DIETARY FIBER INTAKE, THE GUT MICROBIOME,... (2*)[(4)]

967. . . A RANDOMIZED CONTROLLED-FEEDING STUDY OF... (2*)

968. . . ALTERED DIURNAL FEEDING PATTERNS LINKED WITH... (6*)

969. . . MATERNAL EMULSIFIER EXPOSURE EXACERBATES THE SUSCEPTIBILITY... (2*)

970. . . IMPAIRED THERMOGENESIS IN BROWN ADIPOSE TISSUE... (2*)

971. . . EXPLORING THE CANCER GENOME ATLAS (TCGA)... (5*)

972. . . SINGLE CELL (SC) RNA SEQ OF... (2*)[(4)]

973. . . EXPLORING THE CANCER GENOME ATLAS (TCGA)... (5*)

974. . . INTEGRATIVE MOLECULAR MARKER ANALYSES OF EARLY-ONSET... (2*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
1016. . . . LOSS OF TGFB2 IN DIFFUSE TYPE... (5*)
1017. . . . GENOMIC LANDSCAPE AND IMMUNE CHARACTERISTICS OF... (2*)
1018. . . . IDENTIFICATION OF THE CANCER-SUPPRESSING CANCER-ASSOCIATED FIBROBLASTS... (5*)
1019. . . . VITAMIN D RECEPTOR PROTECTS INTESTINAL BARRIERS... (2*)|(4)
1020. . . . DEOXYCHOLATE ACID INDUCED-GUT DYSBIOSIS DISRUPTS BILE... (2*)|(National Natural Science Foundation of China (81700456 to M.Q.X) , Medical Health Technology Project of Zhejiang, China (2018KY104 to M.Q.X)
1021. . . . NFATS POSITIVELY CONTROLS GLYCOSLYSION IN INTESTINAL... (2*)
1022. . . . LOSS OF OLFACTORY G PROTEIN-COUPLED RECEPTOR... (2*)
1023. . . . VITAMIN D RECEPTOR REGULATES EPITHELIAL-MESENCHYMAL TRANSITION... (2*)
1024. . . . FUSOBACTERIUM NUCLEATUM SECRETES OUTER MEMBRANE VESICLES... (2*)
1025. . . . EFFECTS OF ACUPUNCTURE ON SYMPTOMS, MICROBIOTA,... (2*)
1026. . . . LOW DOSE INTERLEUKIN-2 FOR THE TREATMENT... (6*)|(2)
1027. . . . SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-TL1A... (3*)|(Pfizer Inc)
1028. . . . USTEKINUMAB IS ASSOCIATED WITH BETTER EFFECTIVENESS... (1*)
1029. . . . GASTRIC SLEEVE SURGERY WITH DUODENAL SWITCH... (4*)
1030. . . . A PHASE 2, OPEN-LABEL, MULTICENTER, 2X2... (3*)|(AzurRx BioPharma Inc.)
1031. . . . A DISTINCT BRAIN-GUT MICROBIOME PROFILE EXISTS... (2*)|(4)
1032. . . . PLASMA METABOLOMICS REVEAL A TARGETED PANEL... (4*)|(3) (Investigator-initiated grant from Servier)
1033. . . . UTILITY OF COMBINING ENDOSCOPIC ULTRASOUND WITH... (5*)
1034. . . . SEX DIFFERENCES IN PEDIATRIC ACUTE RECURRENT... (2*)
1035. . . . A PROSPECTIVE ENDOSCOPIC AND HISTOLOGIC STUDY... (2*)|(4)
1036. . . . RECURRENT NEOPLASIA AFTER ENDOSCOPIC TREATMENT FOR... (5*)
1037. . . . INDEPENDENT VALIDATION OF AN ACCURATE METHYLATED... (4*)|(3) (Assays provided by Exact Sciences.)
1038. . . . INDEPENDENT VALIDATION OF TISSUECYPER TO PREDICT... (3*)|(Cernostics Inc.)
1039. . . . EPITHELIAL-DERIVED SELENOPROTEIN P ATTENUATES OXIDATIVE STRESS... (2*)|(6)
1040. . . . CLAUDIN-1 ENHANCES LIPID DROPLET ACCUMULATION TO... (2*)
1041. . . . CLUSTERIN AGGRAVATES COLITIS AND COLITIS-ASSOCIATED... (2*)|(4)
1042. . . . INHIBITION OF NF-κB SIGNALING IN DCLK1+... (2*)|(4)
1043. . . . CLUSTERIN PROTEIN-COUPLED RECEPTOR LIGAND PRODUCTION BY... (2*)|(4)
1044. . . . ARYL HYDROCARBON RECEPTOR LIGAND PRODUCTION BY... (2*)|(4)
1045. . . . INDEPENDENT VALIDATION OF TUMORIGENESIS AND METASTASIS... (2*)
1046. . . . A SINGLE RESIDUE IN MYELOID TRANSLOCATION... (2*)|(4)
1047. . . . REGULATION OF SOX-2 EXPRESSION BY BONE... (2*)|(4)
1048. . . . ASSOCIATION BETWEEN PERSISTENT ORGANIC POLLUTANT... (4*)
1049. . . . IMMUNE RECOGNITION OF EPITOPES DERIVED FROM... (4*)
1050. . . . KUMA062 EFFECTIVELY DIGESTS GLUTEN IN THE... (3*) (The study was sponsored by PvP Biologics, Inc.)
1051. . . . HEALTHY LIFESTYLE, ENDOSCOPIC SCREENING, AND COLORECTAL... (2*)
1052. . . . SCREENING AND SURVEILLANCE COLONOSCOPY FINDINGS ARE... (2*)
1053. . . . CRC SCREENING REDUCES LONG-TERM ALL-CAUSE AND... (2*)
1054. . . . LONG-TERM RISK OF COLORECTAL CANCER AND... (4*)
1055. . . . LONG TERM FOLLOW-UP OF THE ITALIAN... (4*)
1056. . . . COLORECTAL CANCER MORTALITY IN VETERANS WITH... (4*)|(2)
1057. . . . CONTINUOUS NRF2 ACTIVATION SENSITIZES PANCREATIC CANCER... (5*)
1058. . . . PANCREATIC STELLATE CELL RECRUITMENT SENSITIVITY TO... (4*)|(2)
1059. . . . PANCREATIC CYSTS... (7*)
1060. . . . THE DIAGNOSTIC INCIDENCE OF PANCREATIC CYSTS... (5*)
1061. . . . A DISTINCT BRAIN-GUT MICROBIOME PROFILE EXISTS... (2*)|(4)
1062. . . . REPLACEMENT BY ELEVATING... (2*)|(7)
1063. . . . COMPREHENSIVE CHARACTERIZATION OF THE GENOMIC LANDSCAPE... (4*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

TRANSITION... [(2*)][National Natural Science Foundation of China, 81871947]

1137. . . . OPIOID-RELATED EMERGENCY DEPARTMENT VISITS AND HOSPITALIZATIONS... (2*)

1138. . . . HIGH-DOSE DAILY OPIOID USE AMONG VETERANS... (2*)

1139. . . . HIGH-VOLUME OPIOID PRESCRIBERS ACCOUNT FOR A... (4*)

1140. . . . PATIENTS WITH INFLAMMATORY BOWEL DISEASE ARE... (5*)

1141. . . . TRENDS AND SOCIOECONOMIC HEALTH OUTCOMES OF... (5*)

1142. . . . MICROBIAL DEGRADATION OF ILEAL MUCUS PROMOTES... (2*)[(1)]

1143. . . . URINE 3-INDOXYL SULFATE, A GUT MICROBIOME-DERIVED... (2*)

1144. . . . FECAL MICROBIOTA TRANSPLANT FOR MULTI-DRUG RESISTANT... (2*)[(3)]

1145. . . . AN EFFECTIVE METHOD OF ERADICATING HELICOBACTER... (2*)

1147. . . . DETECTION OF SEASONAL INFLUENZA RNA IN... (2*)[(3)][(This research was supported by AMED (grant number JP18k0108077), and JSPS KAKENHI (grant number JP18K16183). This research was also supported by grants from the Mochida Memorial Foundation for Medical and Pharmaceutical Research, the Uehara Memorial Foun)

1148. . . . JAK INHIBITORS SUPPRESS COLON CANCER CACHEXIA-ASSOCIATED... (7*)[(4)]

1149. . . . THE DIETARY-SHAPED GUT MICROBIOME ACCELERATES THE... (4*)

1150. . . . HIGH FAT DIET PROMOTES COLORECTAL TUMORIGENESIS... (2*)

1151. . . . THE SULFUR MICROBIAL DIET SCORE AND... (2*)[(6)]

1152. . . . AUTOPHAGY INHIBITS COLORECTAL CARCINOGENESIS INDUCED BY... (4*)[(2)]

1153. . . . TRANSCRIPTIONAL SIGNATURES OF WESTERN-STYLE DIET IN... (4*)

1154. . . . RNF125 CONTROL OF THE HISTONE DEACETYLASE... (2*)

1155. . . . CO-TARGETING MAPK SIGNALING AND ASPARAGINE... (2*)

1156. . . . ALDH1A3 PROMOTES PANCREATIC CANCER METASTASIS VIA... (2*)

1157. . . . CIRCULATING IL-10R2+ MYELOID CELLS IN PERIPHERAL... (5*)

1159. . . . CLINICOPATHOLOGICAL FEATURES OF THE FLAT... (5*)

1160. . . . REAL-WORLD PEDIATRIC INFILXIMAB PHARMACOKINETIC MODEL VERIFIES... (2*)[(6)]

1161. . . . CLINICAL AND HOST BIOLOGICAL FACTORS CAN... (2*)

1162. . . . BASELINE ILEAL LUMINAL NARROWING IS ASSOCIATED... (2*)[(6)][(NIH Funding P30DK078392, CCFA funding)]

1163. . . . STEP-CD STUDY: USTEKINUMAB USE IN PAEDIATRIC... (5*)

1164. . . . EFFICACY, SAFETY, TOLERABILITY OF USTEKINUMAB IN... (3*)[(This study was funded by Janssen Research and Development, LLC)]

1165. . . . CLINICAL HYPNOSIS IN PEDIATRIC CROHN’S DISEASE.... (4*)[(6)]
AGA Poster Presentations
Sa1000. . . . PUBLICATION TRENDS IN GASTROENTEROLOGY AND HEPATOLOGY... (5*)
Sa1001. . . . ANGIOTENSIN CONVERTING ENZYME INHIBITORS, ANGIOTENSIN RECEPTOR... (5*)
Sa1002. . . . PREVALENCE OF ACHALASIA IN THE MEDICARE... (2*)
Sa1003. . . . ACCURACY OF FIBROSCAN CONTINUOUS ATTENUATION PARAMETER... (4*)
Sa1004. . . . PREVALENCE OF COMPLICATIONS RELATED TO CHRONIC... (5*)
Sa1005. . . . PREVALENCE OF GASTROINTESTINAL DISEASE IN AN... (2*)
Sa1006. . . . TRENDS AND CHARACTERISTICS OF ACUTE CARE... (5*)
Sa1007. . . . PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE... (5*)
Sa1008. . . . INCIDENCE OF CLOSTRIDIODES DIFFICILE INFECTION FROM... (4*)
Sa1009. . . . POOR RATES OF RETESTING FOR ERADICATION... (2*)
Sa1010. . . . HEYDE SYNDROME: EPIDEMIOLOGY OF ANGIODYSPLASIA IN... (5*)
Sa1011. . . . HYPERBILIRUBINEMIA IN HOSPITALIZED PATIENTS: ETIOLOGY AND... (4*)
Sa1012. . . . EFFECTS OF SYSTEMIC LUPUS ERYTHEMATOSUS ON... (5*)
Sa1013. . . . EPIDEMIOLOGY AND PREVALENCE OF PSYCHIATRIC DISEASES... (5*)
Sa1014. . . . WHAT IF IT’S STILL THERE? ANALYSIS... (5*)
Sa1015. . . . NATIONAL HEALTH BURDEN OF ASPIRATION PNEUMONIA... (3*) [Aspisafe Solutions Inc.]
Sa1016. . . . CLOSTRIDIODES DIFFICILE INFECTION: NOT AN EQUAL... (5*)
Sa1017. . . . A COMPARISON OF LYMPHOCYTIC COLITIS AND... (5*)
Sa1018. . . . THE EPIDEMIOLOGY OF ANNULAR PANCREAS IN... (5*)
Sa1019. . . . CHRONIC MESENTERIC ISCHEMIA, A HORSE INSTEAD... (5*)
Sa1020. . . . EFFECT OF HELICOBACTER PYLORI ERADICATION ON... (5*)
Sa1021. . . . CAN FECAL CALPROTECTIN LEVELS BE USED... (5*)
Sa1022. . . . EPIDEMIOLOGY OF DEPRESSIVE DISORDERS IN PATIENTS... (5*)
Sa1023. . . . AN INDIAN NATIONAL SURVEY OF THERAPEUTIC... (5*)
Sa1024. . . . HIGH COMPLEXITY AND CONFLICTING RECOMMENDATIONS ARE... (5*)
Sa1026. . . . CHARACTERISTICS OF OPIOID PRESCRIPTIONS TO VETERANS... (2*)
Sa1029. . . . INVESTIGATION OF REPEAT GASTROINTESTINAL BLEEDING AMONG... (5*)
Sa1030. . . . THE OVERALL QUALITY OF EVIDENCE SURROUNDING... (5*)
Sa1031. . . . ENHANCED E-CONSULTS AT A FEDARALLY QUALIFIED... (5*)
Sa1032. . . . DEVELOPMENT OF A PRELIMINARY QUESTION PROMPT... (5*)
Sa1033. . . . FECAL GOLD MINE: TWITTER AS A... (2*)
Sa1034. . . . ALARMING TRENDS IN ERCP ADMISSIONS FOR... (5*)
Sa1035. . . . IDENTIFYING PATIENTS WITH ACUTE GASTROINTESTINAL BLEEDING... (5*)
Sa1036. . . . HARD TO SWALLOW RESULTS: ASSESSMENT OF... (5*)
Sa1037. . . . WHAT TYPES OF QUESTIONS CAN BE... (5*)
Sa1038. . . . DEVELOPMENT OF QUALITY INDICATORS FOR THE... (5*)
Sa1039. . . . TIME AND EFFORT SPENT AFTER WORK... (5*)
Sa1040. . . . PATIENT AND PROCESS-DRIVEN BARRIERS TO GASTROENTEROLOGY... (5*)
Sa1041. . . . CLINICAL CHARACTERISTICS ASSOCIATED WITH INCREASED INPATIENT... (5*)
Sa1042. . . . REPORTING OF CONFLICTS OF INTEREST DURING... (5*)
Sa1043. . . . A SINGLE CENTER STUDY ON THE... (5*)
Sa1044. . . . ASSOCIATION BETWEEN MEDITERRANEAN DIET ADHERENCE AND... (5*)
Sa1045. . . . WHAT IS KNOWN AND WHAT IS... (5*)
Sa1046. . . . ELEMENTS FOR EARLY DETECTION IN PANCREATIC... (5*)
Sa1047. . . . THE CLINICAL FEATURES OF SESSILE SERRATED... (2*)
Sa1048. . . . PATIENT FACTORS AFFECT ERGONOMIC STRAIN OF... (7*)
Sa1049. . . . CANADIAN GASTROENTEROLOGY CAREER PATHWAY EXPERIENCES: A... (5*)
Sa1050. . . . VALIDATION OF A NOVEL ENDOSCOPIC SUTURING... (5*)
Sa1051. . . . WHAT IS THE IMPACT OF TRAINEE... (5*)
Sa1052. . . . SIMULATOR-BASED TRAINING PROGRAMS ACCELERATE ACQUISITION OF... (5*)
Sa1053. . . . MIND THE GAP: WOMEN REPRESENTATION ON... (5*)
Sa1054. . . . USEFULNESS OF JHALA ALGORITHM IN ASSESSMENT... (5*)
Sa1055. . . . SHIFTS IN PERSPECTIVES OF SOCIAL MEDIA... (5*)
Sa1056. . . . ADDRESSING EDUCATIONAL NEEDS TOWARDS ENHANCED CARE... (3*) [This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.]
Sa1057. . . . EVALUATION OF A NUTRITION CURRICULUM DESIGNED... (5*)
Sa1058. . . . FROM ABSTRACT TO PUBLICATION SUCCESS: A... (5*)
Sa1059. . . . COLONOSCOPY QUALITY METRICS DURING GASTROENTEROLOGY FELLOWSHIP:... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1060. . . . COMPARING THE CONTRIBUTION OF INTERNATIONAL MEDICAL... *(5*)

Sa1061. . . . CHARACTERIZATION OF ENGAGEMENT AND CONTENT ANALYSIS... *(5*)

Sa1062. . . . CHANGHAI ADVANCED ENDOSCOPY COURSES FOR ERCP... *(5*)

Sa1063. . . . ARE PARENTAL LEAVE POLICIES HELPING OUR... *(5*)

Sa1064. . . . SURVEYING GASTROENTEROLOGY CONTENT AND METHODS OF... *(5*)

Sa1065. . . . TEACHING GASTROENTEROLOGY TO FIRST YEAR MEDICAL... *(5*)

Sa1066. . . . ADVANCED ENDOSCOPY TRAINING IN PEDIATRICS: THE... *(5*)

Sa1067. . . . IMPLEMENTATION OF A FIRST-YEAR GASTROENTEROLOGY FELLOWS... *(4*)

Sa1068. . . . GI TALK: A COMMUNICATION SKILLS TRAINING... *(5*)

Sa1069. . . . GENDER DISPARITIES IN GASTROENTEROLOGY FELLOWS ACROSS... *(5*)

Sa1070. . . . IMPACT OF A VIRTUAL REALITY SIMULATION... *(5*)

Sa1071. . . . EVALUATING THE IMPACT OF ADVANCED ENDOSCOPY... *(5*)

Sa1072. . . . IMPACT OF PARENTHOOD ON GASTROENTEROLOGY TRAINING... *(5*)

Sa1073. . . . IMPACT OF TRAINEE PARTICIPATION ON ADENOMA... *(5*)

Sa1074. . . . SIGNIFICANT IMPROVEMENT OF PRIMARY CARE DOCTORS'... *(3*)|(Xian Janssen Pharmaceutical Ltd)

Sa1075. . . . HONOKIOL, A NOVEL AGENT THAT PROMOTES... *(2*)

Sa1076. . . . A NOVEL RAT MODEL OF HEARTBURN... *(2*)|(4)

Sa1077. . . . P2X7 RECEPTOR ANTAGONIST RECOVERS MYENTERIC NEURONS... *(4*)

Sa1078. . . . CANNABINOID RECEPTOR EXPRESSION AND THE EFFECT... *(3*)|(2)|(Arena Pharmaceuticals)

Sa1079. . . . ESTABLISHING AN INTESTINAL EPITHELIAL-NEURONAL CO-CULTURE SYSTEM... *(4*)|(2)

Sa1080. . . . THE DEUBIQUITINATING ENZYME USP10 REGULATES Na+/H+... *(2*)

Sa1081. . . . UNIQUE MECHANISMS OF REGULATION OF L-TYPE... *(2*)

Sa1082. . . . MOLECULAR MECHANISM OF STIMULATION OF NA-K-ATPASE... *(2*)

Sa1083. . . . GASTRIC AND PANCREATIC-DERIVED DOPAMINE STIMULATES... *(2*)

Sa1084. . . . MUSCARINIC AND NICOTINIC SIGNALING SYNERGISTICALLY REGULATE... *(2*)

Sa1085. . . . REGULATION OF ELECTROLYTE AND NUTRIENT TRANSPORTERS... *(2*)

Sa1086. . . . AUTOPHAGY REGULATES PUTATIVE ANION TRANSPORTER 1... *(2*)

Sa1087. . . . DEFICIENT ACTIVITY OF A GOBLET CELL-SPECIFIC... *(2*)|(6)

Sa1088. . . . GLOUCOSE-STIMULATED ANION CHANNEL ACTIVITY DECREASED NET... *(3*)

Sa1089. . . . SLC26A3 (DRA) IS STIMULATED BY BOTH... *(2*)

Sa1090. . . . PROTEIN KINASE A-ALPHA REGULATES PGE2 MEDIATED... *(2*)

Sa1091. . . . POLARIZED RESPONSES TO EXTRACELLULAR CYCLIC DINUCLEOTIDES... *(2*)

Sa1092. . . . APICAL BK CHANNELS IN INTESTINAL EPITHELIA... *(6*)

Sa1093. . . . CONTRIBUTION OF EPITHELIAL HYPERPROLIFERATION TO INCREASED... *(6*)

Sa1094. . . . EVIDENCE OF DUODENAL EPITHELIAL BARRIER IMPAIRMENT... *(4*)|(2)

Sa1095. . . . PARD6B REGULATES EPITHELIAL BARRIER IMPAIRMENT... *(2*)

Sa1096. . . . SELECTIVE INHIBITION OF COX-1, BUT NOT... *(2*)

Sa1097. . . . EXPLORING THE MECHANISMS OF LARAZOTIDE IN... *(3*)|(P & G grant IISP opportunity)

Sa1098. . . . OLEOYLETHANOLAMIDE AMELIORATES DEXTRAN SULFATE SODIUM-INDUCED COLITIS... *(4*)

Sa1099. . . . LACTOBACILLUS RHAMNOSUS GG (LGG) #NAME? ENTERIC... *(2*)

Sa1100. . . . INGESTED MICROPLASTICS POSE A POTENTIALLY SERIOUS... *(4*)

Sa1102. . . . PROTECTIVE EFFECT OF ALISMATIS RHIZOMA ON... *(2*)

Sa1103. . . . ANTI-INFLAMMATORY EFFECT OF TEGOPRAZAN(CJ-12420), A NOVEL... *(5*)

Sa1104. . . . RELATIONSHIP BETWEEN ANTIMICROBIAL REG IIIγ EXPRESSION... *(5*)

Sa1105. . . . EFFECT OF ANTIBIOTICS-INDUCED DYSBIOSIS ON MACROPHAGE... *(5*)

Sa1106. . . . THE IMPACT OF BILE SALT SEQUESTRANTS... *(3*)

Sa1107. . . . EFFECTS OF QIZHI WEITONG GRANULES ON... *(5*)

Sa1108. . . . SERUM AMYLOID A PROMOTES INFLAMMATION-ASSOCIATED DAMAGE... *(2*)|(6)

Sa1109. . . . CRONKHITE-CANADA SYNDROME: A PRELIMINARY STUDY... *(2*)

Sa1110. . . . ENDOSCOPIC AND HISTOLOGIC INFLAMMATION IN THE... *(5*)

Sa1111. . . . DOWN-REGULATION OF OLFM4 CONTRIBUTES TO METASTASIS... *(5*)

Sa1112. . . . TARGETED DELETION OF COLONIC... *(2*)

Sa1113. . . . LYCIUM BARBARUM POLYSACCHARIDES ATTENUATES COLONIC INFLAMMATION... *(4*)

Sa1114. . . . MODELING CONTEXT-DEPENDENT BUBR1 KINASE SIGNALING USING... *(2*)|(6)

Sa1115. . . . CIRCADIAN MISALIGNMENT BY ENVIRONMENTAL LIGHT:DARK SHIFTING... *(5*)

Sa1116. . . . BISMUTH SUBSALICYLATE ALTERS THE EFFECTS OF... *(3*)|(P & G grant IISP opportunity)

Abstract Funding Source Key
* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NHI, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1117. . . . THE EFFECTS OF SULGLYCOTIDE ON THE... (3*)[Samil pharmaceutical company]

Sa1118. . . . AUTOPHAGY IS REQUIRED FOR THE BENEFICIAL... (4*)

Sa1119. . . . TRISTETRAPROLIN EXPRESSION IN THE INTESTINAL EPITHELIUM... (5*)

Sa1120. . . . DEPLETION OF DELTA-LIKE LIGAND 4 (DLL4)... (2*)

Sa1121. . . . COMPOUND HETEROZYGOTE TRIM22 VARIANTS ARE A... (6*)

Sa1122. . . . TARGETED DRUG DELIVERY FOR INFLAMMATORY BOWEL... (2*)

Sa1123. . . . REGULATORS OF THE GUANYLATE CYCLASE PATHWAY... (2*)

Sa1124. . . . SINGLE CELL TRANSCRIPTOMIC APPROACH TO UNDERSTANDING... (2*)(U01DK1112194 [Baylor], U01DK073983[HU], U01DK112193 [Braden Kuo], U01DK073975 [Temple], U01DK074035 [TTU], U01DK074007 [Louisville – Abell], U01DK073974 [Wake Forest – Koch], U01DK074008)

Sa1125. . . . GENE EXPRESSION (GE) DELIVERY FOR INFLAMMATORY DISORDERS... (2*)

Sa1126. . . . IMMUNE IMPAIRMENTS IN P. PYLORI... (2*)

Sa1127. . . . THE KETOGENIC ENZYME, HMGCS2, PROTECTS INTESTINAL... (2*)

Sa1128. . . . LUBIPROSTONE INCREASED EXPRESSION OF CLAUDIN-1 AND... (4*)

Sa1129. . . . WATER AVOIDANCE STRESS DECREASES INNATE LYMPHOCYTES... (4*)

Sa1130. . . . THE EFFECT OF PHOENIXIN-14 ON... (4*)

Sa1131. . . . EXOSOMES FROM HUMAN MESENCHYMAL STEM CELLS... (2*)

Sa1132. . . . CHARACTERIZATION OF IL10 GENE-DEFICIENT MOUSE INTestinal... (2*)(National Natural Science Foundation of China, 81670477, 81600418, 81600412, 81600419 ; Sun Yat-Sen University

Sa1133. . . . THE ROLE OF INTERFERON-α AND PLASMACYTOID... (4*)

Sa1134. . . . THE GUT-SKIN AXIS IN SAMP1/YITFFC MICE... (2*)

Sa1135. . . . CYSTATHIONINE-γ-LYASE (CSE) DERIVED HYDROGEN SULFIDE (H2S)... (2*)

Sa1136. . . . EFFECT OF TETRAHYDROCANNABINOL ON THE CANONICAL... (4*)

Sa1137. . . . AN ADHESIgenic ROLE OF THBS4 IN... (2*)

Sa1138. . . . MURINE INTRARECTAL INSTALLATION OF PURIFIED RECOMBINANT... (2*)[4]

Sa1139. . . . NEW THERAPEUTIC STRATEGY FOR AMINO ACID... (2*)

Sa1140. . . . MMP-9 DISRUPTION OF INTESTINAL EPITHELIAL TIGHT... (6*)[4]

Sa1141. . . . CSN6 PROMOTES COLORECTAL CANCER BY SUPPORTING... (2*)

Sa1142. . . . THE ROLE FOR LONG NON-CODING RNA... (4*)

Sa1143. . . . CONCORDANCE BETWEEN SOMATIC AND GERMLINE MUTATION... (5*)

Sa1145. . . . NOVEL lncRNA HERES REGULATES WNT SIGNALING... (2*)[This study was funded by the Ministry of Science and Information and Communication Technologies (ICT) (grant numbers 2017M3A9G8084539, 2017R1A2B4006316, and 2018R1A2B2003782)]

Sa1146. . . . CANCER-RELATED GENETIC VARIANTS OF HELICOBACTER PYLORI... (2*)[This work was supported by JSPS (Japan Society for the Promotion of Science) KAKENHI Grant Numbers JP16K09295 to Yoshiyuki Watanabe.)

Sa1147. . . . GENETIC COMPARISON OF YOUNG-ONSET AND LATE-ONSET... (2*)

Sa1148. . . . GENERATION AND CHARACTERIZATION OF HUMAN PANCREATIC... (2*)

Sa1150. . . . CAN LONG TERM USE OF PROTON... (5*)

Sa1151. . . . POST-TRAUMATIC STRESS DISORDER IN NEUROENDOCRINE TUMOR... (5*)

Sa1152. . . . TUMOR RESPONSE TO PEPTIDE RECEPTOR RADIONUCLIDE... (5*)

Sa1153. . . . RACIAL DIFFERENCES IN GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR... (6*)

Sa1154. . . . ORGANOID-BASED PRECLINICAL MODELS RECAPITULATE RENALASE SIGNALING... (2*)

Sa1155. . . . BILE ACIDS AND THE MICROBIOTA PLAY... (2*)[6]

Sa1156. . . . ROLE OF WNT NON-CANONICAL PATHWAY IN... (4*)

Sa1157. . . . HSA_CIRC_0021087 INHIBITS GASTRIC CANCER PROGRESSION BY... (2*)

Sa1158. . . . GENERATION OF PATIENT-DERIVED PANCREATIC CANCER ORGANOID... (5*)

Sa1159. . . . NOTCH2 SIGNaling REGulates DENDRITIC CELLS TO... (2*)

Sa1160. . . . ROLE OF P21 IN CD4+ T... (4*)

Sa1161. . . . INFLAMMATORY IMMUNE RESPONSES ASSOCIATED WITH ORAL... (4*)

Sa1162. . . . COLORECTAL CANCER PROLIFERATION AND SURVIVAL ARE... (2*)[6]

Sa1163. . . . PATIENTS WITH IBD ARE AT AN... (5*)

Sa1164. . . . PREOPERATIVE INTRAVENOUS IRON THERAPY AND SURVIVAL... (2*)

Sa1165. . . . THE DNA MISMATCH REPAIR (MMR) PROTEIN... (2*)[4]

Sa1166. . . . SYSTEMIC LUPUS ERYTHEMATOUS AND COLORECTAL CANCER... (5*)

Sa1167. . . . ADRENALINE-DEPENDENT IMMUNOLOGIC REPROGRAMMING IN ENDOTHELIAL CELLS... (2*)

Sa1168. . . . RHEUMATOID ARTHRITIS AND COLORECTAL CANCER... (2*)

Sa1169. . . . ACHIEVING HISTOLOGIC NORMALIZATION IN LONG-TERM ULCERATIVE... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1332. . . . GASTRIC CORPUS MUCOSAL HYPERPLASIA AND NEOENDOCRINE... (4*)
Sa1333. . . . BILE ACIDS PROMOTE GASTRIC INTESTINAL METAPLASIA... (2*)
Sa1334. . . . CLINICOPATHOLOGICAL FEATURES AND TREATMENTS EFFECTS ON... (5*)
Sa1335. . . . NEOPLASIA RISK AND RESECTION COMPLICATIONS... (5*)
Sa1336. . . . HYPERGASTRINEMIA IS ASSOCIATED WITH PROXIMAL AND... (2*)[7]
Sa1337. . . . DIFFERENTIAL EXPRESSION OF CIRCULATING MICRORNAS IN... (4*)[6]
Sa1338. . . . NATURAL HISTORY OF AUTOIMMUNE GASTRITIS: PROSPECTIVE... (5*)
Sa1339. . . . INTEROBSERVER CONSISTENCY ON THE HISTOLOGICAL ASSESSMENT... (5*)
Sa1340. . . . IMPACT OF OBESITY ON RATES AND... (2*)
Sa1341. . . . HELICOBACTER PYLORI INFECTION IS ASSOCIATED WITH... (5*)
Sa1342. . . . GASTRIC CANCER OCCURRENCE DESPITE PRIOR ENDOSCOPY:... (5*)
Sa1343. . . . CLASSIFICATION OF AUTOIMMUNE GASTRITIS BASED ON... (5*)
Sa1344. . . . STAT3 SIGNALING ACTIVATES CDX2 VIA INDUCTION... (5*)
Sa1345. . . . THE GASTRIC PRECANCEROUS CONDITIONS STUDY (GAPS)... (4*)[6]
Sa1346. . . . HYPERGASTRINEMIA DUE TO P-CAB (AN... (5*)
Sa1347. . . . MTHFR C677T GENETIC POLYMORPHISM INVOLVED IN... (2*)
Sa1348. . . . CORRELATION BETWEEN SERUM GASTRIC BIOMARKERS AND... (5*)
Sa1349. . . . A NON-INVASIVE TEST IN THE MANAGEMENT... (5*)
Sa1351. . . . COMPARISON BETWEEN PROACTIVE VERSUS STANDARD PERCUTANEOUS... (5*)
Sa1352. . . . MOLECULAR PHENOTYPING OF INFECTED Pancreatic Necrosis... (6*)
Sa1353. . . . MORTALITY IN PATIENTS WITH ACUTE PANCREATITIS... (5*)
Sa1354. . . . THE VALIDATION OF PANCREATITIS ACTIVITY SCORING... (5*)
Sa1355. . . . CAN ARTIFICIAL INTELLIGENCE (AI) PREDICT... (5*)
Sa1356. . . . NEED FOR INTERVENTION IN NECROTIZING PANCREATITIS... (5*)
Sa1357. . . . BILIARY INTERVENTIONS IN PATIENTS WITH STERILE... (5*)
Sa1358. . . . VALUE OF MEASUREMENT OF WHOLE BODY... (5*)
Sa1359. . . . LONGITUDINAL ASSESSMENT OF HBA1C LEVELS IN... (3*)[4][AbbVie]
Sa1360. . . . IMMUNE CHECKPOINT-INHIBITOR INDUCED ACUTE PANCREATITIS: A... (5*)
Sa1361. . . . PATIENT-CONTROLLED ANALGESIA LEADS TO INCREASED HOSPITAL... (5*)
Sa1362. . . . INCREASED FLUID RATE HASTENS RECOVERY OF... (5*)
Sa1363. . . . USE OF ACOUSTIC RADIATION FORCE IMPULSE... (5*)
Sa1364. . . . Pancreatic Cancer in Acute Pancreatitis: A... (5*)
Sa1365. . . . PRACTICE PATTERNS IN THE NUTRITIONAL SUPPORT... (5*)
Sa1366. . . . PREDICTORS OF EMERGENCY DEPARTMENT OPIATE USE... (5*)
Sa1367. . . . PROGRESSION FROM Acute Pancreatitis With Systemic... (2*)
Sa1368. . . . ASSOCIATION OF INCREASED SERUM TRIGLYCERIDE LEVELS... (5*)
Sa1369. . . . DIAGNOSIS AND TREATMENT OF PANCREATIC DUCT... (5*)
Sa1370. . . . EPIDEMIOLOGY AND RISK OF ANXIETY AND... (5*)
Sa1371. . . . SPLANCHNIC VEIN THROMBOSIS IN ACUTE Pancreatitis... (5*)
Sa1372. . . . ISCHEMIC PANCREATITIS IS A RARE BUT... (5*)
Sa1373. . . . PREOPERATIVE ERCP HAS NO IMPACT ON... (2*)
Sa1374. . . . SINGLE OPERATOR PANCREATOSCOPY WITH INTRADUCTAL LITHOTRIPSY... (5*)
Sa1375. . . . FOLATE AND VITAMIN B12 DEFICIENCY INCREASES... (2*)
Sa1376. . . . Pancreas Cancer Associated Mortality is Low... (7*)[2]
Sa1377. . . . Lifetime Smoking in Persons with Chronic... (2*)
Sa1378. . . . Chronic Pancreatitis (CP) Has a Profound... (2*)
Sa1379. . . . WHAT IS A BENEFIT OF ISLET... (5*)
Sa1380. . . . SEVERE PAIN IN CHRONIC Pancreatitis Is... (2*)
Sa1381. . . . PREDICTIVE FACTORS OF RELAPSE IN AUTOIMMUNE... (5*)
Sa1382. . . . CLASSIFICATION OF EARLY-ONSET AND LATE-ONSET Idiopathic... (5*)
Sa1383. . . . A COMPARISON OF UROLOGIST VS. GASTROENTEROLGIST-DIRECTED... (5*)
Sa1384. . . . FRACTMENTED INPATIENT CARE IS PREVALENT AMONG... (5*)
Sa1385. . . . CHRONIC PANCREATITIS IS ASSOCIATED WITH INCREASED... (5*)
Sa1386. . . . ISLET AUTOTRANSPLANTATION IMPROVES GLYCEMIC CONTROL IN... (5*)
Sa1387. . . . NationWIDE EPIDEMILOGICAL SURVEY OF AUTOIMMUNE Pancreatitis... (7*)[2]
Sa1388. . . . LOOKING FOR A SUBROGATE BIOMARKER OF... (5*)
Sa1389. . . . THE RISK OF VITAMIN D DEFICIENCY,... (5*)
Sa1390. . . . MANAGEMENT AND SURVEILLANCE OF EXOCRINE Pancreatic... (5*)
Sa1391. . . . Antioxidant Decreases the Frequency of Pain... (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1392. . . . NATIONWIDE EPIDEMIOLOGICAL SURVEY OF CHRONIC... (5*)
Sa1393. . . . LIFESTYLE MODIFICATIONS IN CHRONIC PANCREATITIS ... (5*)
Sa1394. . . . OPIATE DEPENDENCE IS A SIGNIFICANT RISK... (5*)
Sa1550. . . . HEAVY ALCOHOL USE AND LIVER DISEASE... (5*)
Sa1551. . . . TEMPORAL TRENDS OF MORTALITY AND HEALTHCARE... (5*)
Sa1552. . . . CARDIOVASCULAR OUTCOMES IN PATIENTS WITH NON-ALCOHOLIC... (5*)
Sa1553. . . . PROTON PUMP INHIBITOR THERAPY REDUCES FERRITIN... (5*)
Sa1554. . . . NATIONAL TRENDS AND OUTCOMES OF GENETICALLY... (5*)
Sa1555. . . . POLYCYTHEMIA AND ANEMIA IN HEREDITARY HEMOCROMATOSIS... (5*)
Sa1556. . . . IMPAIRED INTESTINAL CHYLOMICRON SECRETION DISSOCIATES REVERSAL... (2*)
Sa1557. . . . PRAGMATIC USE OF NON-INVASIVE DIAGNOSTIC METHODS... (4*)
Sa1558. . . . THE ROLE OF IAA IN NONALCOHOLIC... (2*)
Sa1559. . . . ELEVATED LIVER ENZYMES NOT CORRELATED WITH... (5*)
Sa1560. . . . PROTEIN TRUNCATING SPLICE VARIANT (RS72613567) IN... (4*)
Sa1561. . . . CANNABIS IS ASSOCIATED WITH REDUCED IN-PATIENT... (5*)
Sa1562. . . . NON-ALCOHOLIC STEATOHEPATITIS-ASSOCIATED ALTERATION OF INFLAMMATORY LIPID... (3*)
Sa1563. . . . FIB-4 INDEX CORRELATES WITH MEASURES OF... (4*)
Sa1564. . . . CHARACTERISTICS OF NON-ALCOHOLIC FATTY LIVER DISEASE... (5*)
Sa1565. . . . CHILD-TURCOTTE-PUGH CLASS AT TRANSPLANTATION PREDICTS POST-TRANSPLANTATION... (5*)
Sa1566. . . . LIVER SURFACE NODULARITY AS AN ESTIMATE... (5*)
Sa1567. . . . MRI INTENSITY PATTERNS IN PATIENTS WITH... (5*)
Sa1568. . . . EUS-GUIDED SAMPLING AND PROFILING OF PORTAL... (5*)
Sa1569. . . . TIMELY DIAGNOSIS AND STAGING OF NAFLD... (5*)
Sa1615. . . . GASTRIC DYSMOTILITY NEGATIVELY IMPACTS BOTH GASTROINTESTINAL... (2*)
Sa1616. . . . SACRAL NERVE STIMULATION LEADS TO LONG-TERM... (5*)
Sa1617. . . . OVERLAPPING SYMPTOMS OF GASTROESOPHAGEAL REFLUX AND... (4*)
Sa1618. . . . A RETROSPECTIVE REVIEW OF LINACLOTIDE TREATMENT... (5*)
Sa1619. . . . IS CELIAC DISEASE TESTING NECESSARY IN... (5*)
Sa1620. . . . POLYETHYLENE GLYCOL 3350 CHANGES STOOL CONSISTENCY... (4*)
Sa1621. . . . EFFECT OF MIRTAZAPINE IN CHILDREN WITH... (5*)
Sa1622. . . . SLEEP DISTURBANCES IN SCHOOL-AGE CHILDREN WITH... (2*)
Sa1623. . . . URINARY EXOSOMES ISOLATED FROM PEDIATRIC PATIENTS... (4*)
Sa1624. . . . PYRIDOSTIGMINE FOR TREATMENT OF CHILDREN WITH... (5*)
Sa1625. . . . POLYETHYLENE GLYCOL AND HYPEROSMOLAR ENSLAVE... (4*)
Sa1626. . . . HYPNOSIS TO REDUCE DISTRESS IN CHILDREN... (1*)
Sa1627. . . . THE NOT SO RARE ABSENT RAIH... (5*)
Sa1628. . . . UTILIZATION AND COST FOR PEDIATRIC IRRITABLE... (5*)
Sa1629. . . . COMPARISON OF THE BRISTOL STOOL FORM... (5*)
Sa1630. . . . APRAPITANT FOR ACUTE TREATMENT OF SEVERE... (5*)
Sa1631. . . . INTRAPYLORIC BOTULINUM INJECTIONS IMPROVE FEEDING OUTCOMES... (2*)
Sa1632. . . . COMPARING VULNERABILITIES AND TRIGGERS IN PEDIATRIC... (5*)
Sa1633. . . . COMPLEMENTARY AND ALTERNATIVE MEDICINE USE IN... (1*)
Sa1634. . . . ALLERGY-RELATED DISEASES DURING CHILDHOOD AND RISK... (6*)(2)
Sa1635. . . . CINE-MRI VERSUS COLONIC MANOMETRY IN THE... (5*)
Sa1636. . . . PEDIATRIC ROME IV CRITERIA HAS SUBSTANTIAL... (5*)
Sa1637. . . . IBS MOTHERS IN JAPAN WHO HAVE... (2*)
Sa1638. . . . STANDARDIZING LONG-TERM GASTROINTESTINAL MOTILITY RECORDINGS IN... (5*)
Sa1639. . . . AZITHROMYCIN IS EQUALLY ABLE TO INDUCE... (4*)
Sa1640. . . . NONINVASIVE MEASUREMENT OF SMALL BOWEL SLOW... (4*)
Sa1641. . . . THE EFFECTS OF DIABETES MELLITUS ON... (5*)
Sa1642. . . . THE EFFECTS OF VENOUS THROMBOEMBOLISM IN... (5*)
Sa1643. . . . RISK FACTORS AND INCIDENCE OF 90-DAY... (5*)
Sa1644. . . . TRENDS IN MANAGEMENT OF ACUTE COLONIC... (5*)
Sa1645. . . . DIVERTICULAR DISEASE WITH AND WITHOUT BLEEDING... (5*)
Sa1646. . . . VIRTUAL REALITY AS AN ALTERNATIVE TO... (4*)
Sa1647. . . . COMPARISON OF SECOND FORWARD VIEW EXAMINATION... (5*)
Sa1649. . . . HOT AVULSION VS COLD AVULSION IN... (5*)
Sa1650. . . . INCIDENCE OF INVASIVE COLORECTAL CANCER AFTER... (5*)
Sa1651. . . . PLASMA BASED CELL-FREE CIRCULATING TUMOR DNA... (3*)[(Guardant Health)
Sa1652. . . . ARTIFICIAL INTELLIGENCE-AUGMENTED VISUALIZATION WITH REAL TIME... (2*)

Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1669. . . . ANORECTAL MANOMETRY IN UPRIGHT POSITION WITH... (4*)
Sa1695. . . . ANORECTAL MANOMETRY...
Sa1674. . . . THE POTENTIAL IMPACT OF THE LOW-SODIUM... (5*)
Sa1675. . . . STATINS REDUCE THE RISK OF ALL... (5*)
Sa1676. . . . EARLY ADVERSE LIFE EVENTS AND POST-TRAUMATIC... (4*)
Sa1677. . . . VOLUMETRIC RECTAL SENSATION TESTING: IS IT... (5*)
Sa1678. . . . PELVIC FLOOR PROLAPSE ASSOCIATED WITH GI-SPECIFIC... (5*)
Sa1679. . . . ANAL AND VAGINAL AREA-PRESSURE BI-LOOPS: TOWARD... (2*)
Sa1680. . . . EFFECTS OF CONCENTRIC PELVIC FLOOR RESISTANCE... (2*)
Sa1681. . . . FECAL INCONTINENCE (FI) STOOL APP IS... (5*)
Sa1683. . . . SENSITIVITY AND RECTAL CAPACITY IN PATIENTS... (5*)
Sa1684. . . . PREVALENCE OF DISORDERS OF ANORECTAL FUNCTION... (5*)
Sa1685. . . . BIOFEEDBACK AS A TOOL FOR RESOLUTION... (5*)
Sa1686. . . . FACTORS INFLUENCING EFFICACY OF BIOFEEDBACK THERAPY... (5*)
Sa1687. . . . TRANSLATION OF BIOENGINEERED FUNCTIONALLY INNERVATED HUMAN... (2*)
Sa1688. . . . THE PREDICTORS OF NON-ADHERENCE TO BIOFEEDBACK... (5*)
Sa1689. . . . CLINICAL PRESENTATION AND CHARACTERISTICS OF PELVIC... (5*)
Sa1690. . . . ANAL DISTENSIBILITY IN CONSTIPATED WOMEN ... (2*)
Sa1691. . . . ANALYSIS OF THE SENSITIVITY OF HIGH... (2*)
Sa1692. . . . FATIGABILITY OF EXTERNAL ANAL SPHINCTER MUSCLES... (2*)
Sa1693. . . . IN CONSTIPATED YOUNG MEN ACQUIRED VOIDING... (5*)
Sa1694. . . . ANORECTAL MANOMETRY AS A DIAGNOSTIC TEST ... (7*)
Sa1695. . . . ANORECTAL MANOMETRY...
Sa1696. . . . PATIENTS WITH REFRACTORY CHRONIC CONSTIPATION OFTEN... (5*)
Sa1697. . . . CHANGES IN ANORECTAL FUNCTION IN PATIENTS... (5*)
Sa1698. . . . EXTERNAL ANAL SPHINCTER STRENGTH TRAINING EXERCISE... (2*)
Sa1699. . . . GEOMETRIC CHARACTERISTICS OF THE ANAL CANAL...
Sa1700. . . . DYNAMIC ECHODEFECOGRAPHY FOR ASSESSMENT OF FUNCTIONAL... (5*)
Sa1701. . . . EFFECTS OF OPIOID POTENCY AND DURATION... (5*)
Sa1702. . . . DOES AGE INFLUENCE ANORECTAL PHYSIOLOGICAL PARAMETERS?... (5*)
Sa1704. . . . MR DEFECCOGRAPHY IN THE ASSESSMENT OF... (4*)
Sa1705. . . . FAILED BALLOON EXPULSION IS THE ONLY... (5*)
Sa1706. . . . ELDERLY PATIENTS DERIVE MORE CLINICAL BENEFITS...
Sa1707. . . . EVIDENCE OF ABNORMAL CONTRACTION OF THE... (2*)
Sa1708. . . . SMALL INTESTINAL BACTERIAL OVERGROWTH IN REFRACTORY... (5*)
Sa1709. . . . EVALUATION OF REFRACTORY CONSTIPATION: ONE TEST... (5*)
Sa1710. . . . A NEW ROLE OF THE HTR2B... (2*)
Sa1711. . . . ABNORMAL SLEEP DURATION IS ASSOCIATED WITH... (7*)
Sa1712. . . . SAFETY AND EFFICACY EVALUATION OF PLECANATIDE...
Sa1715. . . . ELOBIXIBAT, ILEAL BILE ACID TRANSPORTER INHIBITOR, ... (3*)
Sa1716. . . . ACID SUPPRESSION THERAPY DOES NOT AFFECT... (3*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA AASLD, etc.)
Biofeedback is effective

Pelvic floor biofeedback is effective treatment...

Evaluation of major adverse cardiac events...

The effect of treatment...

Elobixibat on gut...

Adverse cardiac events...

The effect of plecanatide on gut...

Plecanatide for patients with chronic idiopathic...

Disordered defecation associated with poor bowel...

Opioid related disorders in patients with...

Costly waste: emergency department visits and...

Plecanatide for patients with chronic idiopathic...

Concentration of serotonin and its metabolites...

Attrition of methyltnaltrexone treatment-emergent adverse events...

Cumulative laxation response with methyltnaltrexone: implications...

Thioguanine and low dose thiopurines and...

How useful is constipation stool app...

Efficacy of prucalopride in patients with...

Clinical characteristics and anorectal physiology...

Expanding criteria for diagnosing slow transit...

Pattern of methane levels with lactulose...

Right-sideds colonic diverticula are negatively associated...

Constipatin is associated with increased odds...

Safety and efficacy of a new...

Pseudomelenosis coli causes disturbed colonic motility...

Failure of prescribing bowel regimens to...

Lactulose increases small bowel but not...

Differences in efficacy and safety of...

Factors associated with the importance of...

A real-world comparison of the effectiveness...

Thioguanine and low dose thiopurines and...

Acceptability of treatment regimen in inflammatory...

Impact of line of therapy, therapeutic...

Impact of a patient support program...

How useful is constipation stool app...

Efficacy of prucalopride in patients with...

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1765. . . . PERCEPTION OF REMISSION AND PREFERENCE FOR... (3*)[This study was funded by Shire, a member of the Takeda group of companies. Medical writing support was provided by Maxine Cox of PharmaGenesis London, London, UK, with funding from Shire International GmbH, a member of the Takeda group of companies.]

Sa1766. . . . EFFECT OF INDIANA OPIOID PRESCRIPTION LEGISLATION... (4*)

Sa1767. . . . PROVIDER COLLABORATION AND INFLUENCE MAY IMPACT... (5*)

Sa1768. . . . A MAJORITY OF YOUNG PATIENTS WITH... (5*)

Sa1769. . . . ASSESSING PATIENT DECISION MAKING ON BIOLOGIC... (3*)[Pfizer Pharmaceuticals]

Sa1770. . . . PREDICTORS OF MYCHART® MESSAGING USE IN... (5*)

Sa1772. . . . VENOUS THROMBEMBOLISM PROPHYLAXIS USE IN IBD... (5*)

Sa1773. . . . POST-OPERATIVE PROPHYLAXIS WITH ANTI-TNF IN PATIENTS... (5*)

Sa1774. . . . ARE WE ADDRESSING THE TOP TEN... (5*)

Sa1775. . . . FELLOW INVOLVEMENT DOES NOT CHANGE THE... (5*)

Sa1776. . . . TRENDS IN MEDICAL MANAGEMENT OF CROHN'S... (5*)

Sa1777. . . . URGENT MEDICAL ACCESS FOR PATIENTS WITH... (5*)

Sa1778. . . . RISK FACTORS FOR NON-ADHERENCE TO SELF-INJECTABLE... (5*)

Sa1779. . . . WHAT HEALTH CARE EXPERIENCE DID PATIENTS... (5*)

Sa1780. . . . A VACCINATION STUDY AT A GROUP... (5*)

Sa1781. . . . MONITORING OF PREVENTIVE CARE IN PATIENTS... (3*)[Pfizer Grant]

Sa1782. . . . HIGHER INDUCTION PROPOFOL DOSING DECREASES INDUCTION... (5*)

Sa1783. . . . FASTER SEDATION TIMES FOR INFLAMMATORY BOWEL... (5*)

Sa1784. . . . SCREENING FOR MELANOMA AND NON-MELANOMA SKIN... (5*)

Sa1785. . . . OPIOID USE IN IBD PATIENTS: INCREASED... (5*)

Sa1786. . . . INFLAMMATORY BOWEL DISEASE PATIENTS' PERSPECTIVES OF... (3*)[Roche/Genentech]

Sa1787. . . . CROHN'S DISEASE: PREDICTORS OF HOSPITAL DISPOSITION... (5*)

Sa1788. . . . LOW LEVELS OF VITAMIN D AND... (5*)

Sa1789. . . . THE IMPACT OF INFLAMMATORY BOWEL DISEASE... (1*)

Sa1790. . . . A RANDOMIZED CONTROLLED TRIAL OF THE... (6*)

Sa1791. . . . USE OF A POINT-OF-CARE SCREENING TOOL... (5*)

Sa1792. . . . PATIENT-REPORTED HEALTH-RELATED QUALITY OF LIFE OUTCOMES... (3*)[Takeda]

Sa1793. . . . EFFICACY AND SAFETY OF IRON CARBOXYMALTOSE... (3*)[VIFOR]

Sa1794. . . . MODERATE ENDURANCE-AND MUSCLE TRAINING IS... (6*)[THIS STUDY WAS SUPPORTED BY THE GERMAN CROHN AND COLITIS FOUNDATION (DCCV E.V.)]

Sa1795. . . . DISEASE-SPECIFIC AVOIDANCE IS ASSOCIATED WITH FATIGUE... (5*)

Sa1796. . . . ADJUNCT PHARMACOTHERAPY USE FOR POUCH-RELATED SYMPTOMS... (5*)

Sa1797. . . . REAL WORLD USE OF THE IBD... (5*)

Sa1798. . . . ANOREXIA NERVOSA IS ASSOCIATED WITH WORSE... (5*)

Sa1799. . . . AVOIDANT/RESTRICTIVE FOOD INTAKE DISORDER IN AN... (5*)

Sa1800. . . . EFFECT OF PATIENT-REPORTED OUTCOMES, PROMIS MEASURES... (2*)

Sa1801. . . . INFLAMMATORY BOWEL DISEASE PATIENTS WITH ACTIVE... (3*)[Takeda Pharmaceuticals U.S.A., Inc.]

Sa1802. . . . NATIONAL TRENDS IN ANXIETY AND DEPRESSION... (5*)

Sa1803. . . . NATIONAL TRENDS IN ANXIETY AND DEPRESSION... (5*)

Sa1804. . . . GOALS AND CONCERNS REPORTED BY PATIENTS... (7*)

Sa1805. . . . BRAIN DERIVED NEUROTROPHIC FACTOR IS ELEVATED... (2*)

Sa1806. . . . USING A HUMAN-CENTERED DESIGN APPROACH FOR... (3*)[Takeda]

Sa1807. . . . USTEKINUMAB MAINTAINED CLINICALLY MEANINGFUL IMPROVEMENT IN... (3*)[This study was funded by Janssen Research & Development, LLC]

Sa1808. . . . C-REACTIVE PROTEIN IS ASSOCIATED WITH DEPRESSION... (5*)

Sa1809. . . . ROUTINE PSYCHOLOGICAL SCREENING IN INFLAMMATORY BOWEL... (5*)

Sa1810. . . . APPLICABILITY OF THE VISCERAL SENSITIVITY INDEX... (4*)

Sa1811. . . . PREVALENCE AND RISK FACTORS FOR SLEEP... (5*)

Sa1812. . . . EATING DISORDERS IN AN OUTPATIENT ACADEMIC... (5*)

Sa1813. . . . THE IMPACT OF INFLAMMATORY BOWEL DISEASE... (5*)

Sa1814. . . . PERCEIVED HEALTH AND ACTIVITY LIMITATIONS IN... (5*)

Sa1815. . . . PATIENT ATTITUDES REGARDING CONTINUATION AND DE-ESCALATION... (5*)

Sa1816. . . . EFFECTS OF SUBCUTANEOUS VEDOLIZUMAB ON HEALTH-RELATED... (3*)[Takeda]

Sa1817. . . . REAL WORLD PREVALENCE OF BOWEL MOVEMENT... (3*)[The study was funded by Eli Lilly and Company]

Sa1818. . . . FINDINGS FROM A LARGE SAFETY NET... (5*)

Abstract Funding Source Key

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1820. . . . THE URGENCY NUMERIC RATING SCALE (NRS)... (5*)
Sa1821. . . . THE FOOD-RELATED QUALITY OF LIFE... (2*) (4)
Sa1822. . . . WORK LIMITATION AMONG ADULTS WITH INFLAMMATORY... (5*)
Sa1823. . . . DO ESTROGEN CONTRACEPTIVES WORSEN DISEASE SEVERITY... (2*)
Sa1824. . . . A PROSPECTIVE COHORT STUDY OF ADHERENCE... (2*)
Sa1825. . . . ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM... (3*) (Takeda)
Sa1826. . . . CHRONIC OPIOID USE IN INFLAMMATORY BOWEL... (5*)
Sa1827. . . . PREGNANCY OUTCOMES IN WOMEN WITH PSORIASIS... (3*) (This study was supported by Janssen Research and Development, LLC and Janssen Biologies B.V.)
Sa1828. . . . INCIDENCE AND PREDICTORS OF FLARE IN... (5*)
Sa1829. . . . CHARACTERISTICS AND LONG-TERM OUTCOMES OF PREGNANCY-ONSET... (5*)
Sa1830. . . . FRAILTY IS INDEPENDENTLY ASSOCIATED WITH INCREASED... (6*)
Sa1831. . . . VEDOLIZUMAB LEVELS IN BREAST MILK: RESULTS... (3*) (Takeda)
Sa1832. . . . DIFFERENCE IN OUTCOMES OF HOSPITALIZATION ACROSS... (5*)
Sa1833. . . . FECAL BIOMARKERS MAY NOT ACCURATELY DETECT... (3*) (4) (TechLab, Inc)
Sa1834. . . . RACE INFLUENCES CLINICAL OUTCOMES OF PATIENTS... (4*)
Sa1835. . . . THE IMPACT OF OBESITY ON OUTCOMES... (5*)
Sa1836. . . . FRAILTY AS A RISK FACTOR FOR... (5*)
Sa1837. . . . INFLAMMATORY BOWEL DISEASE READMISSIONS IN THE... (5*)
Sa1838. . . . SAFETY AND EFFICACY OF CONTRACEPTIVE USE... (5*)

Sa1839. . . . TRENDS IN COMMON LABORATORY MARKERS DURING... (5*)
Sa1840. . . . PATIENTS WITH INFLAMMATORY BOWEL DISEASE DISCONTINUE... (5*)
Sa1841. . . . USTEKINUMAB IS SAFE IN ELDERLY CROHN’S... (5*)
Sa1842. . . . COMPARISON OF MODES OF DELIVERY AND... (1*)
Sa1843. . . . TRENDS AND RISK FACTORS OF ELDERLY-ONSET... (5*)
Sa1844. . . . ELEVATED FECAL CALPROTECTIN IN EARLY PREGNANCY... (5*)
Sa1845. . . . THE RISK OF ADVERSE PREGNANCY-RELATED OUTCOMES... (5*)
Sa1846. . . . EXCLUSIVE ENTERAL NUTRITION(EEN) IS EFFECTIVE FOR... (5*)
Sa1847. . . . DIETARY PRACTICES AND BELIEFS OF PATIENTS... (3*) (Takeda: Investigator Initiated Sponsored Research Grant)
Sa1848. . . . DIETARY PRACTICES AND BELIEFS OF BRITISH... (3*) (Takeda: Investigator Initiated Sponsored Research Grant)
Sa1850. . . . COLITIS PATIENTS WITH PSC MAY... (4*)
Sa1851. . . . LOW PREVALENCE OF NONALCOHOLIC FATTY LIVER... (4*)
Sa1852. . . . VEDOLIZUMAB DRUG LEVELS IN MATERNAL AND... (1*)
Sa1853. . . . DISPARITIES IN IBD-RELATED INPATIENT COMPLICATIONS BETWEEN... (2*) (Oriana Damas supported by NIDDK: 1K23DK117054-01A1)
Sa1854. . . . WOMEN WITH IMMUNE MEDIATED INFLAMMATORY DISEASES... (5*)
Sa1855. . . . PREGNANCY COMPLICATIONS IN WOMEN WITH INFLAMMATORY... (5*)
Sa1856. . . . FRAILTY ESTIMATED BY GERIATRIC NUTRITIONAL RISK... (2*)
Sa1857. . . . EARLY DISCONTINUATION OF ADALIMUMAB THERAPY IN... (5*)

Sa1858. . . . DISPARITIES IN SOCIOECONOMIC STATUS AND HOUSEHOLD... (2*)
Sa1859. . . . SEXUAL FUNCTION AND CONTRACEPTION USE IN... (5*)
Sa1860. . . . DOES RISK OF ADVERSE PREGNANCY-RELATED OUTCOMES... (5*)
Sa1861. . . . SHARED DECISION MAKING IN PREGNANCY IN... (2*) (3) (MSD Grant)
Sa1862. . . . FERTILITY RATE IN WOMEN WITH INFLAMMATORY... (5*)
Sa1863. . . . SNAPSHOT OF PREGNANCY-ONSET... (5*)
Sa1864. . . . PROSPECTIVE STUDY OF PHARMACOKINETICS OF INFLIXIMAB... (3*) (Research grant obtained for Mundipharma)
Sa1865. . . . ASSOCIATION BETWEEN VEDOLIZUMAB LEVELS, ANTI-VEDOLIZUMAB LEVELS... (5*)
Sa1866. . . . LOW DRUG CONCENTRATIONS AND ANTI-DRUG ANTIBODY... (3*) (7) (Biosciences, San Diego, CA)
Sa1867. . . . LOWER VEDOLIZUMAB TROUGH LEVELS BEFORE INTERVAL... (3*) (Supported by an unrestricted educational grant from Takeda)
Sa1868. . . . AN EVALUATION OF THE EXPOSURE-EFFICACY RELATIONSHIP... (3*) (Takeda)
Sa1869. . . . COMBINATION OF SERUM ENDOSCOPIC HEALING INDEX... (3*) (7) (Prometheus Biosciences, San Diego, CA)
Sa1870. . . . USTEKINUMAB LEVELS DIFFERENTIATE PATIENTS WITH ENDOSCOPICALLY... (3*) (Prometheus Laboratories)
Sa1871. . . . USTEKINUMAB LEVELS MEASURED DURING INDUCTION ARE... (3*) (Testing provided by Prometheus)
Sa1872. . . . IMMUNOGENICITY OF TUMOR NECROSIS FACTOR ANTAGONISTS... (5*)
Sa1873. . . . OBJECTIVE DISEASE ACTIVITY ASSESSMENT AND THERAPEUTIC... (3*) (TARGET PharmaSolutions, Inc. is the sponsor of TARGET-IBD.)

Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds   (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)   (3) = Industry or Commercial Entity   (4) = Institutional Funds   (5) = No Study Funding   (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)   (7) = Professional Organization (e.g. AGA, AASLD, etc.)
<table>
<thead>
<tr>
<th>Abstract Funding Source Key</th>
</tr>
</thead>
<tbody>
<tr>
<td>* = Primary Source</td>
</tr>
</tbody>
</table>

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1103. . . . ACTIVATION OF EPIDERMAL GROWTH FACTOR RECEPTOR... (2*)
Su1094. . . . THE ER STRESS SENSOR IRE1p LINKS... (2*)
Su1095. . . . DEGLYCOXYLATED AZITHROMYCIN ENHANCES INTESTINAL SMOOTH MUSCLE... (2*)
Su1096. . . . ROLE OF P21-ACTIVATED KINASE, PAK4, IN... (2*)
Su1097. . . . TLIA-MEDIATED BACTERIAL TRANSCYTOSIS BY A MLCK... (2*)[Ministry of Science and Technology, Taiwan (MoST 107-2320-B-002-041-MY3)]
Su1098. . . . FAILURE TO INDUCE OXPHOS IMPAIRS EPITHELIAL... (2*)
Su1099. . . . INHIBITION OF JAG1/NOTCH1 SIGNALING EXACERBATES INTESTINAL... (2*)
Su1100. . . . GLUCOSE-INDUCED MESENTERIC ARTERIAL RELAXATION VIA ENDOTHELUM-DEPENDENT... (4*)
Su1101. . . . DOWNREGULATION OF MITF MEDIATED AUTOPHAGIC FLUX... (4*)
Su1102. . . . EXPLORING THE MOLECULAR SIGNALING PATHWAYS OF... (4*)
Su1103. . . . VITAMIN D/VDR SIGNALING PATHWAY REGULATES COLONIC... (2*)
Su1104. . . . ALPHA-TOCOPHYLQUINONE ACTIVATES ARYL HYDROCARBON RECEPTOR AND... (4*)(2)
Su1105. . . . TRIM 21 PROTECTS FROM ULCERATIVE COLITIS... (4*)
Su1106. . . . KRÜPPEL-LIKE FACTOR 4 MODULATES GOBLET CELL... (2*)
Su1107. . . . CYTOKINE-TRIGGERED STAT ACTION PROMOTES METASTASIS THROUGH... (7*)[Crohn’s & Colitis Foundation (CCF)]
Su1108. . . . THE THYROID HORMONE NUCLEAR RECEPTOR Trα1... (2*)[6]
Su1110. . . . PS3-DREAM DIFFERENTIALLY CONTROLS TRANSCRIPTION OF CELL... (2*)
Su1111. . . . CLOCK GENE EXPRESSION LEVELS CAN... (5*)
Su1112. . . . TRANSGENIC EXPRESSION OF MICRONOA-195 DISRUPTS TUFT... (2*)
Su1113. . . . ESTABLISHING HUMAN COLONIC ORGANOIDS FROM TISSUE... (6*)[4][QGe1SA, Lausanne, Switzerland]
Su1114. . . . CILIARY NEUROTROPHIC FACTOR DEFICIENCY IS A... (2*)
Su1115. . . . SINGLE CELL RNA-SEQUENCING REVEALS AGE-ASSOCIATED ALTERATIONS... (4*)
Su1116. . . . HIGH AUTOPHAGIC VESICLE CONTENT IDENTIFIES A... (2*)
Su1117. . . . HUMAN COLONIC ORGANOIDS EXPRESS A SUBSET... (2*)[4]
Su1118. . . . THE ROLE OF BUTYRATE ON NHEB-DEFICIENT... (2*)
Su1119. . . . TERT6 PROTEIN CONTRIBUTES TO INTESTINAL CELL... (2*)
Su1120. . . . CHALLENGING THE INTESTINAL BARRIER FUNCTION IN... (5*)
Su1121. . . . THE EFFECT OF PSYCHOLOGICAL STRESS INDUCED... (5*)[4]
Su1122. . . . DEVELOPMENT OF BARRETT’S ESOPHAGUS (BE) AND... (2*)
Su1123. . . . SLFN3 AFFECTS THE MORPHOLOGICAL RESPONSE TO... (2*)
Su1124. . . . SMALL INTESTINE EPITHELIAL ORGANOIDS AS A... (4*)
Su1125. . . . A MODEL TO STUDY ISCHEMIA-REPERFUSION INJURY... (4*)
Su1126. . . . THE ESTABLISHMENT OF GASTRIC FUNDIC AND... (2*)
Su1127. . . . INTEGRATED MAPPING OF CHROMATIN ACCESSIBILITY AND... (2*)[4]
Su1128. . . . STROMAL STEM CELL NICHE COMPOSITION AND... (2*)
Su1129. . . . A NEW PHENOMIC ANALYSIS PLATFORM HIGHLIGHTS... (4*)[2]

Su1130. . . . LRIG1-BASED LINEAGE TRACING HAS DISTINCT PATTERNS... (2*)[4]
Su1132. . . . ORAL MICROBIOME COMPONENTS MIGHT DETERIORATE BARRIER... (4*)
Su1133. . . . AUTOIMMUNE ESOPHAGITIS PATIENT SAMPLES CONTAIN AUTOANTIBODIES... (4*)
Su1134. . . . ESSENTIAL ROLE OF CALCIUM SIGNALING IN... (4*)
Su1135. . . . SODIUM CAPRATE INCREASES BICARBONATE SECRETION VIA... (2*)[3][(Shire/Takeda Pharmaceuticals)]
Su1136. . . . THE GASTRIC CARDIA REVISITED: SURPRISING RESULTS... (4*)
Su1137. . . . LYMPHOCYTIC ESOPHAGITIS: IS IT A MEMDICATION... (5*)
Su1138. . . . ALLYL ISOTHIOCYANATE, AN ACTIVATOR OF TRPA1... (2*)[4](4)
Su1139. . . . ELECTROACUPUNCTURE RESTORES INTESTINAL MUCOSAL BARRIER THROUGH... (2*)[(2018 National Natural Science Foundation of China Key International Cooperative Research Project: “Mechanisms involving the brain-gut-microbiota axis in the treatment of functional dyspepsia with the theory of Balancing Digestive Functions by Regulating)]
Su1140. . . . A RISK-BASED DIAGNOSTIC ALGORITHM OPTIMIZES THE... (5*)
Su1141. . . . HEART RATE VARIABILITY IN PEOPLE WITH... (5*)
Su1142. . . . ARSENIC AS A MEDIATOR OF HEPATIC... (5*)
Su1143. . . . EFFICACY AND SAFETY OF PEMBROLIZUMAB FOR... (5*)
Su1144. . . . ENDOSCOPIC ULTRASOUND GUIDED VERTEPORFIN PHOTODYNAMIC THERAPY... (2*)
Su1145. . . . TUMOR SIZE, TUMOR STAGE, AND SURVIVAL... (2*)[6]
Su1146. . . . PANCO: AN OPEN-LABEL, SINGLE-ARM PILOT STUDY... (3*)[OncoSil Medical Ltd]
Su1147. . . . Pancreatic Ductal Adenocarcinoma (PDAC) Patient-Derived Tumor... (4*)[2]
Su1148. . . . DEPRESSION DIAGNOSIS PRECEDING AND FOLLOWING A... (5*)
Su1150. . . . OUTCOMES OF INITIAL PANCREATIC CANCER SURVEILLANCE... (4*)
Su1151. . . . DEEP LEARNING FOR HISTOLOGICAL ANALYSIS OF... (2*)
Su1152. . . . A SIMPLE MODEL TO SCREEN FOR... (5*)
Su1153. . . . NOVEL SMALL MOLECULE INHIBITOR OF ASPARTATE-β-HYDROXYLASE... (2*)
Su1154. . . . WHEN SHOULD WE OPERATE ON PANCREATIC... (2*)[[6]
Su1155. . . . BISPHOSPHONATE USE DOES NOT IMPACT SURVIVAL... (5*)
Su1156. . . . RISK FACTORS AND INCIDENCE OF PANCREATIC... (5*)
Su1157. . . . EFFICACY OF MODIFIED FOLFIRINOX AS SECOND-LINE... (5*)
Su1158. . . . HIGH MORBIDITY AND MORTALITY ASSOCIATED WITH... (5*)
Su1159. . . . FACTORS ASSOCIATED WITH "MISSED CANCERS" IN... (5*)
Su1160. . . . GENETIC RISK OF Pancreatic CANCER IN... (4*)
Su1161. . . . TRENDS IN 5-YEAR SURVIVAL RATES OF... (5*)
Su1162. . . . COMPOUNDS LN35663290 AND LN35690555 SUPPRESS GROWTH... (2*)
Su1163. . . . THE CLEARANCE OF TUMOR-DERIVED H2S BY... (5*)
Su1164. . . . EXPLOITING BIM DEPENDENCY OVERCOMES PD-L1-MEDIATED DRUG... (2*)
Su1165. . . . TARGETING NRF2 USING SPECIFIC INHIBITOR IN... (2*)[[4]
Su1166. . . . IDO1 INHIBITION AUGMENTS THE ANTI-TUMOR EFFECTS... (2*)
Su1167. . . . EXPRESSION OF PD-L1 AND CTLA-4 IMMUNOHISTOCHEMICAL... (5*)
Su1168. . . . ENHANCED EXPRESSION OF ASPARAGINE SYNTHETASE UNDER... (5*)
Su1169. . . . RNA BINDING PROTEIN IMP1 MODULATES EXOSOME... (7*)[[2]
Su1170. . . . GAIN-OF-FUNCTION OF ION CHANNEL TRPV1 REMODELS... (2*)
Su1171. . . . NADPH OXIDASES AND REACTIVE OXYGEN SPECIES... (2*)
Su1172. . . . HYDROGEN SULFIDE (H2S) INHIBITS DENDRITIC CELL... (2*)
Su1173. . . . DELETION OF THE MISMATCH REPAIR PROTEIN... (2*)[[4]
Su1174. . . . CHARACTERIZATION OF IMMUNE MICROENVIRONMENT IN LYNCH... (2*)
Su1175. . . . CLINICAL SIGNIFICANCE OF PROGRAMMED DEATH-LIGAND 1... (5*)
Su1176. . . . CELL TYPE CONTRIBUTIONS OF THE INTERLEUKIN... (2*)[[4]
Su1178. . . . LONG MYOSIN LIGHT CHAIN KINASE DOWNREGULATES... (2*)
Su1179. . . . PANETH CELL- DERIVED WNT3 SUPPORTS INTESTINAL TUMORIGENESIS... (2*)[[4]
Su1180. . . . CXCR4 EXPRESSION ASSOCIATES WITH 5-HYDROXYMETHYLCYTOSINE MODIFICATION... (2*)[[4]
Su1181. . . . THE ROLE OF INFLAMMATION IN REDOX... (2*)[[4][European Union Funds, Innovative Economy Programme]
Su1182. . . . STOOL INTERLEUKIN-1β AS A POTENTIAL DIAGNOSTIC... (2*)
Su1183. . . . DIETARY FIBER INTAKE IS NOT ASSOCIATED... (2*)
Su1184. . . . EFFICACY AND SAFETY OF MONOCLONAL ANTIBODIES... (5*)
Su1185. . . . IMMUNE CHECKPOINT INHIBITOR-RELATED COLITIS ASSESSMENT AND... (6*)[[3][Celgene (Oxford-Celgene Postdoctoral Fellowship)]
Su1186. . . . DEOXYCHOLIC ACID ENHANCES INTESTINAL LYMPHOCYTE MIGRATION... (5*)
Su1187. . . . ALMOST EVERYTHING CAUSES DIARRHEA: GASTROINTESTINAL MANIFESTATIONS... (6*)
Su1188. . . . ABDOMINAL CT SHOULD NOT BE USED... (5*)
Su1189. . . . SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN... (5*)
Su1190. . . . IS THERE AN ASSOCIATION BETWEEN SUBSTANCE... (5*)
Su1191. . . . ADULT-ONSET AUTOIMMUNE ENTEROPATHY: A SCOPING REVIEW... (5*)
Su1192. . . . CONCURRENT THERAPY WITH IMMUNE CHECKPOINT INHIBITORS... (2*)[[7]
Su1193. . . . STING ACTIVATION INDUCES REG3γ EXPRESSION IN... (2*)
Su1194. . . . MODIFICATION OF THE INFLAMMATION-RELATED PHENOTYPE OF... (2*)[[4]
Su1195. . . . DIFFERENTIAL ANTIBIOTIC AND ANTI-FUNGAL TREATMENT REQUIREMENTS... (2*)
Su1196. . . . THE ROLE OF THE SMALL INTESTINAL... (5*)
Su1197. . . . EXPLORING THE MOLECULAR BASIS OF FECAL-MICROBIAL... (4*)[[6]
Su1198. . . . METAGENOMICS AND METABOLOMICS OF THE GASTROINTESTINAL... (2*)[[7]
Su1199. . . . THE IMPACT OF BIOLOGICAL TREATMENT AND... (5*)
Su1200. . . . CLINICAL CHARACTERISTICS AND PRESENTATION OF PATIENTS... (5*)
Su1201. . . . DIFFERENCES IN SMALL INTESTINAL MICROBIOME PATTERNS... (6*)
Su1202. . . . QUANTITATIVE PCR AS A NOVEL APPROACH... (2*)
Su1203. . . . EFFECT OF FECAL MICROBIOTA TRANSPANTATION ON... (4*)
Su1204. . . . VARIATIONS OF THE MUCOSA ASSOCIATED MICROBIOTA... (2*)
Su1205. . . . GLYPHOSATE EXPOSURE ALTERS THE HOST MICROBIOME... (2*)[[4]
Su1206. . . . ASSOCIATION OF GUT MICROBIOTA WITH GASTROINTESTINAL... (5*)
Su1207. . . . PREVALENCE AND RISK FACTORS OF HELICOBACTER... (2*)

Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1208. . . . FECAL MICROBIOTA RELATED TO THE SEASONAL... (5*)
Su1209. . . . TRANSITION OF GUT MICROBIOTA IN SAME... (4*)
Su1210. . . . RESIDENT MICROBIOTA SELECTIVELY MODULATE INTESTINAL PERMEABILITY... (2*) (4)
Su1211. . . . THE FIRST STUDY TO DETERMINE THE... (6*)
Su1212. . . . THE UTILITY OF REPEATED GI PCR... (5*)
Su1213. . . . GENDER DETERMINES RESPONSE AND RECOVERY OF... (6*)
Su1214. . . . AN ALTERED COMPOSITION OF GUT MICROBIOTA... (5*)
Su1215. . . . GROWTH INHIBITION OF CLOSTRIDIUM DIFFICILE BY... (5*)
Su1216. . . . REPEAT COLONOSCOPY AND INCREASED NUMBER OF... (5*)
Su1217. . . . ECOLOGICAL AND NETWORK ANALYSES OF THE... (1*)
Su1218. . . . EVALUATION OF GUT MICROBIOTA COMPOSITION IN... (6*)
Su1219. . . . GUT MICROBIAL STRAINS AND METABOLITES IN... (2*)
Su1220. . . . ATTENUATION OF STRESS-INDUCED ACTIVATION OF SUPRASPINAL... (3*) (Ironwood Pharmaceuticals)
Su1221. . . . COMBINATION OF ESTROGENS AND EARLY LIFE... (2*)
Su1222. . . . SEX-DIFFERENCE IN THE GASTROINTESTINAL PHENOTYPE DEPENDS... (2*)
Su1223. . . . MOTILITY DYSFUNCTION AND VISCERAL HYPERSENSITIVITY PERSIST... (2*)
Su1224. . . . VASOACTIVE INTESTINAL PEPTIDE REGULATES ILEAL GOBLET... (4*) (2)
Su1225. . . . PRESSURE-INDUCED EPITHELIAL ION TRANSPORT OF THE... (2*) (7)
Su1226. . . . IN VIVO GAVAGE OF MONOSODIUM GLUTAMATE... (2*)
Su1227. . . . ROLE OF TRANSIENT RECEPTOR POTENTIAL VANILLOID... (2*)
Su1228. . . . MOR AND DOR SELECTIVE AGONISTS EVOKE... (6*)
Su1229. . . . PANETH CELL LOSS IS ASSOCIATED WITH... (2*)
Su1230. . . . IS EXERCISE THE BEST MEDICINE? EXAMINING... (5*)
Su1231. . . . VALIDATION OF AN IN VITRO HUMAN... (2*)
Su1232. . . . LIPOPOLYSACCHARIDE O-ANTIGEN SPECIFIC TRANSIENT RECEPTOR POTENTIAL... (2*)
Su1233. . . . TOWARDS A VISCERAL HYPERSENSITIVITY-ASSOCIATED MICROBIOME SIGNATURE... (2*)
Su1234. . . . THE INFLUENCE OF SEX AND THE... (2*)
Su1235. . . . ENRICHED ENVIRONMENT HOUSING ALLEVIATES POST-COLITIS PAIN... (4*)
Su1236. . . . TRP53-MEDIATED CELL CYCLE ARREST OF PRECURSORS... (2*) (7)
Su1237. . . . ALTERED STRUCTURE AND FUNCTION OF MITOCHONDRIA... (2*)
Su1238. . . . LACTOBACILLUS RHAMNOSUS GG COLONIZATION IN... (5*)
Su1239. . . . INCREASED ENTERIC NEURON NUMBER ACCOMPANIES INCREASED... (2*) (4)
Su1240. . . . EXPANSION OF INTESTINAL STEM CELLS THROUGH... (1*)
Su1241. . . . INTESTINAL INFLAMMATION ALTERS THE EXPRESSION OF... (4*)
Su1242. . . . A TWO DIMENSIONAL ENTEROID MODEL TO... (2*)
Su1243. . . . BENCH TO BED-SIDE AND BACK TRANSLATION... (2*)
Su1244. . . . DOSE-DEPENDENT EFFECTS OF SYNBIOTIC SULFORAPHANE ON... (2*)
Su1245. . . . THE ACTIVITY OF LGR5+ CRYPT BASE... (2*)
Su1246. . . . SPECIFIC BACTERIA ISOLATED FROM HUMAN BREAST... (4*) (2)
Su1247. . . . FXR AGONIST TROPIFEXOR AMELIORATES CHOLESTATIC... (4*)
Su1248. . . . DOPPLER-GUIDED SECOND-LOOK ENDOSCOPY IN PEPTIC ULCER... (4*)
Su1249. . . . FULL-THICKNESS RESECTION DEVICE (FTRD) FOR TREATMENT... (5*)
Su1250. . . . AN INGESTIBLE WIRELESS BIOSENSOR TO DETECT... (3*)
Su1251. . . . THE MAGNETIC FLEXIBLE ENDOSCOPE (MFE): A... (2*)
Su1252. . . . A TRANNASAL IMAGE-GUIDED APPROACH FOR BRUSH... (6*)
Su1253. . . . MESENTERIC ARtery CALCIUM SCORING: A POTENTIAL... (5*)
Su1254. . . . MANAGEMENT OF CARCINOID TUMORS OF THE... (5*)
Su1255. . . . DIGITAL Ki67 LABELING INDEX FOR GASTROINTESTINAL... (4*)
Su1256. . . . STRETCHABLE ADHESIVE-INTEGRATED ELECTRONICS FOR MULTI-ELECTRODE CUTANEOUS... (4*)
Su1257. . . . INTRAHEPATIC AND INTRAMESENTERIC DYNAMIC CONTRAST MAGNETIC... (1*)
Su1258. . . . INDEX ENDOSCOPY AND INTERVENTION DOES NOT... (5*)
Su1259. . . . A DIAGNOSTIC METHOD FOR GASTRIC CANCER... (5*)
Su1260. . . . THE EFFECT OF PROTON PUMP INHIBITOR... (1*)

Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1362. . . . A POPULATION-BASED STUDY COMPARING THE GASTRIC... [2*]

Su1363. . . . HELICOBACTER PYLORI ERADICATION THERAPY EFFECTIVELY IMPROVES...[5*]

Su1364. . . . ERADICATION OF HELICOBACTER PYLORI INFECTION DECREASES...[4*]

Su1365. . . . ASSOCIATIONS OF OLGA AND OLGIM STAGING...[2*]

Su1366. . . . CULTURE-GUIDED VS EMPIRICAL HIGH-DOSE PROTON PUMP...[4*]

Su1367. . . . EXHALED 13C DURING A 13C-UREA BREATH...[4*][2]

Su1368. . . . REAL TIME DETERMINATION OF H PYLORI...[5*]

Su1369. . . . INCREMENTAL YIELD OF RAPID UREASE TEST...[4*]

Su1370. . . . THE OPTIMAL CUTOFF VALUE OF SEROLOGIC...[5*]

Su1371. . . . SEROLOGY AS A DIAGNOSTIC TOOL...[5*]

Su1372. . . . HELICOBACTER PYLORI ACTIVELY SUPPRESS INNATE IMMUNE...[2*]

Su1373. . . . REGULATION OF APOPTOTIC AND DNA...[2*]

Su1374. . . . COEVOLUTIVE ANALYSIS OF HELICOBACTER PYLORI ISOLATED...[4*]

Su1375. . . . HELICOBACTER PYLORI-INDUCED CANCER-ASSOCIATED FIBROBLASTS INHIBIT TGFβ-DEPENDENT...[4*]

Su1376. . . . EFFECTIVENESS OF MAASTRICHT V GUIDELINES APPLICATION...[5*]

Su1377. . . . LEVOFLOXACIN SEQUENTIAL THERAPY VERSUS BISMUTH QUADRUPLE...[2*][4]

Su1378. . . . PHARMACOKINETICS AND EXPOSURE-RESPONSE OF RHB-105, A...[3*][Redhill Biopharma, Ltd.]

Su1379. . . . ANNUAL ERADICATION RATE OF BISMUTH-CONTAINING QUADRUPLE...[5*]

Su1382. . . . INEFFECTIVENESS OF 14-DAY VONOPRAZAN-BASED DUAL THERAPY...[4*]

Su1383. . . . CURRENT STATUS OF VONOPRAZAN-CONTAINING ERADICATION TREATMENT...[5*]

Su1384. . . . ANTIBIOTIC RESISTANCE AND ITS RELATED GENE...[2*]

Su1385. . . . EFFICACY OF PROBIOTICS COMBINED WITH BISMUTH...[5*]

Su1386. . . . CULTURE-BASED TAILOR-MAID ANTIBIOTIC REGIMEN IS THE...[5*]

Su1387. . . . POLYPHENOLIC BIOFRATIONS EXTRACTED FROM AVOCADO (PERSEA...[4*]

Su1390. . . . GASTRIC INTESTINAL METAPLASIA BEFORE AND AFTER...[1*][This work was partly supported by the Sichuan Provincial Science and Technology Department under Grant 2016[0101];Affiliated Hospital of Southwest Medical University under Grant 15039.)

Su1391. . . . EFFICACY AND SAFETY OF VONOPRAZAN, SITAFLOXACIN...[5*]

Su1392. . . . TRIPLE THERAPY IS STILL AN EFFECTIVE...[5*]

Su1393. . . . EFFICACY OF RIFABUTIN FOR THE RESCUE...[5*]

Su1394. . . . SELECTION OF CLARITHROMYCIN IN FIRST-LINE HELICOBACTER...[5*]

Su1395. . . . EFFECTS OF HELICOBACTER PYLORI ERADICATION FOR...[5*]

Su1396. . . . A HIGH-THROUGHPUT METABOLIC ASSAY AND A...[2*][4]

Su1397. . . . FACTORS PREDICTIVE OF HELICOBACTER PYLORI INFECTION...[5*]

Su1398. . . . SEVEN-DAY VONOPRAZAN AND LOW-DOSE AMOXICILLIN DUAL...[4*]

Su1399. . . . PATIENTS WITH PEPTIC ULCER BLEEDING ADMITTED...[5*]

Su1400. . . . ONE #NAME? INCIDENCE OF NON-VARICEAL UPPER...[5*]

Su1401. . . . ONE #NAME? INCIDENCE OF NON-VARICEAL UPPER...[5*]

Su1402. . . . MISOPROSTOL EXPOSURE IS NOT ASSOCIATED WITH...[5*]

Su1403. . . . CLIPPING OVER-THE-SCOPE IS COST EFFECTIVE FOR...[2*]

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1460. . . . ASSOCIATION OF FREE FATTY ACID LEVELS... (5*)
Su1461. . . . ADVERSE HEALTHCARE RESOURCE OUTCOMES IN PATIENTS... (5*)
Su1462. . . . CHOLECYSTECTOMY VS NO SURGERY IN PATIENTS... (5*)
Su1463. . . . SARCOPENIA IS ASSOCIATED WITH WORSE OUTCOMES... (5*)
Su1464. . . . HIGH MORBIDITY AND MORTALITY BURDEN OF... (5*)
Su1465. . . . DRUG-INDUCED PANCREATITIS IS THE LEADING RISK... (2*)
Su1466. . . . IMPACT OF HIV STATUS ON OUTCOMES... (5*)
Su1467. . . . USE OF NSAIDS IS ASSOCIATED WITH... (5*)
Su1468. . . . A SIMPLE ALGORITHM TO IDENTIFY BILARY... (5*)
Su1469. . . . STATIN USE IS ASSOCIATED WITH DECREASED... (5*)
Su1470. . . . INTRA-ABDOMINAL HYPERTENSION IS A STRONG PREDICTOR... (5*)
Su1471. . . . LONG TERM CONSEQUENCES OF ACUTE NECROTIZING... (5*)
Su1472. . . . SAFETY AND SUCCESS OF EARLY (<4)... (5*)
Su1473. . . . PREDICTORS OF DIABETES MELLITUS FOLLOWING DISCHARGE... (5*)
Su1474. . . . INFLUENCE OF PRE-EXISTING DIABETES MELLITUS ON... (5*)
Su1475. . . . SEVERITY OF ACUTE PANCREATITIS HOSPITALIZATIONS IN... (5*)
Su1476. . . . IDENTIFICATION OF A RISK PROFILE FOR... (5*)
Su1477. . . . TRANSITION OF CLINICAL FEATURES OF ACUTE... (5*)
Su1478. . . . EARLY (<4 WEEKS) VERSUS STANDARD... (≥... (5*)
Su1479. . . . TREND OF ACUTE PANCREATITIS IN JAPAN... (5*)
Su1480. . . . CONTROLLING GLYCEMIC HOMEOSTASIS ALLEVIATES ISLET B... (4*)
Su1481. . . . PANCREAS-DERIVED DOPAMINE INHIBITS INSULIN SECRETION IN... (2*)
Su1482. . . . THE DURABILITY OF ENDOSCOPIC ULTRASOUND-GUIDED ABLATION... (4*)
Su1483. . . . THE EFFECT OF ASPRIN ON RATE... (5*)
Su1484. . . . VALIDATION OF BASELINE CHARLSON COMORBIDITY INDEX... (5*)
Su1485. . . . INFLAMMATORY BOWEL DISEASE IS ASSOCIATED WITH... (5*)
Su1486. . . . LONG-TERM SURVEILLANCE OF LOW-RISK PRESUMED MUCINOUS... (5*)
Su1487. . . . MOLECULAR STABILITY, REGRESSION, AND PROGRESSION IN... (3*)|(Interpace Diagnostics)
Su1488. . . . APPLICATION OF A RISK STRATIFICATION TOOL... (5*)
Su1489. . . . RISK OF NEOPLASTIC PROGRESSION IN PATIENTS... (5*)
Su1490. . . . CHARACTERIZATION OF PANCREATIC INTRADUCTAL PAPILLARY NEOPLASM-DERIVED... (5*)
Su1491. . . . THE EFFECT OF STATINS ON RATE... (5*)
Su1492. . . . EUS-GUIDED PANCREATIC CYST CHEMOABLATION AS A... (5*)
Su1493. . . . THE IMPACT OF ENDOSCOPIC ULTRASOUND-GUIDED CONFOCAL... (7*)
Su1494. . . . A 10-YEAR FOLLOW-UP DESCRIBING THE NATURAL... (5*)
Su1495. . . . A MULTIDISCIPLINARY PANCREATIC CYST CONFERENCE REDUCES... (5*)
Su1496. . . . PREOPERATIVE ENDOSCOPIC ULTRASOUND (EUS) OR ENDOSCOPIC... (5*)
Su1497. . . . PREDICTORS OF ADVANCED NEOPLASIA AND LONG... (5*)
Su1498. . . . PERCENTAGE OF CYST GROWTH RATE AS... (5*)
Su1499. . . . PREVALENCE AND RISK FACTORS FOR INTRADUCTAL... (5*)
Su1500. . . . MOLECULAR ANALYSIS OF EUS-AQUIRED PANCREATIC CYST... (5*)
Su1501. . . . THE ROLE OF ENDOSCOPIC ULTRASOUND-GUIDED THROUGH-THE-NEEDLE... (5*)
Su1502. . . . PREVALENCE OF AND FACTORS INFLUENCING PANCREATIC... (5*)
Su1503. . . . RANGE OF NORMAL LIVER STIFFNESS AND... (5*)
Su1504. . . . USE OF NOVEL CYTOPLEX ASSAY TO... (4*)|(2)
Su1505. . . . HEALTH-RELATED QUALITY OF LIFE, EMOTIONAL, AND... (2*)
Su1506. . . . TRENDS AND VARIATIONS IN THE MANAGEMENT... (5*)
Su1507. . . . ESTABLISHING A PEDIATRIC TO ADULT (P2A)... (5*)|(2)
Su1508. . . . IS ULTRASOUND ENOUGH? EVALUATING IMAGING FOR... (5*)
Su1672. . . . THE EMERGING ROLE OF FRAILTY AS... (5*)
Su1673. . . . SEPSIS IS THE LEADING CAUSE OF... (5*)
Su1674. . . . HANDGRIP STRENGTH DICIINE IN CHRONIC LIVER... (5*)
Su1675. . . . BARIATRIC SURGERY IN CANDIDATES FOR LIVER... (5*)
Su1676. . . . VALIDATION OF ENCEPHALAPP STROOP FOR MINIMAL... (2*)|(3)| (Investigator initiated grant from Grifols Pharmaceuticals)
Su1677. . . . METHYLENE BLUE INFUSION FOR CRITICALLY ILL... (5*)
Su1678. . . . IMPACT OF RACE AND ETHNICITY ON... (2*)|(3)| (Investigator initiated grant from Grifols Pharmaceuticals)
Su1681. . . . THE HEPATORENAL SYNDROME PATIENT JOURNEY: PORTRAIT... (3*)|(Mallinckrodt)
Su1682. . . . URGENT ENDOSCOPY IS ASSOCIATED WITH LOWER... (5*)
Su1683. . . . PREDICTORS OF 30 AND 90 DAY... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds   (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)   (3) = Industry or Commercial Entity   (4) = Institutional Funds
(5) = No Study Funding   (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)   (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1684. ... EFFICACY OF ORAL THROMBOPOIETIN RECEPTOR AGONIST... [3*][Shionogi Inc.]

Su1685. ... SMALL INTESTINE VARICES AT A HIGH-VOLUME... [4*]

Su1686. ... COMPARING OVERALL GI AND NON-GI BLEEDING... [5*]

Su1687. ... UTILITY OF THE ENCEPHALAPP STROOP TEST... [4*]

Su1688. ... LOWER GASTROINTESTINAL BLEEDING IN PATIENTS WITH... [5*]

Su1689. ... MULTIDRUG RESISTANT BACTERIAL INFECTION CHARACTERISTICS AND... [5*]

Su1712. ... ALTERED MITOCHONDRIAL GENE EXPRESSION IN DUODENAL... [2*]

Su1713. ... MINIMAL IMPACT OF ACUTE INJECTION AND... [5*]

Su1714. ... LYROSOPHATIDIC ACID RECEPTOR EXPRESSION IS REDUCED... [2*][4]

Su1715. ... AURICULAR VAGAL NERVE STIMULATION IMPROVED DYSMOTILITY... [5*]

Su1716. ... INTRAVENOUS IMMUNOGLOBULIN IN REFRACTORY GASTROINTESTINAL PATIENTS... [5*]

Su1717. ... CHEMOKINE ELEVATION IN PATIENTS WITH THE... [4*]

Su1718. ... MEDIUM ENERGY GASTRIC ELECTRICAL STIMULATION CAN... [5*]

Su1719. ... IMPROVED GASTRIC ACCOMMODATION IN WOMEN WITH... [3*][Censa Pharmaceuticals Inc, Wellesley, MA, USA]

Su1720. ... CAN TEMPORARY GASTRIC ELECTRICAL STIMULATION HELP... [5*]

Su1721. ... THE FREQUENCY AND CLINICAL IMPLICATIONS OF... [2*]

Su1722. ... GASTROINTESTINAL VASCULAR CHANGES IN GENETIC AND... [5*]

Su1723. ... CARDIAC SAFETY AND CLINICAL EFFICACY OF... [5*]

Su1724. ... WHOLE GENOME SEQUENCING ANALYSIS OF GASTROPAARESIS... [3*]

Su1725. ... TRENDS AND SOCIOECONOMIC HEALTH OUTCOMES OF... [5*]

Su1726. ... GASTRIC PER-ORAL ENDOSCOPIC MYOTOMY (G-POEM) FOR... [5*]

Su1727. ... SUPPLEMENTATION OF 17B-ESTRADIOL normalizes RAPID GASTRIC... [2*]

Su1728. ... GASTROINTESTINAL SYMPTOMS DURING GASTRIC EMPTYING SCINTIGRAPHY... [5*]

Su1729. ... PILOTING A PROSPECTIVE PEDIATRIC GASTROPAARESIS SYMPTOM... [5*]

Su1730. ... SEX AND BODY MASS INDEX HAVE... [5*]

Su1731. ... THE RELATION BETWEEN CHANGES IN GASTRIC... [5*]

Su1732. ... OVERABUNDANCE OF HISTAMINE PRODUCING ENTEROBACTERIACEAE... [2*]

Su1733. ... TRENDS AND OUTCOMES OF IDIOPATHIC AND... [5*]

Su1734. ... MAJORITY OF HOSPITALIZED PATIENTS LABELED AS... [5*]

Su1735. ... GASTRODUODENAL MANOMETRIC AND GASTRIC EMPTYING SCINTIGRAPHIC... [5*]

Su1736. ... ALTERATION OF INTESTINAL PERMEABILITY AND EFFECT... [5*]

Su1737. ... LESSONS LEARNED FROM 8 YEARS... [5*]

Su1738. ... THE GOLDILOCKS PRINCIPLE: 24 HOUR AMBULATORY... [4*]

Su1739. ... SAFETY PHARMACOLOGY EVALUATIONS OF TAK-906, A... [3*][This study was sponsored by Altos Therapeutics, LLC. Medical writing support was provided by Alex Kisbey of Oxford PharmaGenesis, Oxford, UK and was funded by Takeda Pharmaceutical Company Ltd.]

Su1740. ... SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF... [3*][CinRx Pharma]

Su1741. ... PATHOPHYSIOLOGICAL EVIDENCE PROVIDED BY PYLORIC SMOOTH... [5*]

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1759. . . . TRANSCUTANEOUS ELECTRICAL STIMULATION JUMP-STARTS GASTRIC EMPTYING... (5*)

Su1760. . . . VISCERAL HYPOSENSITIVITY AND HYPERSENSITIVITY MASK A... (4*)

Su1761. . . . SMALL INTESTINAL BACTERIAL OVERGROWTH: IS IT... (5*)

Su1762. . . . RELATIONSHIP BETWEEN SYMPTOMS DURING A GASTRIC... (2*)

Su1763. . . . DIAGNOSTIC RISK STRATIFICATION IN POST-EGD PATIENTS... (5*)

Su1764. . . . TAK-906, A NOVEL DOPAMINE D2/D3 RECEPTOR... ([3*] (This study was sponsored by Altos Therapeutics, LLC. Formatting and editing support were provided by Oxford PharmaGenesis, Oxford, UK and funded by Takeda Pharmaceutical Company Ltd.)

Su1765. . . . GASTROPARESIS INCREASES THE RISK FOR LUNG... (5*)

Su1766. . . . DIFFERENCES IN CLINICAL PRESENTATION BETWEEN PATIENTS... (3*) (Progenity, Inc.)

Su1767. . . . FACTORS ASSOCIATED WITH BARRETT'S ESOPHAGUS IN... (5*)

Su1768. . . . PREVALENCE OF GASTROPARESIS AND FUNCTIONAL DYSPEPSIA... (3*) (This study is funded by Takeda Pharmaceutical Company Limited.)

Su1769. . . . REAL-WORLD EVIDENCE ON PREVALENCE OF GASTROPARESIS... (3*) (The study was funded by Takeda Pharmaceutical Company Limited.)

Su1770. . . . MEASUREMENT OF THE PYLORIC SPINCHTER USING... (5*)

Su1771. . . . IMPACT OF POLYP FEATURES AND COLONOSCOPIST... (2*)

Su1772. . . . MULTI-CANCER DETECTION OF EARLY-STAGE CANCERS WITH... (3*) (GRAIL)

Su1773. . . . MORE FECAL IMMUNOCHEMICAL TESTS ARE NEEDED... (3*) (Exact Sciences Corp.)

Su1774. . . . YOUNG ONSET COLORECTAL ADENOMA: A SYSTEMATIC... (2*)[7]

Su1775. . . . TWO YEARS REAL WORLD CLINICAL... (5*)

Su1776. . . . LOW RISK ADENOMAS VERSUS NO ADENOMAS... (5*)

Su1777. . . . A MULTICENTERED RETROSPECTIVE STUDY OF CLINICAL... (5*)

Su1778. . . . YIELD OF AND RISK FACTORS FOR... (4*)[2]

Su1779. . . . A RANDOMIZED CONTROLLED TRIAL OF AN... (4*)

Su1780. . . . THE "PREDICT, RESECT AND DISCARD" STRATEGY... (5*)

Su1781. . . . IMPROVEMENT OF ASIA-PACIFIC COLORECTAL SCREENING SCORE... (2*) (Supported by the National Natural Science Foundation of China (Grant No. 81770559, 81370500) and Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2016-12M-3-001))

Su1782. . . . ENDORSEMENT OF WATER EXCHANGE (WE) COLONOSCOPY... (2*)[7]

Su1783. . . . TEST CHARACTERISTICS OF FECAL IMMUNOCHEMICAL TESTS... (4*)

Su1784. . . . CHARACTERISTICS AND OUTCOMES AMONG INDIVIDUALS WITH... (2*)

Su1785. . . . ADR BY GENDER, RACE AND ETHNICITY... (5*) (Health Care Service Corporation, the parent company of Blue Cross Blue Shield of Illinois, Texas, Oklahoma, New Mexico and Montana provided the claims data and performed the statistical analysis)

Su1786. . . . HIGHER FECAL HB CONCENTRATION PREDICTS RISK... (5*)

Su1787. . . . LONG-TERM IMPACT OF A PHYSICIAN... (5*)

Su1788. . . . CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH... (2*)[4]

Su1789. . . . OPTIMAL TIMING OF SURVEILLANCE COLONOSCOPY AFTER... (4*)

Su1790. . . . THE PREVALENCE OF METACHRONOUS ADVANCED COLORECTAL... (5*)

Su1791. . . . MANDATED BOSTON BOWEL PREP SCALE IMPLEMENTATION... (5*)

Su1792. . . . IMPROVING FECAL IMMUNOCHEMICAL TESTING RATES FOR... (5*)

Su1793. . . . PROXIMAL VERSUS DISTAL COLON ADR: A... (5*) (Health Care Financing Corporation which represents Blue Cross Blue Shield of Illinois, Texas, Oklahoma, New Mexico and Montana provided the claims data for this study and contributed the statistical analysis)

Su1794. . . . UPTAKE RATE OF COLORECTAL CANCER SCREENING... (2*)

Su1795. . . . PREVALENCE AND RISK FACTORS FOR SESSILE... (6*)

Su1796. . . . GO BEFORE YOU GO: IMPLEMENTATION OF A SAME DAY... (5*)

Su1797. . . . PREVALENCE AND PREDICTORS OF COLORECTAL NEOPLASMS... (5*)

Su1798. . . . COLOGUARD POSITIVE SCREENING: REAL WORLD POSITIVE... (5*)

Su1799. . . . POLYP SIZE VERSUS NUMBER: WHAT IS... (5*)

Su1800. . . . CHARACTERIZING THE ROLE OF GAIN-OF-FUNCTION SYK... (2*)[7]

Su1801. . . . MULTI-RACIAL RISK SCORE INTEGRATION TO PREDICT... (4*)[2]

Su1802. . . . MOLECULAR PREDICTION IN INFLAMMATORY BOWEL DISEASE... (2*)

Su1803. . . . THE CLINICAL PHENOTYPE OF COLLAGENOUS COLITIS... (5*)

Su1804. . . . GENETIC ANALYSIS OF ULCERATIVE COLITIS IN... (5*)

Su1805. . . . THE LONG-TERM CORTICOSTEROID SPARING EFFECT OF... (6*)

Su1806. . . . RISK OF ANAL CANCER IN PATIENTS... (5*)

Su1807. . . . QUALITY OF LIFE, FECAL CALPROTECTIN AND... (5*)

Su1808. . . . PROVIDER RELATIONSHIPS MAY BE AN IMPORTANT... (5*)

Su1809. . . . EVALUATING ACCESS TO IBD CARE ACROSS... (2*)[4]

Su1810. . . . OUTCOMES OF IBD MANAGEMENT BASED ON... (5*)

Su1811. . . . DIFFERENCES IN CARE AND OUTCOME AMONG... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1812. . . . IDEAL VIAL SIZE FOR INFLEXIMAB IN... (5*)
Su1813. . . . COST-EFFECTIVENESS OF VEDOLIZUMAB IV VERSUS ADALIMUMAB. (3*)|(Takeda Pharmaceuticals U.S.A, Inc.)
Su1814. . . . SEVERE AND REFRACTORY CROHN'S DISEASE: PATTERNS (5*)
Su1815. . . . REAL-WORLD HEALTHCARE RESOURCE UTILIZATION AMONG PATIENTS... (3*)|(Takeda Pharmaceuticals U.S.A, Inc.)
Su1816. . . . COST-EFFECTIVENESS OF 5-ASA THERAPY IN COMBINATION... (5*)
Su1817. . . . FOCUSING ON THE FUTURE: REDUCING BARRIERS... (2*)|(4)
Su1818. . . . ANALYSIS OF VENOUS THROMBOEMBOLISM PROPHYLAXIS NON-ADHERENCE... (6*)
Su1819. . . . THE EFFECTIVENESS OF A STANDARDIZED BIOLOGIC... (5*)
Su1820. . . . A SYSTEMATIC REVIEW: ARE THE QUALITY... (5*)
Su1821. . . . SAME-PAGE CARE IS ASSOCIATED WITH IMPROVED... (6*)
Su1822. . . . POOR PATIENT-REPORTED OUTCOMES WERE OBSERVED IN... (3*)|(This study was sponsored by Corrona, LLC. Corrona is supported through contracted subscriptions with multiple pharmaceutical companies. The abstract was a collaborative effort between Corrona and Bristol-Myers Squibb with financial support provided by Bri)
Su1823. . . . PATIENT AND PHYSICIAN PERSPECTIVES ON THE... (3*)|(Gegle Corporation)
Su1824. . . . CONSIDERABLE WORK PRODUCTIVITY LOSS IN PATIENTS... (3*)|(This study was sponsored by Corrona, LLC. Corrona is supported through contracted subscriptions with multiple pharmaceutical companies. The abstract was a collaborative effort between Corrona and Bristol-Myers Squibb with financial support provided by Bri)
Su1825. . . . QUALITY OF LIFE AND EFFECTIVENESS OF... (3*)|(This study had a financial support of Takeda Pharma GmbH)
Su1826. . . . CROHN'S DISEASE EXPERIENCES AMONG A PEDIATRIC... (3*)|(Eli Lilly and Company)
Su1827. . . . ALIGNMENT OF IBD SYMPTOMS REPORTED BY... (3*)|(Study sponsored by: Jansen Scientific Affairs, LLC, Horsham, PA, USA)
Su1828. . . . PATIENTS WITH IBD SEEK EXTRA SUPPORTIVE... (5*)
Su1829. . . . ASSOCIATIONS BETWEEN DIETARY INTAKE, PHYSICAL ACTIVITY... (2*)
Su1830. . . . PATIENT REPORTED IBD CONTROL SCORES CORRELATES... (5*)
Su1831. . . . MEASURING VALUE: IDENTIFYING A BALANCED MEASURE... (6*)
Su1832. . . . USE OF CLINICAL INFLAMMATORY BOWEL DISEASE... (2*)
Su1833. . . . THE PREVALENCE AND PREDICTORS OF FUTILE... (5*)
Su1834. . . . ACCURACY OF SELF-REPORTED VACCINATION STATUS IN... (1*)
Su1835. . . . WHAT IS THE INCIDENCE OF HERPES... (5*)
Su1836. . . . THE QUALITY AND REPORTING OF INFLAMMATORY... (5*)
Su1837. . . . OPIOID USE AMONG PATIENTS WITH INFLAMMATORY... (5*)
Su1838. . . . A COCHRANE REVIEW OF INTERVENTIONS FOR... (2*)|[Non-applicable]
Su1839. . . . INTERVENTIONS FOR MANAGING IRON DEFICIENCY... (2*)
Su1840. . . . EFFECTIVENESS OF DOSE DE-ESCALATION OF BIOLOGIC... (5*)
Su1841. . . . INCREASED RISK OF ANTIBODY TO... (5*)
Su1842. . . . RISK OF NEW OR RECURRENT CANCERS... (5*)
Su1843. . . . SUPRA-THERAPEUTIC LEVELS OF INFLEXIMAB DO NOT... (5*)
Su1845. . . . THE SAFETY OF ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY... (5*)
Su1846. . . . SARCOPENIA PREDICTS INFECTION IN PATIENTS WITH... (5*)
Su1847. . . . ABDOMINAL VISCERAL-TO-SUBCUTANEOUS FAT INDEX IS ASSOCIATED... (5*)
Su1848. . . . META-ANALYSIS OF THE INCIDENCE OF DERMATOLOGICAL... (5*)
Su1849. . . . THE SAPPHIRE REGISTRY: SAFETY OF IMMUNOSUPPRESSION... (6*)
Su1850. . . . RISK OF INCIDENT PARADOXICAL IMMUNE-MEDIATED INFLAMMATORY... (6*)
Su1851. . . . RISK OF PRIMARY GASTROINTESTINAL LYMPHOMA IN... (5*)
Su1852. . . . EFFECTS OF VEDOLIZUMAB ON EXTRAINTESTINAL MANIFESTATIONS... (5*)
Su1853. . . . CHARACTERISTICS OF SKIN LESIONS ASSOCIATED WITH... (4*)
Su1854. . . . MALES WITH INFLAMMATORY BOWEL DISEASE TAKING... (4*)
Su1855. . . . RISK OF HEPATITIS FLARE IN PATIENTS... (5*)
Su1856. . . . SEROCONVERSION FOR LATENT TUBERCULOSIS IN TRAVELLERS... (4*)
Su1857. . . . SAFETY OF TOFACITINIB ON POSTOPERATIVE OUTCOMES... (5*)
Su1858. . . . SEVERITY OF HEPATIC STEATOYSIS AND... (7*)|(4)
Su1859. . . . METABOLIC EFFECTS OF SYSTEMIC CORTICOSTEROID USE... (5*)
Su1860. . . . HIGHER VEDOLIZUMAB SERUM LEVELS DO NOT... (5*)
Su1861. . . . MULTICENTER SURVEY ON MESALAMINE INTOLERANCE IN... (5*)
Su1862. . . . POOLED SAFETY ANALYSES FROM PHASE 3... (3*)|(Gilead Sciences, Galapagos NV)
Su1863. . . . PREOPERATIVE VEDOLIZUMAB THERAPY IS ASSOCIATED WITH... (5*)
Su1864. . . . VEDOLIZUMAB IS SAFE IN VETERAN PATIENTS... (5*)
Su1865. . . . PANETH CELL PHENOTYPE AT ILEAL RESECTION... (4*)
Su1866. . . . A PRGNOSTIC MODEL AND NOMOGRAM PREDICTING... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CIPA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1867. . . . BIG DATA ANALYTICS DEMONSTRATE A NOVEL,... (2*)

Su1868. . . . EPIGENETIC PREDICTION OF CROHN'S DISEASE RECURRENCE:... (2*)

Su1869. . . . FAecal CALPROTECTIN IS A USEFUL NON-INVASIVE... (4*)

Su1870. . . . WHEN LESS IS MORE AND MORE... (4*)

Su1871. . . . VALIDATION OF THE RED FLAGS INDEX... (3*)](Takeda)

Su1872. . . . TRENDS IN FAecal CALPROTECTIN LEVELS... (5*)

Su1873. . . . HOSPITALIZATIONS FOR ACUTE HERPES AND VARICELLA... (5*)

Su1874. . . . USEFULNESS OF THE FAecal CALPROTECTIN AS... (4*)

Su1875. . . . PROSPECTIVE VALIDATION OF FAecal CALPROTECTIN AS... (5*)

Su1876. . . . 10 YEAR TRENDS OF RADIATION SPARING... (5*)

Su1877. . . . ENRICHMENT OF POST-TRANSLATIONAL MODIFICATIONS IN INFLAMMATORY... (4*)

Su1878. . . . ENHANCED MESENTERIC FAT VOLUME - A... (5*)

Su1879. . . . NOVEL APPROACH TO BIND AND SPECIFICALLY... (2*)

Su1880. . . . MACHINE LEARNING APPROACHES VALIDATE SEROLOGICAL MARKERS... (4*)

Su1881. . . . MULTIPLE ENDOPHENOTYPES OF ULCERATIVE COLITIS CORRELATE... (2*)

Su1882. . . . ENDOSCOPIC ASSESSMENT IN ACUTE SEVERE ULCERATIVE... (5*)

Su1883. . . . THROMBOCYTOSIS IN ACUTE INFLAMMATORY BOWEL DISEASE... (5*)

Su1884. . . . A MUCOSAL MARKER PREDICTING TOFACITINIB INDUCED... (3*)](Research Grant by Pfizer.)

Su1885. . . . SCREENING FOR STEATOHEPATITIS AND FIBROSIS AMONG... (5*)

Su1886. . . . OXIDATIVE STRESS CORRELATES WITH DISEASE ACTIVITY... (2*)](European Union Funds, Innovative Economy Programme)

Su1887. . . . POINT-OF-CARE BOWEL ULTRASOUND FOR DETECTING ILEO-COLONIC... (5*)

Su1888. . . . INTESTINAL ULTRASOUND THROUGHOUT PREGNANCY IN INFLAMMATORY... (5*)

Su1889. . . . INTER-OBSERVER AGREEMENT OF AN EXPERT PANEL... (5*)

Su1890. . . . ULCERATIVE COLITIS PATIENTS WITH QUIESCENT OR... (4*)](6)

Su1891. . . . THE IMPACT OF HUMAN IMMUNODEFICIENCY VIRUS... (5*)

Su1892. . . . A SINGLE CENTRE CROSS SECTIONAL COHORT... (1*)

Su1893. . . . ENHANCED MESENTERIC FAT VOLUME IS ASSOCIATED... (2*)](4)

Su1894. . . . ILEAL OR COLONIC HISTOLOGIC ACTIVITY DOES... (5*)

Su1895. . . . PREVALENCE AND CLINICAL SIGNIFICANCE OF ANASTOMOTIC... (5*)

Su1896. . . . VALIDATION OF DISEASE SEVERITY INDEX FOR... (2*)

Su1897. . . . TRANSMURAL HEALING WITH VEDOLIZUMAB IN PATIENTS... (3*)](Takeda)

Su1898. . . . ASSOCIATION BETWEEN SERUM AND TISSUE PROTEIN... (5*)

Su1899. . . . PATIENT-REPORTED OUTCOMES (PRO-2) AND INTESTINAL ULTRASOUND... (3*)

Su1900. . . . DIAGNOSTIC ACCURACY OF A SERUM-BASED BIOMARKER... (3*)](Research support from Prometheus Biosciences.)

Su1901. . . . SCORING... (5*)

Su1902. . . . A SERUM BIOMARKER PANEL CAN ACCURATELY... (5*)](Research support from Prometheus Biosciences.)

Su1903. . . . THE PREVALENCE AND PROGNOSIS OF DIFFUSE... (5*)

Su1904. . . . CAN WE PREDICT THE PRESENCE OF... (5*)

Su1905. . . . CORRELATION BETWEEN MICROBIAL MARKERS AND FAecal... (5*)

Su1906. . . . A STOOL MARKER-BASED STRATEGY TIMELY AND... (5*)

Su1907. . . . GLUCOCORTICOID METABOLISM IS ASSOCIATED WITH DISEASE... (4*)

Su1908. . . . NEUTrophIL-TO-LYMPHOCYTE RATIO IS ASSOCIATED WITH DISEASE... (4*)

Su1909. . . . PERIPHERAL BLOOD MONOCYTOSIS IS ASSOCIATED WITH... (5*)

Su1910. . . . EFFECT OF HISTOLOGICAL ACTIVITY ON CLINICAL... (5*)

Su1911. . . . CORRELATION BETWEEN HISTOLOGIC AND ENDOSCOPIC SCORING... (5*)

Su1912. . . . CDEIS SCORE OF 2 IS OPTIMAL... (2*)

Su1913. . . . MAGNITUDE OF INCREMENTAL BENEFIT OF ACHIEVING... (2*)

Su1914. . . . NOVEL SERUM SOLUBLE MARKERS OF HISTOLOGICAL... (5*)

Su1915. . . . CHANGES IN THE INTESTINAL MICROBIOTA OF... (2*)](This work was supported by a grant from the National Research Foundation (NRF) of Korea, funded by the Korea government (MSIP) (number: 2014R1A2A11052136, 2017R1A2B4006767, and 2019R1A2C2010404.)

Su1916. . . . RAPID HISTO-ENDOSCOPIC MUCOSAL HEALING WITH... (3*)](This post-hoc analysis was entirely funded by Dr. Falk Pharma GmbH.)

Su1917. . . . FAecal MELOPOEROXIDASE - A POTENTIAL NON-INVASIVE... (1*)](New Zealand Society of Gastroenterology Research Fellowship Grant)

Su1918. . . . CROHN'S DISEASE SMALL BOWEL STRICTURES: DEVELOPMENT... (4*)

Su1919. . . . DIFFERENCES IN EXTRA CELLULAR MATRIX REMODELING... (4*)

Su1920. . . . DETECTION AND CHARACTERIZATION OF EXTRA-INTESTINAL MANIFESTATIONS... (3*)](Acknowledgements: This research was funded by a grant from Abbvie.)

Su1921. . . . THE ESCALATION OF THERAPY OR INTERVENTION... (5*)

Su1922. . . . NEUTrophIL TO LYMPHOCYTE RATIO (NLR) AND... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1923. . . . DIAGNOSTIC ACCURACY OF A HOME-PERFORMED FECAL... (5*)
Su1924. . . . CIRCULATING EXTRACELLULAR VESICLES CORRELATE WITH DISEASE... (4*)[(2)
Su1925. . . . EARLY PREDICTION OF OUTCOME IN ACUTE... (5*)
Su1926. . . . FECAL CALPROTECTIN AND C-REACTIVE PROTEIN LEVELS... (3*)[(Arena Pharmaceuticals, Inc.)
Su1927. . . . GASTROINTESTINAL IMAGING IN CHRONIC GRANULOMATOUS DISEASE... (2*)
Su1928. . . . EVALUATING ASSOCIATION BETWEEN FECAL CALPROTECTIN AND... (3*)[(Genentech, Inc.)
Su1929. . . . A HYBRID APPROACH OF HANDLING MISSING... (3*)[(Takeda)
Su1930. . . . PCR CYCLE TIME AND CLOSTRIDIODES DIFFICILE... (5*)
Su1931. . . . PATIENT-REPORTED SYMPTOMS OVER A PERIOD OF... (5*)
Su1932. . . . COMPARISON OF PROSTAGLANDIN E–MAJOR URINARY METABOLITE... (1*)
Su1933. . . . FECAAL CALPROTECTIN AS THERAPEUTIC TARGET IN... (5*)
Su1934. . . . A DIRECT COMPARISON OF FECAL CALPROTECTIN... (5*)
Su1935. . . . PERIANAL EXAMINATION AT TIME OF COLONOSCOPY... (5*)
Su1936. . . . HISTOLOGIC INFLAMMATION DEFINED BY THE ROBARTS... (5*)
Su1937. . . . PREDICTORS OF PROGNOSIS AND OUTCOMES AFTER... (2*)
Su1938. . . . PATIENT REPORTED OUTCOMES: THE ICHOM STANDARD... (5*)
Su1939. . . . DEMOGRAPHIC DATA AND THERAPY BEFORE PROCTOCOLECTOMY... (4*)
Su1940. . . . ACUTE SEVERE ULCERATIVE COLITIS IN PREGNANCY... (5*)
Su1941. . . . READMISSION RELATED HEALTH CARE UTILIZATION AND... (5*)
Su1942. . . . IMPACT OF EXTRA-INTESTINAL MANIFESTATION ON HEALTH... (5*)
Su1943. . . . THE ROLE OF ANTIMICROBIAL MARKERS IN... (3*)[(Prometheus Laboratories covered the costs for the serological analyses.)
Su1944. . . . IMPACT OF CIRRHOSIS ON OUTCOMES IN... (5*)
Su1945. . . . IMPACT OF COLONOSCOPY ON OUTCOMES FOR... (5*)
Su1946. . . . IMMUNOGLOBULIN DEFICIENCIES IN PATIENTS WITH INFLAMMATORY... (2*)
Su1947. . . . ABDOMINAL PAIN IS INDEPENDENTLY ASSOCIATED WITH... (4*)
Su1948. . . . BURDEN OF DISEASE: SUBSTANCE ABUSE IN... (5*)
Su1949. . . . INCIDENCE OF OCCULT COLORECTAL CANCER IN... (4*)
Su1950. . . . PHENOTYPE AND NATURAL HISTORY OF INFLAMMATORY... (5*)
Su1951. . . . PRE-POUCH ILEITIS IS A RISK FACTOR... (5*)
Su1952. . . . SEROLOGICAL AND GENETIC MARKERS ARE ASSOCIATED... (5*)
Su1953. . . . THE NATURAL HISTORY OF COLECTOMY AMONG... (4*)
Su1954. . . . COLITIS DUE TO CYTOMEGALOVIRUS ASSOCIATED WITH... (5*)
Su1955. . . . EAST VERSUS WEST: INDICATIONS, POSTOPERATIVE MANAGEMENT... (5*)
Su1956. . . . PERIPHERAL BLOOD EOSINOPHILIA IS ASSOCIATED WITH... (5*)
Su1957. . . . ELDERLY-ONSET INFLAMMATORY BOWEL DISEASE IS ASSOCIATED... (5*)
Su1958. . . . CUMULATIVE RISK OF SURGERY IN PATIENTS... (2*)
Su1959. . . . NATURAL HISTORY OF ELDERLY-ONSET INFLAMMATORY BOWEL... (2*)
Su1960. . . . THIRTY DAY READMISSIONS AMONG PATIENTS WITH... (5*)
Su1961. . . . DECREASING PREVALENCE OF INFLAMMATORY BOWEL DISEASE... (5*)
Su1962. . . . DECREASING PREVALENCE OF CLOSTRIDIODES DIFFICILE INFECTION... (5*)
Su1963. . . . THE PREVALENCE OF STROKE IS INCREASED... (5*)
Su1964. . . . IMPACT OF HAVING INFLAMMATORY BOWEL DISEASE... (5*)
Su1965. . . . INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNOBIOLOGIC... (5*)
Su1966. . . . BIOLOGIC INITIATION WITHIN 12 MONTHS OF... (3*)[(Eli Lilly and Company)
Su1967. . . . DISEASE BURDEN AND PATIENT-REPORTED OUTCOME MEASURES... (5*)
Su1968. . . . LOW BIOSIMILAR USE IN PATIENTS WITH... (5*)
Su1969. . . . TRENDS IN IMMUNOMODULATOR AND BIOLOGIC USE... (5*)
Su1970. . . . BARIATRIC SURGERY IN INFLAMMATORY BOWEL DISEASE... (5*)
Su1971. . . . REAL-WORLD EFFECTIVENESS AND SAFETY OF USTEKINUMAB... (5*)
Su1972. . . . INCIDENCE OF POUCHITIS AND ANTIBIOTIC PRESCRIBING... (5*)
Su1973. . . . OUTCOMES OF FECAL DIVERSION FOR PERIANAL... (5*)
Su1974. . . . FATIGUE IS THE SELF-REPORTED SYMPTOM IN... (2*)
Su1975. . . . CREATION OF A PROSPECTIVE, LONGITUDINAL ADULT... (6*)[(5)
Su1976. . . . THE PREVALENCE OF INCIDENTAL TERMINAL ILEITIS... (5*)
Su1977. . . . HIGH VOLUMES OF SKELETAL MUSCLE AND... (5*)
Su1978. . . . PROTEIN ENERGY MALNUTRITION IS ASSOCIATED WITH... (5*)
Su1979. . . . NOVEL ASSOCIATIONS OF ADIPOSE TISSUE (AT)... (2*)
Su1980. . . . THE GEM PROJECT: IMPAIRED GUT BARRIER... (6*)[(2)
Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (Grant no. NRF-2017R1D1A1B03034172))

Su2020. … ENDOSCOPIC SLEEVE GASTROPLASTY AND POST-PROCEDURAL NUTRITIONAL... (5*)

Su2021. … THE ROLE OF MALNUTRITION IN THE... (5*)

Su2022. … PROGNOSTIC ROLE OF ZINC DEFICIENCY ASSOCIATED... (5*)

Su2023. … NUTRITIONAL IMPLICATIONS RELATED TO FOLLOWING A... (2*)

Su2019. … GLYCINE PROTECTS FROM TLR4 AND NLRP3... (2*)

Su2018. … ADJUNCTIVE EXACERBATION,... (5*)

Su2017. … OBSERVED REDUCTION IN TIME EMERGENCY DEPARTMENT... (5*)

Su2016. … NUTRITIONAL MALNUTRITION IN THE... (2*)

Su2015. … PROGNOSTIC ROLE OF ZINC DEFICIENCY ASSOCIATED... (5*)

Su2014. … NUTRITIONAL IMPLICATIONS RELATED TO FOLLOWING A... (2*)

Su2013. … NUTRITIONAL IMPLICATIONS RELATED TO FOLLOWING A... (2*)

Su2012. … THE ASSOCIATION OF SELF-REPORTED METABOLIC RISK... (2*)

Su2011. … THE EFFECT OF DIET COMPOSITION ON... (4*)

Su2010. … SEX DIFFERENCES IN THE ASSOCIATION BETWEEN... (5*)

Su2009. … AN ANALYSIS OF THE BURDEN OF... (5*)

Su2008. … A PHASE III STUDY OF TEDUGLUTIDE... (3*)

Su2007. … APRAGLUTIDE, A NOVEL LONG-ACTING GLUCAGON-LIKE PEPTIDE-2... (3*)

Su2006. … MEGACYSTIS MICROCOLON INTESTINAL HYPERPERISTALIS SYNDROME: A... (5*)

Su2005. … α-GLYCERYLHYDROIC ACID, A COMPOUND EXTRACTED FROM... (2*)

Su2004. … ILEAL MUCOSA-ASSOCIATED MICROBIOME SIGNATURE IN CHILDREN... (5*)

Su2003. … MAPPING OF THE BACTERIAL AND FUNGAL... (4*)

Su2002. … THE IMPACT OF SOCIAL DETERMINANTS OF... (2*)

Su2001. … EFFECTIVENESS OF ONE-STOP COLORECTAL AND BREAST... (6*)

Su2000. … ABNORMAL EATING PATTERN AND RISK OF... (2*)

Su1999. … PERIODONTAL DISEASE, TOOTH LOSS AND RISK... (7)

Su1998. … ENVIRONMENTAL EFFECT OF RESOLVED HUMAN CMV... (6)

Su1997. … DIABETES AND METABOLIC DISORDER IN... (5*)

Su1996. … THE MACHINE LEARNING ALGORITHM CAN HELP PREDICT... (5*)

Su1995. … MACHINE LEARNING ALGORITHM CAN HELP PREDICT... (5*)

Su1994. … ORAL IRON THERAPY PROMOTES A PROINFLAMMATORY... (4*)

Su1993. … DIABETES AND Pancreatic Cancer: A POPULATION-BASED... (5*)

Su1992. … THE FREQUENCY OF METABOLIC DISORDER IN... (5*)

Su1991. … GENDER-SPECIFIC EFFECT OF DIETARY AND PHYSICAL... (4*)

Su1990. … LncRNA ZFAS1 INTERACTS WITH POLYADENYLATED-BINDING PROTEIN... (2*)

Su1989. … AGE-SPECIFIC HEALTHCARE UTILIZATION TRENDS IN A... (4*)

Su1988. … ENVIRONMENTAL EFFECT OF RESOLVED HUMAN CMV... (2*)

Su1987. … THE IMPACT OF SOCIAL DETERMINANTS OF... (2*)

Su1986. … TRENDS IN INFLAMMATORY BOWEL DISEASE (IBD)... (3*)

Su1985. … ENROLLMENT CHARACTERISTICS OF ULCERATIVE COLITIS AND... (5*)

Su1984. … CLINICAL PRESENTATION AND OUTCOMES OF PRIMARY... (5*)

Su1983. … AN UPDATE ON CLINICAL OUTCOME AND... (5*)

Su1982. … HIGHER LEVELS OF FECAL CALPROTECTIN PREDICT... (5*)

Su1981. … TRENDS IN... (3*)

Su1980. … BACTERIAL AND FUNGAL... (5*)

Su1979. … AGE-SPECIFIC HEALTHCARE UTILIZATION TRENDS IN A... (4*)

Su1978. … ENVIRONMENTAL EFFECT OF RESOLVED HUMAN CMV... (2*)

Su1977. … THE IMPACT OF SOCIAL DETERMINANTS OF... (2*)

Su1976. … THE MACHINE LEARNING ALGORITHM CAN HELP PREDICT... (5*)

Su1975. … MICROBIOLOGICAL AND IMMUNOLOGICAL INFLAMMATORY IMMUNE RESPONSES... (4*)

Su1974. … ORAL IRON THERAPY PROMOTES A PROINFLAMMATORY... (4*)

Su1973. … DIABETES AND Pancreatic Cancer: A POPULATION-BASED... (5*)

Su1972. … THE FREQUENCY OF METABOLIC DISORDER IN... (5*)

Su1971. … TRENDS IN INFLAMMATORY BOWEL DISEASE (IBD)... (3*)

Su1970. … HIGHER LEVELS OF FECAL CALPROTECTIN PREDICT... (5*)

Su1969. … CLINICAL PRESENTATION AND OUTCOMES OF PRIMARY... (5*)

Su1968. … ENVIRONMENTAL EFFECT OF RESOLVED HUMAN CMV... (2*)

Su1967. … THE IMPACT OF SOCIAL DETERMINANTS OF... (2*)

Su1966. … THE MACHINE LEARNING ALGORITHM CAN HELP PREDICT... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1015. . . GLOBAl INCIDENCE AND MORTALITY OF ESOPHAGEAL... (5*)
Mo1016. . . EPIDEMIOLOGY OF CARCINOID TUMORS OF THE... (5*)
Mo1017. . . THE ASSOCIATION OF MODIFIABLE RISK FACTORS... (2*)
Mo1018. . . TUMOR LOCATION IS AN INDEPENDENT PREDICTOR... (5*)
Mo1019. . . DOES LIVING REMOTELY IMPACT ACCESS TO... (5*)
Mo1020. . . THE GLOBAL REALITY OF GASTRIC CANCER... (2*)
Mo1021. . . TRENDS IN MORTALITY FROM YOUNG-ONSET GASTRIC... (4*)
Mo1022. . . PANCREATIC CANCER IN HISPANIC PATIENTS: A... (5*)
Mo1023. . . DOES LIVING REMOTELY IMPACT STAGE OF... (5*)
Mo1024. . . LOWER INCOME LEVEL IS ASSOCIATED WITH... (5*)
Mo1025. . . TRENDS IN ACCESS TO TESTING/TREATMENT FOR... (5*)
Mo1026. . . YIELD OF OUTPATIENT ENDOSCOPY FOR DYSPEPSIA... (5*)
Mo1027. . . GLOBAL INCIDENCE, MORTALITY AND TEMPORAL TREND... (5*)
Mo1028. . . HPV16 LINEAGE B IS ASSOCIATED WITH... (2*)
Mo1029. . . NEW NASH BASED SCREENING CRITERIA ENHANCES... (5*)
Mo1030. . . COMPLICATIONS OF METABOLIC SYNDROME MAY DISTINGUISH... (5*)
Mo1031. . . PROTECTIVE ROLE OF THE PRO-RESOLVING LIPID... (4*)
Mo1032. . . THE CDC42/RAC NUCLEOTIDE EXCHANGE FACTOR,... (2*)
Mo1033. . . EFFECT AND MECHANISMS OF CONSTITUTINE TL1A... (4*)
Mo1034. . . INTESTINAL PROTECTION INDUCED BY TREATMENT WITH... (4*)
Mo1035. . . EFFECTS OF ASIV ON INTESTINAL EPITHELIAL... (1*)
Mo1036. . . SUB-MUCOSAL COLLAGEN DEPOSITION IS ASSOCIATED WITH... (5*)
Mo1037. . . PDGFC SIGNALING IS A POTENTIAL THERAPEUTIC... (2*)
Mo1038. . . ACTL6A DRIVES GASTRIC CANCER PROGRESSION THROUGH... (2*)
Mo1039. . . EARLY DETECTION OF ESOPHAGEAL ADENOCARCINOMA PROGRESSION... (4*)
Mo1040. . . THE ROLE OF MKP-5-P38/MAPK PATHWAY IN... (2*)
Mo1041. . . PROBIOTIC-DERIVED FERRICHROME INHIBITS THE GROWTH OF... (4*)
Mo1042. . . COLORECTAL CANCER ASSOCIATED-E. COIL INDUCE THE... (2*)
Mo1043. . . Porphyrin combined use accelerates chemotherapeutic effects... (5*)
Mo1044. . . VERTEPORFIN INHIBITS THE GROWTH OF BOTH... (4*)
Mo1045. . . EFFECTS OF 17β-ESTRADIOL ON COLORECTAL CANCER... (2*)
Mo1047. . . PLATELET-DERIVED GROWTH FACTOR(PDGF) REGULATES MESENCHYAL STEM... (4*)
Mo1048. . . EXOSOME-DELIVERED circRNA_1400 REGULATES... (5*)
Mo1049. . . CXCL1 AND MASPIN EXPRESSION IN INCOMPLETE... (4*)
Mo1050. . . CABOZANTINIB TREATMENT OF PANCREATIC DUCTAL... (4*)
Mo1051. . . CD44 VARIANT ISOFORM 9 AND ITS... (4*)
Mo1052. . . FUSOBACTERIUM CONTRIBUTES TO COLORECTAL CANCER METASTASIS... (2*)
Mo1053. . . REDUCED ANGIOTENSIN II TYPE 2 RECEPTOR... (2*)
Mo1054. . . TGR5 IS INVOLVED IN BILE ACIDS... (2*)
Mo1055. . . EXTREMELY SENSITIVE NEXT GENERATION SEQUENCING MUTATION... (4*)
Mo1056. . . PRIMARY SCLEROSING CHOLANGITIS-RELATED CHOLANGIOCARCINOMA PROLIFERATES FASTER... (5*)
Mo1057. . . GENETIC CHARACTERIZATION OF MOLECULAR TARGETS IN... (4*)
Mo1058. . . TRENDS IN ACCESS TO ENDOSCOPY FOR DYSPEPSIA... (5*)
Mo1059. . . NEW FECAL BACTERIAL SIGNATURE OF COLORECTAL... (2*)
Mo1060. . . THE GALNT14 GENOTYPE PREDICTS POSTOPERATIVE OUTCOME... (4*)
Mo1061. . . IDENTIFICATION OF A NOVEL EXTRACELLULAR MATRIX... (5*)
Mo1062. . . MATRIX GLA PROTEIN PROMOTES COLON CANCER... (4*)
Mo1063. . . GENOMEWIDE TRANSCRIPTOMIC PROFILING IDENTIFIES A NONINVASIVE... (5*)
Mo1064. . . ETV1 ASSESSMENT USING EUS-FNA SAMPLE IS... (5*)
Mo1065. . . CLINICOPATHOLOGICAL SIGNIFICANCE OF CD44, CD44 VARIANTS,... (5*)
Mo1066. . . GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) IS HIGHLY... (2*)
Mo1067. . . HSP70 AS A MOLECULAR MARKER FOR... (2*)
Mo1068. . . SCREENING BIOMARKERS ASSOCIATED WITH GASTRIC CANCER... (2*)
Mo1069. . . GASTRIC JUICE PIR-1245: A PROMISING PROGNOSTIC... (5*)
Mo1070. . . THE FIRST EVIDENCE FOR SLFN11 EXPRESSION... (2*)
Mo1071. . . CANCER NUCLEAR FEATURES EXTRACTED FROM PATHOLOGY... (2*)
Mo1072. . . EARLY MONITORING OF PLASMA METHYLATED SEPTIN... (4*)
Mo1073. . . NOVEL FECAL PROTEIN BIOMARKER TEST FOR... [6(*)](2[)](1)(Sciences)
Mo1074. . . THE ROLE OF USTERINUMAB IN COLORECTAL... (5*)
Mo1075. . . SYSTEMATIC CHARACTERIZATION OF PROGNOSTIC VALUES OF... (2*)
Mo1076. . . SPATIALLY RESOLVED ANALYSIS OF FAECAL METABOLITES... (2*)\[3[)](Waters Corporation)
Mo1077. . . EPGENETIC AGE ACCELERATION AND COLORECTAL SURGERY... (2*)
Mo1078. . . ARSENIC INDUCES DOWREGULATION ON TUMOR SUPPRESSOR... (4*)
Mo1081. . . LYMPH NODE INVOLVEMENT IN GASTRIC ADENOCARCINOMA... (5*)
Mo1082. . . KCNQ1OT1, THE LARGEST NON-CODING RNA OF... (4*)
Mo1083. . . MACHINE LEARNING-BASED PREDICTIVE MODELS ARE MORE... (5*)
Mo1084. . . GENOMIC PROFILING IDENTIFIES A NOVEL BIOMARKER... (5*)
Mo1086. . . MALIGNANT CONVERSION BASED ON NATURAL HISTORY... (5*)
Mo1087. . . THE EFFICACY OF PDT USING 5-AMINOLEVULINIC... (4*)
Mo1088. . . THE DIAGNOSTIC ROLE OF 18F-FLOURODEOXYGLUCOSE POSITRON... (5*)
Mo1089. . . HIGHER INCIDENCE OF ADVANCED GASTRIC NEOPLASMS... (5*)
Mo1090. . . TRENDS IN INCIDENCE AND STAGE AT... (2*)\[This study was supported by grants from the National Natural Science Foundation of China (Grant No. 81660040 and No. 81560398) and the Natural Science Foundation of Jiangxi Province (grant No. 20161AGG70014), Foundation of Jiangxi Educational Committee (g)
Mo1091. . . LOW GRADE GASTRIC MUCOSA-ASSOCIATED LYMPHOID TISSUE... (5*)
Mo1092. . . RISK PREDICTION MODEL FOR DETECTING GASTRIC... (2*)
Mo1093. . . ALPN-101, A FIRST-IN-CLASS DUAL ICOS/CD28 ANTAGONIST,... (3*)\[Alpine Immune Sciences]
Mo1094. . . OPS-2071 HEALS T CELL MEDIATED COLITIS,... (5*)
Mo1095. . . ATRIAL NATHRIETIC PEPTIDE ATTENUATES INTESTINAL INFLAMMATION... (2*)
Mo1096. . . BTK DEFICIENCY LEADS TO NLRP3 INFLAMMASOME... (2*)
Mo1098. . . EFFECTS OF SHORT-CHAIN FATTY ACIDS SUPPLEMENTATION... (4*)
Mo1099. . . AN ESCHERICHIA COLI STRAIN WITH EXTRA... (2*)
Mo1100. . . ESCHERICHIA COLI NISSLE 1917 EXPRESSING ELAFIN... (2*)
Mo1101. . . PROPHYLACTIC ADMINISTRATION OF PHENOLIC COMPOUNDS EXTRACTED... (4*)
Mo1103. . . EFFECT OF WEICHANG’AN PILL ON TH17/TREG... (3*)
Mo1104. . . MONONUCLEAR MYELOID CELL TARGETTED HISTONE DEACETYLASE...
(4*)\[3[)](GlaxoSmithKline - Stevenage - UK)
Mo1105. . . GB004, A NOVEL GUT-TARGETED PROLIV HYDROXYLASE...
(3*)\[Gossamer Bio, Inc.)
Mo1106. . . INFLAMMATION AND CHRONICITY - A NOVEL... (6*)
Mo1107. . . THE GEM PROJECT: CROHN’S DISEASE POLYGENIC...
(6*)\[2[)]
Mo1108. . . AN INTEGRATED GENOMIC AND TRANSCRIPTOMIC ANALYSIS...
(5*)
Mo1109. . . DEVIATION FROM ADDITIVE MODEL IN GENETICS...
(2*)\[4[)
Mo1110. . . INTEGRATING EQTL EVIDENCE AND GWAS SUMMARY...
(2*)\[4[)
Mo1111. . . RNASET2 RISK VARIANT AS A NOVEL...
(4*)
Mo1112. . . IDENTIFYING NOVEL HIGH-IMPACT RARE DISEASE-CAUSING MUTATIONS...
(2*)
Mo1113. . . GENOTYPING OF NUDT15 R139C PRIOR TO...
(4*)
Mo1114. . . ACCURATE PREDICTION OF THERAPEUTIC RESPONSE TO...
(6*)
Mo1115. . . WHOLE-BLOOD EXPRESSION PROFILES IN INFLAMMATORY BOWEL...
(2*)
Mo1116. . . GENOME-WIDE DNA METHYLATION PROFILING IN DIFFERENTIATING...
(2*)
Mo1117. . . INCREASED ABUNDANCE OF BACTERIAL BILE SALT...
(2*)\(7[)
Mo1118. . . DEVELOPMENT OF AN EASY AND RAPID...
(4*)
Mo1119. . . NOVEL GENETIC VARIANTS ASSOCIATED WITH RISK...
(4*)
Mo1120. . . PHENOME WIDE ASSOCIATION STUDY USING INFLAMMATORY...
(5*)
Mo1121. . . TARGETED MUCOSAL TRANSCRIPTOMICS ANALYSIS...
REVEALS DIFFERENTIAL...
(2*)
Mo1122. . . INTEGRATED NETWORK ANALYSIS USING PATIENT-SPECIFIC...
SINGLE...
(2*)
Mo1123. . . META-ANALYSIS OF GENE EXPRESSION DISEASE SIGNATURES...
(5*)
Mo1124. . . RNA-SEQ GENE EXPRESSION PROFILE REVEALS THAT...
(2*)\(7[)
Mo1125. . . GENETIC ANALYSIS OF ULCERATIVE COLITIS RESPONSE...
(5*)
Mo1126. . . FAMILY-SPECIFIC HOST GENETIC AND GUT MICROBIAL...
(2*)
Mo1127. . . REPERTIORE ANALYSIS OF MEMORY T—CELL RECEPTORS...
(1*)
Mo1128. . . INFLUENCE OF NUDT15 AND TPMT ON...
(5*)
Mo1129. . . THE IMPACT OF A SNP-DOSERESPONSE-EFFECT ON...
(2*)
Mo1130. . . SGK2 KNOCKDOWN BY GENE EDITING PROMOTES...
(2*)
Mo1131. . . QUANTITATIVE PROTEOMIC ANALYSIS OF MACROPHAGES FROM...
(5*)
Mo1132. . . TLR4 SIGNALING PROTECTS THE INTESTINAL EPITHELIUM...
(2*)
Mo1133. . . ACTIVATION OF ARYL HYDROCARBON RECEPTOR ATTENUATES...
(2*)
Mo1189. . . . DYSPHAGIA IN EOSINOPHILIC ESOPHAGITIS IMPROVES WITH... (2*)[(R01DK101856, T32DK007634)]

Mo1190. . . . ESOPHAGEAL DISTENSION DYSFUNCTION DURING SWALLOW-INDUCED PERISTALSIS... (2*)

Mo1191. . . . ANTI-TUMOR NECROSIS FACTOR THERAPY AND EOSINOPHILIC... (5*)

Mo1192. . . . ACID SUPPRESSANT MEDICATIONS AND EOSINOPHILIC ESOPHAGITIS... (5*)

Mo1193. . . . PREDICTORS OF RESPONSE TO DIETARY THERAPY... (6*)[The Belletete Foundation]

Mo1194. . . . GENDER-STRATIFIED OCCURRENCE OF EOSINOPHILIA AND PERIPHERAL RESPONSE TO DIETARY THERAPY... (5*)

Mo1195. . . . POOR ENVIRONMENTAL QUALITY OF LIFE AND... (2*)

Mo1196. . . . PREVALENCE AND COMORBID OCCURRENCE OF ESOPHAGEAL EOSINOPHILIC ESOPHAGITIS... (5*)

Mo1197. . . . THE COMORBID OCCURRENCE OF EOSINOPHILIC ESOPHAGITIS... (5*)

Mo1198. . . . RETROSPECTIVE REVIEW OF MILD ESOPHAGEAL EOSINOPHILIA... (5*)

Mo1199. . . . PERIPHERAL EOSINOPHILIA AND HYPOALBUMINEMIA ARE ASSOCIATED... (2*)

Mo1200. . . . INDIVIDUALS WITH EOSINOPHILIC ESOPHAGITIS ARE AT... (2*)

Mo1202. . . . LONG-TERM TREATMENT WITH PROTON PUMP INHIBITORS... (5*)

Mo1203. . . . EOSINOPHILIC ESOPHAGITIS – VISUAL SCORE: A... (5*)

Mo1204. . . . EOSINOPHILIC ESOPHAGITIS QUALITY OF LIFE QUESTIONNAIRE... (5*)

Mo1205. . . . INCIDENCE OF BIOPSY-VERIFIED EOSINOPHILIC ESOPHAGITIS: NATIONWIDE... (5*)

Mo1206. . . . FACTORS RELATED TO SUBJECTIVE SYMPTOMS IN... (5*)

Mo1207. . . . HIGH HEALTH CARE UTILIZATION OF ENDOSCOPY... (2*)

Mo1208. . . . COMPOUNDED FLUTICASONE SLURRY IS AN EFFECTIVE... (5*)

Mo1209. . . . TREATMENT OF LYMPHOCYTIC ESOPHAGITIS IN A... (5*)

Mo1210. . . . CONTRIBUTORS TO DELAY IN DIAGNOSIS... (5*)

Mo1212. . . . PATIENT CHARACTERISTICS AND DISEASE SEVERITY IN... (5*)

Mo1213. . . . LAMINA PROPRIA YIELD USING PERPENDICULAR PLACEMENT... (4*)

Mo1214. . . . PROVOCATIVE TESTS DURING HIGH-RESOLUTION MANOMETRY MAY... (5*)

Mo1215. . . . LYMPHOCYTIC ESOPHAGITIS HAS BETTER OUTCOMES COMPARED... (5*)

Mo1216. . . . PREVALENCE OF NONADHERENCE IN MAINTENANCE THERAPY... (5*)

Mo1217. . . . QUALITATIVE PATIENT INTERVIEWS TO ASSESS CONTENT... (3*)[Sanofi and Regeneron Pharmaceuticals, Inc.]

Mo1218. . . . EFFICACY OF BENRALIZUMAB, A MONOCLONAL ANTIBODY... (5*)

Mo1219. . . . IMPACT OF EOSINOPHILIC ESOPHAGITIS DISEASE ACTIVITY... (2*)

Mo1220. . . . FREQUENCY AND PREDICTIONS OF LOSS TO... (2*)

Mo1221. . . . MORTALITY IN EOSINOPHILIC ESOPHAGITIS - NATIONWIDE,... (2*)

Mo1222. . . . EOSINOPHILIC ESOPHAGITIS AND ASYMPTOMATIC ESOPHAGEAL EOSINOPHILIA... (5*)

Mo1223. . . . DEMOGRAPHIC AND CLINICAL CORRELATES OF THE... (5*)

Mo1224. . . . SEASONAL AND REGIONAL VARIATIONS OF HOSPITAL... (5*)

Mo1225. . . . EPIDEMIOLOGY AND SEASONAL PATTERNS OF HOSPITALIZATIONS... (5*)

Mo1226. . . . CORRELATION OF TREATMENT OPTIONS AND... (5*)

Mo1227. . . . IN HUMAN ESOPHAGEAL SMOOTH MUSCLE CELLS,... (4*)

Mo1228. . . . DUPILUMAB NORMALIZES THE EOSINOPHILIC ESOPHAGITIS DISEASE... (3*)[Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.]

Mo1229. . . . TH2-CYTOKINES SUPPRESS CD73-POSITIVE CELL-MEDIATED EPITHELIAL REGENERATION... (2*)

Mo1230. . . . DIFFERENTIALLY CORRELATED GENE MODULES SUGGEST DIFFERENTIALLY... (5*)

Mo1231. . . . RNA SEQUENCING REVEALS ALTERED SELENOPROTEIN EXPRESSION... (2*)[4]

Mo1232. . . . CHARACTERIZATION OF SALIVARY, GASTRIC AND ESOPHAGEAL... (5*)

Mo1233. . . . OESOPHAGEAL MUCOSA INNERVATION IN PAEDIATRIC EOSINOPHILIC... (4*)

Mo1234. . . . UTILITY OF MAJOR BASIC PROTEIN, EOTAXIN-3,... (2*)

Mo1235. . . . EOSINOPHILIC ESOPHAGITIS DISEASE ACTIVITY... (5*)

Mo1236. . . . MAST CELL LEVEL AND CLINICAL CORRELATES... (3*)[Education grant from Allakos.]

Mo1237. . . . ESTABLISHMENT OF NORMAL TISSUE MAST CELL... (4*)[Educational Grant provided by Allakos.]

Mo1238. . . . TIME DEPENDENT ESOPHAGEAL CLEARANCE OF GLIADIN... (4*)

Mo1239. . . . SMOKING PROMOTES CHEMO-RESISTANCE THROUGH INDUCING WEE1... (2*)[4]

Mo1240. . . . QUANTIFICATION OF LYMPHOVASCULAR INVASION IS USEFUL... (5*)

Mo1241. . . . GITR STIMULATION ENHANCES THE ANTI-TUMOR IMMUNE... (4*)

Mo1242. . . . INDIVIDUAL RISK CALCULATOR TO PREDICT LYMPH... (5*)

Mo1243. . . . GLUTATHIONE S-TRANSFERASE OMEGA 2 (GSTO2)... (5*)

---

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds

(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1304. CLINICOPATHOLOGICAL CHARACTERISTICS AND LYMPH NODE METASTASIS... (4*)
Mo1306. HIGH GRADE DYSPLASIA (HGD) AND ESOPHAGEAL... (5*)
Mo1307. CLINICAL AND GENOMIC CHARACTERISTICS OF SUPERFICIAL... (2*)
Mo1308. CLINICAL SIGNIFICANCE OF EARLY EVALUATION DURING... (5*)
Mo1309. IS THERE A NON-BARRETT’S PATHWAY TO... (5*)
Mo1310. ADENOCARCINOMA AFTER BARIATRIC SURGERY: A... (5*)
Mo1311. DOES CONTROLLING ESOPHAGEAL PH > 4... (3*) (Tsumura & Co.)
Mo1312. ESOPHAGEAL FOLLOW-UP OF RADICALLY RESECTED HIGH-RISK... (5*)
Mo1313. STUDY ON EXPANSION OF INDICATION OF... (5*)
Mo1314. RISK OF GENERALIZATION IN PATIENTS WITH... (5*)
Mo1315. DIETARY TRIGGERS IN IRRITABLE BOWEL SYNDROME... (2*) (Companies WinCove, Ingredia, Ingredion, Nexira, Naturex, Bioiberica, Wecare, Roquette and Darling Ingredients.)
Mo1316. FREQUENCY AND INTENSITY OF GASTROINTESTINAL SYMPTOMS... (5*)
Mo1317. ASSOCIATION BETWEEN INTESTINAL LACTASE AND SYMPTOMS... (5*)
Mo1318. PREVALENCE OF SELF-REPORTED FOOD INTOLERANCES AMONG... (5*)
Mo1319. USEFULNESS OF FECAL CALPROTECTIN IN PRIMARY... (5*)
Mo1320. IMPACT OF HUMAN MILK OLIGOSACCHARIDES ON... (3*) (Glycom A/S sponsored the trial)
Mo1321. THE UTILITY OF GLUCOSE HYDROGEN BREATH... (4*)
Mo1322. HUMAN MILK OLIGOSACCHARIDES IMPROVE BOWEL HABITS... (3*) (Glycom, Inc.)
Mo1323. SEX-BASED DIFFERENCES IN FECAL SHORT-CHAIN FATTY... (2*)
Mo1324. 36 MONTH SURVEILLANCE DATA CONFIRMS SAFETY... (3*) (IM HealthScience, LLC)
Mo1325. INFLAMMATORY STATUS OF POST-INFECTIONI URRITABLE BOWEL... (2*)
Mo1326. IRRITABLE BOWEL SYNDROME (IBS) SYMPTOMS AND... (4*)
Mo1327. ANALYSIS OF A RANGE OF ABDOMINAL... (3*) (This study was funded by Allergan plc. Writing assistance by Complete HealthVizion, funded by Allergan plc.)
Mo1328. EPIDEMIOLOGY OF PSYCHIATRIC DISORDERS IN IRRITABLE... (5*)
Mo1329. RIFAXIMIN IS EFFICACIOUS FOR THE TREATMENT... (3*) (Salix Pharmaceuticals)
Mo1330. EFFECT OF MOXIBUSTION ON SYMPTOMS AND... (2*)
Mo1331. LONG-TERM NATURAL HISTORY OF SYMPTOMS AND... (5*)
Mo1332. ASSOCIATIONS OF FOOD INTOLERANCES WITH IRRITABLE... (5*)
Mo1333. PHASE 1 RESULTS OF ORP-101, A... (4*) (The studies discussed in this abstract were funded by OrphoMed, Inc.)
Mo1334. SEXUAL DYSFUNCTION (SDX) WORSENS QUALITY OF... (5*)
Mo1335. HUMAN MILK OLIGOSACCHARIDES IMPROVE SYMPTOMS OF... (3*) (Glycom Inc)
Mo1336. HIGHLY SENSITIVE DIAGNOSIS OF IRRITABLE BOWEL... (6*)
Mo1338. A POOLED ANALYSIS OF TWO PHASE... (3*) (Salix Pharmaceuticals)
Mo1339. RELATIVE ABUNDANCES OF MICROBIAL GENES INVOLVED... (2*)
Mo1340. MILD TRAUMATIC BRAIN INJURY CAUSED BY... (4*)
Mo1341. STRESS-INDUCED ACTIVATION OF CORTICOTROPIN-RELEASING HORMONE, VASOPRESSIN,... (2*)
Mo1342. ROLE OF TOLL-LIKE RECEPTOR 5 IN... (4*)
Mo1343. TRANSCRIPTOMIC ANALYSIS OF LASER CAPTURE MICRODISSECTED... (4*)
Mo1344. DEVELOPMENT OF A NOVEL CIRCULAR RNA-BASED... (5*)
Mo1345. DIABETES MELLITUS IS A RISK FACTOR... (5*)
Mo1346. GENETIC VARIANTS IN THE PLATELET-DERIVED GROWTH... (2*) (As Duke Cancer Institute members, QW acknowledge support from the Duke Cancer Institute as part of the P30 Cancer Center Support Grant (Grant ID: NIH CA014236). QW was also supported by a start-up fund from Duke Cancer Institute, Duke University Medical C)
Mo1347. ROLE OF COMPUTED TOMOGRAPHY IN THE... (5*)
Mo1348. AN EARLY INSIGHT INTO GENOMIC STRUCTURAL... (4*)
Mo1349. 3-D MULTIPLEX HISTOLOGY OF HUMAN PANCREAS... (2*)
Mo1350. PREDICTORS OF FAMILY HISTORY OF PANCREATIC... (4*)
Mo1351. PANCREATIC STEATOSIS ON CT-IMAGING IN PATIENTS... (5*)
Mo1352. RECOMBINANT CO-CULTURE PANCREATIC DUCTAL ADENOCARCINOMA TUMOROIDS... (5*)
Mo1353. RISK OF INCIDENT PANCREATIC CANCER IN... (5*)
Mo1354. A NOVEL EZF1-P300-VMP1 PATHWAY MEDIATES GEMCITABINE-INDUCED... (4*)
Mo1355. EXPERT REVIEW IDENTIFIES A HIGH PREVALENCE... (5*)
Mo1356. AN INSIGHT INTO FIBROGENIC STIMULANTS IN... (4*)
Mo1357. FEASIBILITY OF DIGITAL PCR-BASED QUANTIFICATION AND... (2*)
Mo1358. THE IMPACT OF SKELETAL MUSCLE MASS... (5*)
Mo1359. SURGICAL RESECTION IMPROVES GLUCOSE HOMEOSTASIS IN... (2*)
Mo1360. USAGE OF A PANEL OF BIOMARKERS... (4*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds   (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)   (3) = Industry or Commercial Entity   (4) = Institutional Funds
(5) = No Study Funding   (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)   (7) = Professional Organization (e.g. AGA, AASLD, etc.)
<table>
<thead>
<tr>
<th>Title</th>
<th>Abstract Funding Source Key</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mo1526. . . . PREDICTORS OF HEALTH-RELATED QUALITY OF LIFE... (5*)</td>
<td>* = Primary Source</td>
</tr>
<tr>
<td>Mo1527. . . . ASSESSMENT OF RESPONSE TO THERAPY IN... (4*)</td>
<td>(1) = Clinical Practice Funds</td>
</tr>
<tr>
<td>Mo1528. . . . HIGH RATE OF CONCORDANCE BETWEEN PHYSICIANS... (5*)</td>
<td>(2) = Government (e.g. NIH, CDC, Health Ministry, etc.)</td>
</tr>
<tr>
<td>Mo1529. . . . MALABSORBITIVE BARIATRIC SURGERY AND IBS, LOW... (5*)</td>
<td>(3) = Industry or Commercial Entity</td>
</tr>
<tr>
<td>Mo1530. . . . GENDER DIFFERENCES IN PATIENTS WITH SYSTEMIC... (5*)</td>
<td>(4) = Institutional Funds</td>
</tr>
<tr>
<td>Mo1532. . . . FUNCTIONAL GASTROINTESTINAL SYMPTOMS COMMON AND FREQUENTLY... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1533. . . . VOLATOMICS IN INFLAMMATORY BOWEL DISEASE AND... (2*)[(4)</td>
<td>(5) = No Study Funding</td>
</tr>
<tr>
<td>Mo1534. . . . PREVALENCE OF METHANE POSITIVE SMALL INTESTINAL... (5*)</td>
<td>(6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)</td>
</tr>
<tr>
<td>Mo1535. . . . INTERNET SURVEY ON LAXATIVE USE BY... (3*)[(EA Pharma Co. Ltd)</td>
<td></td>
</tr>
<tr>
<td>Mo1536. . . . FUNCTIONAL DYSEPSIA, PEPTIC ULCER AND HELICOBACTER... (2*)[(6)</td>
<td></td>
</tr>
<tr>
<td>Mo1537. . . . MULTICENTRIC OBSERVATIONAL STUDY TO DETERMINE DUODENAL... (4*)</td>
<td></td>
</tr>
<tr>
<td>Mo1538. . . . EQUATING SCORES OF THE FUNCTIONAL DIGESTIVE... (2*)</td>
<td>(5*) = Professional Organization (e.g. AGA, AASLD, etc.)</td>
</tr>
<tr>
<td>Mo1539. . . . THIRTY DAY UNPLANNED READMISSIONS FOR CYCLICAL... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1540. . . . THE EFFICACY AND SAFETY OF GCWB104... (4*)</td>
<td></td>
</tr>
<tr>
<td>Mo1541. . . . INTEGRATING PSYCHOLOGICAL SCREENING INTO MEDICAL CARE... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1542. . . . DUODENAL EOSINOPHILS ACTIVITY IN DYSEPSIA: ONLY... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1543. . . . A DOUBLE-EDGED SWORD? #NAME? PERIPHERAL MECHANISM... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1544. . . . IS SMALL INTESTINAL DYSBIOSIS (SIBO) RELATED... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1545. . . . DISTINCT TREATMENT CHOICES BETWEEN PRIMARY CARE... (3*)[(Xian Janssen Pharmaceutical Ltd)</td>
<td></td>
</tr>
<tr>
<td>Mo1546. . . . DYSEPSIA SYMPTOMS IN FUNCTIONAL DYSEPSIA (FD)... (4*)</td>
<td></td>
</tr>
<tr>
<td>Mo1547. . . . LHMBT POSITIVE IBS-D PATIENTS PRESENTED A... (2*)</td>
<td></td>
</tr>
<tr>
<td>Mo1548. . . . REEVALUATION OF THE CARDIOVASCULAR SAFETY PROFILE... (3*)[(Alfasigma USA)</td>
<td></td>
</tr>
<tr>
<td>Mo1549. . . . CHARACTERISTICS AND PREDICTIVE MODELING OF POST-INFECTION... (2*)[(Supported by NIH K23 DK 103911 and R03 120745.)</td>
<td></td>
</tr>
<tr>
<td>Mo1550. . . . A NOVEL SCORE TO EVALUATE ABDOMINAL... (3*)[(This study was funded by Allergan plc and Ironwood Pharmaceuticals, Inc.)</td>
<td></td>
</tr>
<tr>
<td>Mo1551. . . . PSYLLIUM REDUCES COLONIC HYdroGEN PRODUCTION FOLLOWING... (2*)</td>
<td></td>
</tr>
<tr>
<td>Mo1552. . . . AN ANALYSIS OF PLACEBO RATE AND... (6*)</td>
<td></td>
</tr>
<tr>
<td>Mo1553. . . . EVALUATION OF SENSORY SENSITIVITY AND SOMATIC... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1555. . . . BILE ACID MALABSORPTION: AN OVERLOOKED DIAGNOSIS... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1556. . . . PREVALENCE OF EXOCRINE PanCREATIC INSUFFICIENCY IN... (3*)[(Abbott Laboratories)</td>
<td></td>
</tr>
<tr>
<td>Mo1557. . . . FACTORS AFFECTING CENTRAL NEUROMODULATOR USE BY... (4*)</td>
<td></td>
</tr>
<tr>
<td>Mo1558. . . . PREVALENCE OF FIRST-EVER DIAGNOSIS OF IRREMITABLE... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1559. . . . QUANTITATIVE ASSESSMENT OF THE BIDIRECTIONAL RELATIONSHIP... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1560. . . . CANNABIS USE IS ASSOCIATED WITH REDUCED... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1561. . . . THE EFFECT OF LONG-ACTING MESALAMINE OF... (3*)[(Supported in part by grants from Shire Pharmaceuticals and the Department of Defense)</td>
<td></td>
</tr>
<tr>
<td>Mo1562. . . . ECONOMIC AND SOCIAL BURDEN OF IRREMITABLE... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1563. . . . DISCRIMINATING BETWEEN PATIENTS WITH IRREMITABLE BOWEL... (2*)[(4)</td>
<td></td>
</tr>
<tr>
<td>Mo1564. . . . THE CLINICAL OUTCOMES OF CLOSTRIDIUM DIFFICILE... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1565. . . . MUCOSAL SEROTONIN REUPTAKE TRANSPORTER (SERT) EXPRESSION... (2*)</td>
<td></td>
</tr>
<tr>
<td>Mo1566. . . . ANTI-VINCULIN AND ANTI-CYTOLETHAL DISTENDING TOXIN B... (6*)</td>
<td></td>
</tr>
<tr>
<td>Mo1567. . . . DIFFERENCES IN BRAIN STRUCTURE PREDICT SYMPTOM... (2*)</td>
<td></td>
</tr>
<tr>
<td>Mo1569. . . . IDENTIFICATION OF COLONIC MUCOSAL MICROBAS ALTERED... (4*)[(2)</td>
<td></td>
</tr>
<tr>
<td>Mo1570. . . . THE INTESTINAL MICROBIOTA FROM A PATIENT... (4*)</td>
<td></td>
</tr>
<tr>
<td>Mo1571. . . . INTRARECTAL ADMINISTRATION OF A TRPV4 ANTAGONIST... (4*)</td>
<td></td>
</tr>
<tr>
<td>Mo1572. . . . MUCOSA-ASSOCIATED INTESTINAL MICROBIOTA AND SERUM CYTOKINES... (2*)</td>
<td></td>
</tr>
<tr>
<td>Mo1573. . . . IRREMITABLE BOWEL SYNDROME WITH DIARRHEA IS... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1574. . . . DIFFERENTIAL mRNA EXPRESSION IN ILEAL MUCOSAL... (2*)</td>
<td></td>
</tr>
<tr>
<td>Mo1575. . . . RELATIONSHIPS OF SHORT CHAIN FATTY ACIDS... (2*)</td>
<td></td>
</tr>
<tr>
<td>Mo1576. . . . DETERMINANTS OF RENTENTION IN CARE AFTER... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1577. . . . BRIEF BEHAVIORAL THERAPY FOR INSOMNIA IN... (6*)</td>
<td></td>
</tr>
<tr>
<td>Mo1578. . . . INDIVIDUALS WITH IBS REPORT HIGH RATES... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1579. . . . I JUST FEEL LIKE AN OUTCAST: STIGMA EXPERIENCES OF PATIENTS LIVING... (4*)</td>
<td></td>
</tr>
<tr>
<td>Mo1580. . . . GASTROENTEROLOGISTS’ PRESCRIBING PATTERNS AND COMFORT-LEVEL VARY... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1581. . . . CHARACTERIZATION OF COGNITIVE FLEXIBILITY IN ESOPHAGEAL... (2*)</td>
<td></td>
</tr>
<tr>
<td>Mo1582. . . . IS THERE AN ASSOCIATION BETWEEN IMPROVEMENT... (2*)</td>
<td></td>
</tr>
<tr>
<td>Mo1583. . . . HYPNOTHERAPY FOR IRREMITABLE BOWEL SYNDROME: THE... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1584. . . . DO I REALLY HAVE TO... (2*)</td>
<td></td>
</tr>
<tr>
<td>Mo1585. . . . FACTORS ASSOCIATED WITH EFFICACY OF COGNITIVE... (2*)</td>
<td></td>
</tr>
</tbody>
</table>
Mo1586. . . . TREATMENT EXPECTANCY FOR GI SYMPTOM IMPROVEMENT... (2*)
Mo1587. . . . PSYCHOPHYSIOLOGICAL CORRELATES OF ESOPHAGEAL HYPERVIGILANCE: BUILDING... (2*)
Mo1588. . . . POST-TRAUMATIC STRESS DISORDER IS PREVALENT AND... (5*)
Mo1589. . . . HYPERACTIVITY AND AGGRESSION ARE ASSOCIATED WITH... (2*)
Mo1590. . . . TRANSIENT EXPOSURE TO ENVIRONMENTAL ENRICHMENT PRODUCES... (2*)
Mo1591. . . . GUT-FOCUSED HYPNOTHERAPY FOR CHILDREN AND ADOLESCENTS... (5*)
Mo1592. . . . GREATER RISK FOR ADVERSE HOSPITALIZATION OUTCOMES... (5*)
Mo1593. . . . KNOWLEDGE AND ATTITUDES OF DISCONTINUING COLON... (4*)
Mo1594. . . . WHICH GUIDELINE TO FOLLOW? A NATIONAL... (4*)
Mo1595. . . . COLORECTAL CANCER SCREENING AMONG AMERICAN ADULTS... (5*)
Mo1596. . . . BASELINE FECAL HEMOGLOBIN CONCENTRATION IS AN... (5*)
Mo1597. . . . COLORECTAL CANCER SCREENING AND YIELD IN... (2*)
Mo1598. . . . ESTIMATING THE IMPACT OF IMPERFECT ADHERENCE... (3*)|(Exact Sciences)
Mo1599. . . . HIGH-RISK SERRATED LESION DETECTION AT CRC... (5*)
Mo1600. . . . HOSPITAL LEVEL POLYPECTOMY RATE WITHIN THE... (2*)
Mo1601. . . . TRENDS IN COLORECTAL CANCER SCREENING COMPLETION... (3*)|(2)|(Exact Sciences Corporation, Madison, WI)
Mo1602. . . . INTERNATIONAL SURVEY OF INTERVAL CANCER AUDIT... (5*)
Mo1603. . . . ADENOMA AND ADVANCED ADENOMA DETECTION RATE... (2*)|(7)
Mo1604. . . . COLONOSCOPY FINDINGS FOLLOWING A FECAL IMMUNOCHEMICAL... (5*)
Mo1605. . . . OLDER ADULTS TOLERANCE OF COLONOSCOPY AND... (4*)
Mo1606. . . . EXERCISE IS ASSOCIATED WITH LOWER RISK... (5*)
Mo1607. . . . INFLUENCE OF MASCULINITY ON COLORECTAL CANCER... (4*)
Mo1608. . . . PERCEPTIONS AND BARRIERS TO COLORECTAL CANCER... (4*)
Mo1609. . . . HIV PATIENTS WITH LOW CD4 COUNTS... (5*)
Mo1610. . . . THE ASSOCIATION OF PATIENTS' PERCEPTION OF... (5*)
Mo1611. . . . PATIENT NAVIGATION AFTER POSITIVE FECAL IMMUNOCHEMICAL... (5*)
Mo1612. . . . COLORECTAL CANCER SCREENING OUTREACH PROGRAMS USING... (2*)
Mo1613. . . . IDENTIFYING BARRIERS TO ADHERENCE TO SURVEILLANCE... (5*)
Mo1614. . . . POST-OPERATIVE HOSPITAL OUTCOMES OF ELECTIVE SURGERY... (5*)
Mo1615. . . . POTENTIAL CLINICAL UTILITY OF SNP-BASED POLYGENIC... (5*)
Mo1616. . . . OPTIMAL SMALL POLYP (6-9 MM) RESECTION... (5*)
Mo1617. . . . WHERE ARE WE TODAY? EFFORTS TO... (5*)
Mo1618. . . . THE USE OF A QUICK AND... (5*)
Mo1619. . . . THE SAFETY AND POLYP DETECTION RATE... (5*)
Mo1620. . . . AGE, NOT GENDER, AFFECTS PATIENT COMPLIANCE... (5*)
Mo1785. . . . INCREASED FECAL BILE ACID EXCRETION IN... (2*)
Mo1786. . . . ELEVATED BREATH METHANE ON LACTULOSE BREATH... (4*)
Mo1787. . . . OUTCOMES OF LOWER DOSING OF BULESONIDE... (5*)
Mo1788. . . . THE DIAGNOSIS OF CARBOHYDRATE MALABSORPTION BY... (5*)
Mo1789. . . . A COMPARISON OF LACTULOSE BREATH TESTS... (5*)
Mo1790. . . . CLINICAL UTILITY AND DIAGNOSTIC YIELD OF... (5*)
Mo1791. . . . APPLICATION OF NORTH AMERICAN CONSSENSUS CRITERIA... (1*)
Mo1792. . . . EFFECTS OF SHORT-TERM PPI INTAKE ON... (5*)
Mo1793. . . . ROBUSTNESS OF IBD DISABILITY INDEX (IBDDI)... (5*)
Mo1794. . . . FECAL MICROBIOTA TRANSPLANTATION FOR C. DIFFICILE... (5*)
Mo1795. . . . FRAILTY IS ASSOCIATED WITH NATIONWIDE READMISSION... (5*)
Mo1796. . . . TUMOR NECROSIS FACTOR ANTAGONISTS ARE SUPERIOR... (5*)
Mo1797. . . . LOSS OF SATB2 EXPRESSION IN COLORECTAL... (4*)
Mo1798. . . . ACTIVE INFLAMMATORY BOWEL DISEASE, PARTICULARLY FISTULIZING... (5*)
Mo1799. . . . THE ROLE OF ACOUSTIC RADIATION FORCE... (5*)
Mo1800. . . . INFLAMMATORY BOWEL DISEASE AND LUNG CANCER... (5*)
Mo1801. . . . DISEASE BURDEN AND OUTCOMES OF INFLAMMATORY... (5*)
Mo1802. . . . HYPERBARIC OXYGEN THERAPY IN PATIENTS WITH... (5*)
Mo1803. . . . CLOSTRIDIODES DIFFICILE INFECTION IS NOT ASSOCIATED... (5*)
Mo1804. . . . PRE-ADMISSION CANNABIS USE IS POSITIVELY CORRELATED... (5*)
Mo1805. . . . CROHN'S DISEASE PHENOTYPE AND ACTIVITY ARE... (5*)
Mo1806. . . . CIRCULATING LEVELS OF VITAMIN D BINDING... (3*)|(Immundiagnostik AG)
Mo1807. . . . EVALUATION AND COMPARISON OF SAFETY CHARACTERISTICS... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1868. Efficacy and Safety of Simultaneous Treatment... (5*)
Mo1869. Efficacy of Dose Intensification of Ustekinumab... (5*)
Mo1870. Assessment of Body Weight Changes in... (4*)
Mo1871. Vedolizumab Treatment in Patients with Refractory... (5*)
Mo1872. Safety and Clinical Efficacy of Double... (5*)
Mo1873. Which Second-Line Biologic After Anti-TNF Failure... (5*)
Mo1874. Blood T Cell Frequencies Predict and... (4*)
Mo1875. Evaluation of Biologic Treatment Patterns Among... (3*) (Janssen Scientific Affairs, LLC)
Mo1876. Treatment Persistence and Maintenance Dosing for... (3*) (Study sponsored by: Janssen Scientific Affairs, LLC, Horsham, PA, USA)
Mo1879. Development of Inflammatory Bowel Disease (IBD)... (5*)
Mo1880. Ustekinumab Dose Escalation Effective in Real-World... (5*)
Mo1881. Ustekinumab Trough Level Predicts Remission and... (1*) (6)
Mo1882. Effectiveness of Ustekinumab Dose Escalation in... (5*)
Mo1883. Real-world Experience: Clinical and Endoscopic Effectiveness... (3*) (Takeda)
Mo1884. Predictors of Vedolizumab Treatment Persistence in... (5*)
Mo1885. Vedolizumab - Perioperative Infection Rates in... (5*)
Mo1886. Real-world Effectiveness of Vedolizumab in Crohn's... (3*) (The study was financially supported by Takeda.)
Mo1887. Impact of Tumor Necrosis Factor Alpha... (2*) (4)
Mo1888. Decoding Delays in Biologic and Small... (6*)
Mo1889. Correlation of Early Infliximab Levels with... (3*) (Janssen Scientific Affairs, LLC)
Mo1890. Vedolizumab Dose Escalation Improves Disease Activity... (5*)
Mo1891. Quality of Transition Care in Pediatric... (5*)
Mo1892. Predicting Sub-optimal Transitions in Adolescents with... (5*)
Mo1893. Phenotype and Outcome of Inflammatory Bowel... (4*)
Mo1894. Approach to Transgender and Gender Non-conforming... (5*)
Mo1895. Population Pharmacokinetic Bayesian Estimates and Vedolizumab... (2*) (4)
Mo1896. Infliximab Serum Levels During Induction Predict... (3*) (KvH has received a research grant from Mundipharma Comm. VA and Celltrion Healthcare Co.)
Mo1897. Total Abdominal Colectomies with Proctectomy Are... (4*)
Mo1898. Low Risk of Lymphoma in Pediatric... (2*)
Mo1899. Sex Differences in Statural Growth Impairment... (2*) (6)
Mo1900. The Incidence and Characteristics of Venous... (2*)
Mo1901. Children with Inflammatory Bowel Disease Experience... (4*)
Mo1902. Non-Monogenic Very Early Onset Inflammatory Bowel... (5*)
Mo1903. High Rates of Surgery Persist For... (5*)
Mo1904. Insurance Type Influences Infliximab Initiation Time... (5*)
Mo1905. The Association Between Hirschsprung's Disease and... (5*)
Mo1906. Feasibility of the First Paediatric Randomized... (4*) (3) (Rebiotix Inc. supplied the fecal transplant product for this study.)
Mo1907. Real World Experience with Ustekinumab in... (5*)
Mo1908. Infliximab Treatment Failure in Children with... (5*)
Mo1909. Evaluation of Non-alcoholic Fatty Liver Disease... (5*)
Mo1910. Safety and Efficacy of Supratherapeutic Serum... (5*)
Mo1911. Normalisation of Stool Calprotectin- Is It... (5*)
Mo1912. Risk of Cancers in Pediatric Inflammatory... (5*)
Mo1913. Microbiota-Modifying Drug CsA13-dependent Fecal Metabolites Exert... (2*) (3) (Merck)
Mo1914. Superior Efficacy of Higher Volume Fresh... (5*)
Mo1915. It is Not Cost Effective To... (5*)
Mo1916. Rising Temporal Trends in the Prevalence... (5*)
Mo1917. Clinical Burden of Recurrent Clostridiodes Difficile... (3*) (Ferring Pharmaceuticals Inc.)
Mo1918. Validation of a Predictive Scoring Tool... (5*)
Mo1919. Bowel Anastomosis is Associated With... (5*)
Mo1920. Epidemiology and Trend Analysis of Clostridiodes... (5*)
Mo1921. Comparative Risk of Clostridium Difficile Infection... (5*)
Mo1922. Role of Serum Procalcitonin in Predicting... (5*)
Mo1923. Relationship Between Ileocecal Resection and Postoperative... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds    (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)    (3) = Industry or Commercial Entity    (4) = Institutional Funds
(5) = No Study Funding    (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)    (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1924. Differences in the Fecal Microbiome and... (4*)
Mo1925. The Impact of Appendectomy In... (5*)
Mo1926. Probiotics for the Prevention of Clostridium... (5*)
Mo1927. Clostridiodes Difficile Ribotype as a Predictor... (5*)
Mo1928. Are Patients with Altered Bile Acid... (5*)
Mo1929. Orally Administered Lyophilized Fecal Microbiota Transplantation... (4*)
Mo1930. The Donor Does Not Matter In... (3*) (This analysis was funded by Rebiotix Inc. (Roseville, MN, USA))
Mo1931. Failure is Not Final: Clinical Response... (3*) (This analysis was funded by Rebiotix Inc. (Roseville, MN, NJ))
Mo1932. Critical Role for Toxin Activating Clostridium... (4*)
Mo1933. Use of Proton Pump Inhibitors Does... (5*)
Mo1934. Is Celiac Disease Associated with Worse... (5*)
Mo1935. Identifying Barriers Among Primary Care Physicians... (5*)
Mo1936. Clostridiodes Difficile Infection in Patients With... (5*)
Mo1937. Acid-Suppressive Therapy as a Risk Factor... (5*)
Mo1938. Sequential Fecal Microbiota Transplantation for Fulminant... (5*)
Mo1939. Temporal Modulation of TCR Repertoire Following... (4*) (2)
Mo1940. Trends in Clostridium Difficile Infection Incidence... (5*)
Mo1941. Clostridium Difficile Infection as a Cause... (5*)
Mo1942. Outcomes of Clostridiodes Difficile Infection In... (5*)
Mo1943. Sequential Fecal Microbiota Transplant by Enema... (2*) (4*) (MERCK Pharmaceuticals provided the fidaxomicin for this research for free. No other contributions were made.)
Mo1944. Comparing Treatment Outcomes between Openbiome Frozen... (4*)
Mo1945. Efficacy and Safety of Fecal Microbiota... (5*)
Mo1946. Association of Fecal Calprotectin and Recurrence... (4*)
Mo1947. Detection of Non-Toxigenic Clostridiodes... (5*)
Mo1948. Outcomes of Inpatient Fecal Transplant Administration... (2*)
Mo1949. One and Done? Evaluation of Efficacy... (3*) (Rebiotix Inc.)
Mo1950. Heterogeneity of Randomized Controlled Trials of... (3*) (Ferring Pharmaceuticals)
Mo1951. Reporting of Randomized Controlled Trial Methodological... (3*) (Ferring)
Mo1952. Patient Sex Does Not Impact Efficacy... (5*)
Mo1953. Metagenomic Analysis of Human Fecal Virome... (2*)
Mo1954. Anaerobic Fecal Microbiota Transplantation Preparations Are... (5*)
Mo1955. High Stress Reactivity is Associated with... (6*) (2)
Mo1956. Association of Fecal Microbiome with Resilience... (2*)
Mo1957. Lactobacillus Rhamnosus GG Colonization in Early... (2*)
Mo1958. Utility of a Consumer-Friendly Portable Hydrogen... (3*) (GOS-based prebiotic provided for free from manufacturer (FrieslandCampina).)
Mo1959. Comparison of Two Ready-To-UseSupplementary Foods (RUSF)... (6*) (3*) (Arla Foods and the Danish Dairy Research Foundation)
Mo1960. Effect of Fiber, Osmolarity, and Protein... (2*)
Mo1961. Clinical Experience of Percutaneous Endoscopic Gastrostomy... (5*)
Mo1962. Combination of Pureed Diet Containing Gelling... (5*)
Mo1963. Sex Differences in Dietary Copper-Fructose Interaction-Induced... (2*)
Mo1965. Effects of Estrogen on the Expression... (2*) (National Natural Science Foundation of China (NSFC))
Mo1966. Commd10 Regulates Adipose Tissue Macrophage Control... (6*)
Mo1967. Cranberry Proanthocyanidins Attenuate Metabolic Disorders, Including... (2*) (4)
Mo1968. Mechanism Underlying Stimulation of Apical B0AT1... (2*)
Mo1969. Obesity-Induced Stimulation of Intestinal Villus Cell... (2*)
Mo1970. Unique Mechanism of Stimulation of Glucose... (2*)
Mo1971. Pharmacotherapy for Obesity - Trends Using... (5*)
Mo1972. Class II/III Obesity is an Independent... (5*)
Mo1973. Ectopic Fat Accumulation in the Liver... (2*)
Mo1974. Weight Regain Following Bariatric Surgery: A... (5*)
Mo1975. Impact of Bariatric Surgery on Esophageal... (5*)
Mo1976. Upper GI Symptoms in Patients Post-Bariatric... (5*)
Mo1977. The Relationship Between Visual Processing Impairments... (5*)
Mo1978. Effect of Weight Loss on Retinochoroidal... (5*)
Tu1000. Appropriateness of Proton Pump Inhibitors After... (5*)
Tu1001. . . . OUTCOMES OF A PROTON PUMP INHIBITOR... (5*)
Tu1002. . . . PROTON PUMP INHIBITOR (PPI) PRESCRIBING PATTERNS... (5*)
Tu1003. . . . LONG TERM USE OF PPI’s DOES... (5*)
Tu1004. . . . PROVINCIAL PRESCRIBING DATA OF PROTON PUMP... (2*)
Tu1005. . . . USE OF PROTON-PUMP INHIBITORS DURING ANTI- COAGULATION... (3*)[(Daiichi Sankyo Co., Ltd.)
Tu1006. . . . THE ASSOCIATION BETWEEN INFLAMMATORY BOWEL DISEASE... (5*)
Tu1007. . . . WORLDWIDE INCIDENCE AND PREVALENCE OF METABOLIC... (4*)
Tu1008. . . . A META-ANALYSIS OF THE VALUE OF... (5*)
Tu1009. . . . CONTAMINATION RATE OF REUSABLE PATIENT-READY DUODENOSCOPES... (5*)
Tu1010. . . . HIGHER ADULT-ATTAINED HEIGHT IS AN INDEPENDENT... (4*)
Tu1011. . . . MYTHS ABOUT OBSTRUCTIVE SLEEP APNEA DEBUNKED... (5*)
Tu1012. . . . INSURANCE STATUS AND LEVEL OF EDUCATION... (5*)
Tu1013. . . . YOUNGER PATIENTS WITH ESOPHAGEAL ADENOCARCINOMA HAVE... (5*)
Tu1014. . . . MODULATION OF THE POSITIVE ASSOCIATION BETWEEN... (4*)
Tu1015. . . . GASTRIC ADENOMA INCREASES THE RISK FOR... (5*)
Tu1016. . . . OCCURRENCE OF ESOPHAGEAL ADENOCARCINOMA IN THE... (3*)
Tu1017. . . . RISK FACTORS IN THE DEVELOPMENT OF... (2*)
Tu1018. . . . INCIDENCE AND MORTALITY RATES OF APPENDICEAL... (5*)
Tu1019. . . . INTEGRATIVE ANALYSIS OF DIFFERENTIAL LNCRNA/MRNA EXPRESSION... (2*)
Tu1020. . . . BILE REFLUX PROMOTES GASTRIC INTESTINAL METAPLASIA... (2*)[(4)
Tu1021. . . . EPITHELIAL TO MESENCHYMAL TRANSITION IN RESPONSE... (2*)[(4)
Tu1022. . . . MITOCHONDRIAL DYSFUNCTION ALTERS METABOLISM OF HEPATIC... (2*)[(4)
Tu1023. . . . GASTROENTEROLOGISTS AND INFECTION DISEASE PHYSICIANS ARE... (5*)
Tu1183. . . . CHARACTERISTICS OF 30-DAY ALL CAUSE READMISSIONS... (5*)
Tu1184. . . . M6A MODIFICATION CONTROLS THE AUTOPHAGIC RESPONSE... (5*)
Tu1185. . . . OLDER AGE AND PRESENCE OF ADVANCED... (3*)[(Research grant from Gilead Sciences)
Tu1186. . . . ECONOMIC BURDEN OF INPATIENT CARE IN... (5*)
Tu1187. . . . IF YOU HAVE TO ASK, YOU... (5*)
Tu1188. . . . MALE GENDER, INSURANCE STATUS, AND RACE/ETHNICITY... (5*)
Tu1189. . . . GASTRIC ELECTRICAL STIMULATOR FOR GASTROPARESIS, A... (5*)
Tu1190. . . . IMPAIRED ACTIVATION OF SYMPATHETIC NERVOUS SYSTEM... (3*)[(Tsumura & Co.)
Tu1191. . . . DISTRIBUTION OF DUODENAL TUFT CELLS IS... (2*)
Tu1192. . . . ACTIVATION OF AKT-PI3K SIGNALING AND MiRNA-MEDIATED... (2*)
Tu1193. . . . COQ10 PROTECTS GASTRIC ENDOTHELIAL CELLS AGAINST... (2*)
Tu1194. . . . DIFFERENT CLASSES OF NONPEPTIDE AGONISTS HAVE... (2*)
Tu1195. . . . ELUCIDATION OF THE MECHANISMS BY WHICH... (2*)
Tu1196. . . . EFFECT OF HELICOBACTER PYLORI ON THE... (2*)
Tu1197. . . . EFFECT OF AMINO ACID-BASED ORAL REHYDRATION... (4*)[(3)][(Entrinsic Health Solutions Inc.(fund based on a research agreement with the University of Florida)]
Tu1198. . . . PROPRIETY BLEND OF AMINO ACIDS DECREASED... (4*)
Tu1199. . . . 24-3P EXHIBITS... (2*)
Tu1200. . . . BILE REFLUX PROMOTES GASTRIC INTESTINAL METAPLASIA... (2*)[(4)
Tu1201. . . . GENOME-WIDE TRANSCRIPTIONAL RESPONSES TO ASPIRIN WITH... (2*)[(4)
Tu1202. . . . EFFECT OF HELICOBACTER PYLORI ON THE... (2*)
Tu1203. . . . BILE REFLUX PROMOTES GASTRIC INTESTINAL METAPLASIA... (2*)[(4)
Tu1204. . . . THE SAFETY, EFFICACY, AND OUTCOMES FOR... (5*)
Tu1205. . . . WHETHER THE FIRST-DEGREE RELATIVES SUFFERING FROM... (1*)
Tu1206. . . . USE OF BIOLOGICS AND IMMUNOMODULATORS DO... (5*)
Tu1207. . . . WHETHER THE FIRST-DEGREE RELATIVES SUFFERING FROM... (1*)
Tu1208. . . . NEUROPEPTIDE W ALLEVIATES HEPATORENAL OXIDATIVE DAMAGE... (4*)
Tu1209. . . . AN ANTISENSE Oligonucleotide for MiCRONRA- 24-3P EXHIBITS... (2*)[(6)
Tu1210. . . . THE SAFETY, EFFICACY, AND OUTCOMES FOR... (5*)
Tu1211. . . . THE EFFICACY OF UPPER ENDOSCOPIC SURVEILLANCE... (5*)
Tu1212. . . . THE SAFETY, EFFICACY, AND OUTCOMES FOR... (5*)
Tu1213. . . . WHETHER THE FIRST-DEGREE RELATIVES SUFFERING FROM... (1*)
Tu1214. . . . WHETHER THE FIRST-DEGREE RELATIVES SUFFERING FROM... (1*)
Tu1215. . . . WHETHER THE FIRST-DEGREE RELATIVES SUFFERING FROM... (1*)
Tu1216. . . . WHETHER THE FIRST-DEGREE RELATIVES SUFFERING FROM... (1*)
Tu1217. . . . WHETHER THE FIRST-DEGREE RELATIVES SUFFERING FROM... (1*)
Tu1218. . . . WHETHER THE FIRST-DEGREE RELATIVES SUFFERING FROM... (1*)
Tu1219. . . . WHETHER THE FIRST-DEGREE RELATIVES SUFFERING FROM... (1*)
Tu1220. . . . WHETHER THE FIRST-DEGREE RELATIVES SUFFERING FROM... (1*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu121. . . . CLINICOPATHOLOGICAL ANALYSIS OF SIX FAMILIES WITH (5*)
Tu122. . . . MALIGNANCY RISK IN FAMILIAL ADENOMATOUS POLYPYSP... (5*)
Tu123. . . . FACTORS THAT AFFECT PENETRANCE OF COLORECTAL... (5*)
Tu124. . . . ADVANCED COLORECTAL POLYPS AS A WAY... (5*)
Tu125. . . . MUTYH ASSOCIATED POLYPOSIS IN THE NON-JEWISH... (5*)
Tu126. . . . SMALL INTESTINAL INVOLVEMENT IN FAMILIAL ADENOMATOUS... (5*)
Tu127. . . . CCL11 EXACERBATES COLITIS VIA MODULATION OF... (2*)
Tu128. . . . INTERLEUKIN-38 IS ELEVATED IN INFLAMMATORY BOWEL... (2*)
Tu129. . . . AUTOTAXIN STIMULATES LPA2 RECEPTOR IN MACROPHAGES... (2*)
Tu130. . . . EXAMINATION OF NEW PREDICTIVE FACTORS USING... (1*)
Tu132. . . . NEW INSIGHTS INTO THE ROLE OF... (2*)
Tu133. . . . REPAIR RECEPTOR CD74 IS NECESSARY FOR... (2*)
Tu134. . . . SACRAL NERVE STIMULATION INHIBITS THE MAPK/NF-κB... (2*)
Tu135. . . . TNF RECEPTOR 1 PROMOTES EARLY-LIFE IMMUNITY... (2*)
Tu136. . . . DANGEROUS LIAISONS: CO-HOUSING WITH MIF/- MICE... (4*)
Tu137. . . . ADENOSINE A3 RECEPTOR REGULATES INTESTINAL EPITHELIAL... (2*)
Tu138. . . . SERUM PCSK9 AS NOVEL BIOMARKER FOR... (5*)
Tu139. . . . CIAP INHIBITION WITH SMAC MIMETICS IN... (2*)
Tu140. . . . SALIDROSIDE AMELIORATES EXPERIMENTAL COLITIS BY ATTENUATING... (5*)
Tu141. . . . SERUM ONCOSTATIN M PREDICTS MUCOSAL HEALING... (5*)
Tu142. . . . INTERLEUKIN-34 DEFICIENCY EXACERBATES EXPERIMENTAL DSS-INDUCED COLITIS... (2*)
Tu143. . . . MATRIX METALLOPROTEINASE 8 (MMP-8) DEFICIENCY RENDERS... (4*)
Tu144. . . . PN-943, AN ORAL α4β7 INTEGRIN ANTAGONIST... (3*)
Tu145. . . . TL1A EXACERBATES CHRONIC EXPERIMENTAL COLITIS THROUGH... (2*)
Tu146. . . . COLONIC MUCOSAL KINASE ACTIVITY, CYTOKINE AND... (3*)
Tu147. . . . DELTA OPIOID RECEPTOR SIGNALING IN ENDOSOMES... (6*)
Tu148. . . . THE ROLE OF PAI-1 IN THE... (2*)
Tu149. . . . THE ROLE OF INFLAMMATION AND MALNUTRITION... (2*)
Tu150. . . . INTESTINAL HELMINTHS PROMOTE ALLOTOLERANCE AND REGULATE... (2*)
Tu151. . . . MAST CELLS ARE SIGNIFICANTLY ACTIVATED IN... (3*)
Tu152. . . . DAMP MOLECULES NMI AND IFP35 MAY... (2*)
Tu153. . . . RANDOMIZED CONTROLLED TRIAL OF COGNITIVE BEHAVIORAL... (6*)
Tu154. . . . GLYCANS ARE DUAL REGULATORY ELEMENTS IN... (2*)
Tu155. . . . MICROBIOTA AND VIRUCENCE FACTORS ASSOCIATED WITH... (6*)
Tu156. . . . CHROMOGRAFIN-A REGULATES THE GUT MICROBIOTA COMPOSITION... (2*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
| Tu1277    | PERIPHERAL GASTROINTESTINAL CIRCADIAN DISRUPTION ASSOCIATED WITH... (3*)[(Pfizer 2019 Inflammatory Bowel Disease Competitive Grant Program)
| Tu1278    | ENDOPLASMIC RETICULUM STRESS-MEDIATED MACROPHAGE-TOMYOFIBROBLAST TRANSITION CONTRIBUTES...(2*)
| Tu1279    | FLAGELLIN-INDUCED CASPASE-1 ACTIVATION OF HUMAN INTESTINAL... (2*)
| Tu1280    | SUCCESSFUL ESTABLISHMENT OF DECELLULARIZED INTESTINAL EXTRACELLULAR... (2*)
| Tu1281    | PROTEINS CITRULLINATION AND CROHN'S DISEASE: PAD4... (5*)
| Tu1282    | PRECLINICAL CHARACTERIZATION OF AN ORAL SMALL... (3*)[(Morphic Therapeutic)
| Tu1283    | PROTECTIVE EFFECT OF SAPPFON IN MOUSE... (2*)
| Tu1284    | CROHN'S DISEASE ILEAL B3 WITH STENOSIS... (7*)
| Tu1285    | HYDROGEN PEROXIDE-MEDIATED CROSSTALK OF EPITHELIAL DUOX2... (2*)[(4)
| Tu1286    | MUCUS FROM HUMAN STEM CELL-DERIVED COLONOIDS... (5*)
| Tu1287    | NEUTROPHILS REGULATE PROGRESSION OF COLON CANCER... (6*)[(7)
| Tu1288    | MACROPHAGE CYSTATHIONINE GAMMA-LYASE CONTRIBUTES TO EXPERIMENTAL... (2*)[(6)
| Tu1289    | PANETH CELL DEFECTS IN CROHN'S DISEASE... (2*)[(6)
| Tu1290    | DYSBIOSIS AND GOBLET CELLS DEPLETION TRIGGERS... (2*)[(4)
| Tu1291    | EFFICACY OF GRANULOCYTE AND MONOCYTE ADSORPTIVE... (4*)
| Tu1292    | EPITHELIAL LONG NON-CODING RNA REGULATE IN-CIS... (2*)
| Tu1293    | EXOGENOUS L-FUCOSE PROTECTS THE INTESTINAL MUCOSAL... (2*)
| Tu1294    | GRANULOCYTE AND MONOCYTE CODING RNA REGULATE IN-CIS... (2*)
| Tu1295    | CHANGES ACCORDING TO DISEASE... (2*)
| Tu1296    | INTESINAL MICROBIOTA CHANGES ACCORDING TO DISEASE... (5*)
| Tu1297    | INVESTIGATING THE ROLE OF BIOACTIVES PRODUCED... (4*)
| Tu1298    | CARBON MONOXIDE IS AN IMPORTANT FACTOR... (2*)
| Tu1299    | MICROBIOTA-TLR2 MEDIATED NESTIN-DERIVED ENTERIC NEUROGENESIS IN... (2*)
| Tu1300    | NEURAL NETWORK ENHANCEMENT AND GLIAL HYPERPLASIA... (5*)
| Tu1301    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1302    | THE EFFECT OF ACUTE STRESS DISORDER... (5*)
| Tu1303    | NEUROGENESIS IN... (2*)
| Tu1304    | NEURAL NETWORK ENHANCEMENT AND GLIAL HYPERPLASIA... (5*)
| Tu1305    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1306    | THE EFFECT OF ACUTE STRESS DISORDER... (5*)
| Tu1307    | NEUROGENESIS IN... (2*)
| Tu1308    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1309    | THE EFFECT OF ACUTE STRESS DISORDER... (5*)
| Tu1310    | NEUROGENESIS IN... (2*)
| Tu1311    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1312    | NEUROGENESIS IN... (2*)
| Tu1313    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1314    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1315    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1316    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1317    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1318    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1319    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1320    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1321    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1322    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1323    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1324    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1325    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1326    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1327    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1328    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1329    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1330    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1331    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1332    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)
| Tu1333    | ALTERATIONS IN EPICENTRIC MODIFIERS IN GASTRIC... (4*)[(6)

Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1334. . . . A STUDY ON THE EFFECT OF... (5*)

Tu1335. . . . SLEEP DISORDERS ARE VERY COMMON IN... (5*)

Tu1336. . . . REFLUX MONITORING WITH IMPEDANCE-PHMETRY: NEW SET... (4*)

Tu1337. . . . ESOPHAGEAL CONTRACTILE SEGMENT IMPEDANCE (CSI) FROM... (5*)

Tu1338. . . . NOVEL ESOPHAGEAL BASELINE IMPEDANCE METRICS CORRELATE... (5*)

Tu1339. . . . PATIENTS WITH BORDERLINE ACID EXPOSURE TIME...[5*]

Tu1340. . . . MUCOSAL INTEGRITY TESTING OR PH MONITORING... (5*)

Tu1341. . . . SALIVARY PEPSIN AS A BIOMARKER OF... (5*)

Tu1342. . . . ABNORMAL BOLUS REFLUX WITH NORMAL ACID... (5*)

Tu1343. . . . REFLUX PROFILES IN POST-BARIATRIC SURGERY PATIENTS... (5*)

Tu1345. . . . THE DIAGNOSTIC USEFULNESS OF E-CADHERIN AND... (1*)

Tu1346. . . . DISTAL MEAN NOCTURNAL BASAL IMPEDANCE AS... (5*)

Tu1347. . . . ESTABLISHING AN OPTIMAL CUT-OFF FOR DISTAL... (5*)

Tu1348. . . . PEPSIN AND BILE ACIDS DETECTION IN... (5*)

Tu1349. . . . CLINICAL UTILITY OF BASELINE IMPEDANCE MEASURED... (5*)

Tu1350. . . . USEFULNESS OF MEAN NOCTURNAL BASELINE IMPEDANCE... (5*)

Tu1351. . . . DIAGNOSTIC ACCURACY OF THE ESOPHAGOGASTRIC JUNCTION... (5*)

Tu1352. . . . MUCOSAL IMPEDANCE ENABLES ACCURATE DETECTION OF... (7*)[3][(Diversatek Healthcare, Inc. provided mucosal impedance balloons and Sandhill Scientific Insight Ultima System with Mucosal Impedance Software at no charge to perform this study, Diversatek Healthcare, Inc.)

Tu1353. . . . DIETARY EVALUATION BEFORE AND DURING IMPEDANCE- PH... (5*)

Tu1354. . . . ANALYSIS OF SYMPTOMS AND REFLUX PARAMETERS... (5*)

Tu1355. . . . IS HIGH-RESOLUTION MANOMETRY USEFUL FOR... (5*)

Tu1356. . . . A PHASE 3. NON-INFERIORITY RANDOMIZED CONTROLLED... (3*)[(Daewoong Pharmaceutical)

Tu1357. . . . 2-YEAR INTERIM ANALYSIS RESULTS OF VISION... (3*)

Tu1358. . . . SAFETY AND Efficacy of an IMPLANTABLE... (4*)[(3*][3][(Torax Medical)

Tu1359. . . . IN VITRO TOPICAL PROTECTION OF ESOPHAGEAL... (2*)

Tu1360. . . . RISK OF CANCER WITH USE OF... (5*)

Tu1361. . . . NOVEL PHYSIOLOGICAL NOMOGRAPH PREDICTS SYMPTOM OUTCOME... (5*)

Tu1362. . . . TWO-YEAR INTERIM ANALYSIS OF SYMPTOMS... (5*)

Tu1363. . . . THE EFFECTS OF SWALLOW STRENGTH TRAINING ON... (2*)

Tu1364. . . . VONOPRAZAN MAINTENANCE THERAPY IS MORE EFFECTIVE... (5*)

Tu1365. . . . ACUTE EFFECT OF CURCUMINOID ON ESOPHAGEAL... (2*)

Tu1366. . . . OESOPHAGEAL ADHESIVE PROPERTIES OF SODIUM ALGINATES... (3*)[(4*][3][(Reckitt Benckiser, UK)

Tu1367. . . . THE EFFECTS OF CONTINUOUS POSITIVE AIRWAY... (5*)

Tu1368. . . . CURRENT ESTIMATE OF PREVALENCE, CLINICAL CHARACTERISTICS... (3*)[(Ironwood Pharmaceuticals)

Tu1369. . . . ESOPHAGO-GASTRIC JUNCTION CONTRACTILE INTEGRAL (EGJ-CI) MAY... (5*)

Tu1370. . . . EFFICACY OF DA-5204 FOR GASTROESOPHAGEAL REFLUX... (5*)

Tu1371. . . . PPI DE-ESCALATION: DO SPECIALTY CLINICS PERFORM... (5*)

Tu1372. . . . INFLUENCE OF DAILY OR ALTERNATE-DAY DOSING... (5*)

Tu1373. . . . WHAT IS THE NEXT TREATMENT OPTION... (5*)

Tu1374. . . . DOES GENDER PLAY A ROLE IN... (5*)

Tu1375. . . . IS IT POSSIBLE TO DRAW PPI... (5*)

Tu1376. . . . UPPER ESOPHAGEAL SPHINCTER DYSFUNCTION ON FUNCTIONAL... (5*)

Tu1377. . . . ESOPHAGEAL REMODELING MIGHT AFFECT THE PROGNOSIS... (5*)

Tu1378. . . . EFFECTIVENESS OF N-ACETYLCYSTEINE ON THE TREATMENT... (5*)

Tu1379. . . . FUNCTIONAL LUMEN IMAGING PROBE TOPOGRAPHY DETECTS... (5*)

Tu1380. . . . ESOPHAGEAL PROVOCATIVE MANEUVERS ARE ASSOCIATED WITH... (4*)

Tu1381. . . . GLOBAL CHANGES IN THE CORRELATION STRUCTURE... (2*)

Tu1382. . . . IS IT REALLY LARYNGOPHARYNGEAL REFLUX? LARYNGEAL... (5*)

Tu1383. . . . EFFECT OF SWALLOW STRENGTH TRAINING ON... (2*)

Tu1384. . . . RISK FACTORS FOR GASTROESOPHAGEAL REFLUX DISEASE... (5*)

Tu1385. . . . ESOPHAGO-GASTRIC JUNCTION CONTRACTILE INTEGRAL (EGJ-CI) MAY... (5*)

Tu1386. . . . USEFULNESS OF BARIUM ESOPHAGRAM WITH NEWLY... (5*)

Tu1387. . . . ACUTE OPIOID ADMINISTRATION IS NOT ASSOCIATED... (5*)

Tu1388. . . . PARTIAL OPIOID AGONIST ARE NOT ASSOCIATED... (5*)

Tu1389. . . . THE CHALLENGES OF EGJOO, IS IT... (5*)

Tu1390. . . . PREDICTORS OF FUNCTIONAL LUMINAL IMPEDANCE PLANIMETRY... (4*)

Tu1391. . . . PREVALENCE OF ESOPHAGEAL DYSMOTILITY AND GASTROESOPHAGEAL... (5*)

Tu1392. . . . PREVALENCE OF DYSPHAGIA FOLLOWING ROUX-EN-Y AND... (5*)

Tu1393. . . . A REFLUX PHENOTYPE EXISTS IN PATIENTS... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1394. . . . LOWER ESOPHAGEAL SPHINCTER AND PERISTALTIC PRESSURES... (5*)
Tu1395. . . . COEXISTING ABNORMAL ESOPHAGEAL BODY MOTILITY PREDICTS... (5*)
Tu1396. . . . BOLUS TRANSIT IN ESOPHAGOFLSTIC JUNCTION OUTFLOW... (5*)
Tu1397. . . . CLINICAL, PSYCHOLOGICAL AND MANOMETRIC CHARACTERISTICS OF... (5*)
Tu1398. . . . DELAYED ESOPHAGEAL AND GASTRIC JUNCTION RELAXATION AND ELEVATED... (5*)
Tu1399. . . . HIGH PROPORTIONS OF OBSTRUCTIVE PHENOTYPES WITHIN... (5*)
Tu1400. . . . ABSENCE OF CONTRACTION RESERVE IN SEVERE... (5*)
Tu1401. . . . EFFECT OF PERORAL ENDOSCOPIC MYOTOMY FOR... (5*)
Tu1402. . . . UNINTENDED MYOTOMY OF THE CRURAL DIAPHRAGM... (5*)
Tu1403. . . . ACHALASIA, HYPERCONTRACTILE AND SPASTIC ESOPHAGEAL MOTILITY... (1*)
Tu1404. . . . CIRCADIAN ALTERATIONS OF ESOPHAGEAL CONTRACTILITY IN... (1*)
Tu1405. . . . ESOPHAGEAL AND GASTRIC MOTILITY ARE RELATED... (1*)
Tu1406. . . . VISCOS BOLUS AND TRENDELENBURG POSITION ALLOW... (2*)
Tu1407. . . . EFFECTS OF EXTERNAL NEURAL STIMULATION ON... (2*)
Tu1408. . . . IMPEDANCE SIGNALS RECORDED DURING ESOPHAGEAL MANOMETRY... (2*)
Tu1409. . . . IDENTIFYING CLINICAL PHENOTYPES OF HYPERCONTRACTILE ESOPHAGEAL... (2*)
Tu1410. . . . INFLUENCE OF PRURALPRAZIDE ON SILDENAFIL-INDUCED INHIBITION... (4*)
Tu1411. . . . LEG ELEVATION MANEUVER IMPROVES MEASURING CONTRACTILE... (4*)

Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.)

Tu1412. . . . IMPACT OF INEFFEFFECTIVE ESOPHAGEAL MOTILITY ON... (4*)
Tu1413. . . . ESOPHAGEAL ACID REFLUX BURDEN IN GERD... (4*)
Tu1414. . . . ARRHYTHMIC ESOPHAGEAL DEGLUTITION: OVEREXPRESSION AND... (2*)
Tu1415. . . . STRENGTH TRAINING USING TECHNIQUE OF SWALLOWING... (2*)
Tu1416. . . . STRENGTH TRAINING USING TECHNIQUE OF SWALLOWING... (2*)
Tu1418. . . . ESOPHAGOFLSTIC JUNCTION-CONTRACTILE INTEGRAL FOR CLINICAL ASSESSMENT... (2*)
Tu1419. . . . THE INFLUENCE OF CRURAL DIAPHRAGM ON... (5*)
Tu1420. . . . UTILITY OF A NEW AUTOMATED ANALYSIS... (5*)
Tu1421. . . . ESOPHAGOFLSTIC JUNCTION MORPHOLOGY AND CONTRACTILE INTEGRAL... (5*)
Tu1422. . . . INCREASED INCIDENCE OF ALTERED COUPLING OF... (2*)
Tu1423. . . . ABNORMALITIES OF DEGLUTITITIVE PHARYNGEAL BIOMECHANICS NEGATIVELY... (2*)
Tu1424. . . . EVALUATION OF DYSPHAGIA SYMPTOM ASSOCIATION WITH... (2*)
Tu1425. . . . HIGH-RESOLUTION IMPEDANCE MANOMETRY PARAMETERS MAY IMPROVE... (2*)
Tu1426. . . . HIGH RESOLUTION MANOMETRY IN UPRIGHT POSITION... (5*)
Tu1427. . . . CHARACTERIZING THE PROXIMAL ESOPHAGEAL SEGMENT... (5*)
Tu1428. . . . ACHALASIA PHENOTYPE IS ASSOCIATED WITH PREDICTABLE... (5*)

Tu1429. . . . A CONVOLUTIONAL NEURAL NETWORK ACCURATELY IDENTIFIES... (5*)
Tu1430. . . . ESOPHAGEAL OUTFLOW RESISTANCE IN PARKINSON'S DISEASE... (5*)
Tu1431. . . . RAPID DRINKING CHALLENGE EVALUATED BY HIGH-RESOLUTION... (5*)
Tu1432. . . . THE VALUE OF REPEAT MANOMETRIC TESTING... (5*)
Tu1433. . . . REGIONAL PHARYNGEAL CONTRACTILE INTEGRALS (PHCI)... (5*)
Tu1435. . . . SUPRAGASTRIC BELCHING INDUCE RE-REFLUX DURING REFLUX... (4*)
Tu1436. . . . IMPLEMENTATION AND ANALYSIS OF A 2-YEAR... (5*)
Tu1437. . . . PERISTALTIC FUNCTION BUT NOT INTEGRATED SPHINCTER... (5*)
Tu1438. . . . DEMOGRAPHIC AND GASTROINTESTINAL SYMPTOM CHARACTERISTICS OF... (4*)
Tu1439. . . . ESOPHAGEAL DYSFUNCTION IS PREVALENT FOLLOWING LUNG... (5*)
Tu1440. . . . EVALUATING THE IMPACT OF POSITION, VOLUME... (4*)
Tu1441. . . . THE CLINICAL SYMPTOMS AND MANOMETRIC CHARACTERISTICS... (1*)
Tu1442. . . . PREVALENCE AND CLINICAL SIGNIFICANCE OF ESOPHAGOFLSTIC... (5*)
Tu1443. . . . THE EFFECTS OF A NOVEL VISCOS... (6*)
Tu1444. . . . FACTORS ASSOCIATED WITH HIATAL HERNIA IN... (5*)
Tu1445. . . . THE ROLE OF ABDOMINAL CT SCAN... (5*)
Tu1446. . . . ROLE OF BROAD-SPECTRUM ANTIBIOTICS IN THE... (5*)
Tu1448. . . . CHARACTERIZATION OF PATIENTS WHO SHOULD RECEIVE... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1607. . . CLINICAL USEFULNESS OF FDG-PET/CT FOR DIFFERENTIATION...

Tu1608. . . THE COMBINATION OF INTRAVENOUS FLUID AND...

Tu1609. . . METHODOLOGY OF PANCREATIC JUICE COLLECTION FROM...

Tu1610. . . ENDOSCOPIC ULTRASOUND (EUS)-GUIDED DRAINAGE OF PANCREATIC...

Tu1611. . . PREVALENCE TREND, HOSPITAL UTILIZATION, AND PREDICTORS...

Tu1612. . . FOXA2 EXPRESSION IS SIGNIFICANTLY ASSOCIATED WITH...

Tu1613. . . GERMLINE RET AND MAPT (TAU) MUTATIONS...

Tu1614. . . GENE CO-EXPRESSION NETWORK ANALYSIS OF PRECURSOR...

Tu1615. . . RISK FACTORS ASSOCIATED WITH FATTY PANCREAS...

Tu1616. . . FAMILIAL PANCREATIC NEUROENDOCRINE TUMORS – ROLE...

Tu1617. . . RNASEQ ANALYSIS OF SEVENTEEN PANCREATITIS TPIAT...

Tu1618. . . VITAMIN D/VITAMIN D RECEPTOR AXIS DYSFUNCTION...

Tu1619. . . WATER AVOIDANCE STRESS PROMOTES MOUSE PANCREATIC...

Tu1621. . . ALTERED COMPOSITION OF GUT MICROBIOTA IN...

Tu1634. . . THE COMPLICATION RATE AND DOWNSTREAM PROCEDURE...

Tu1635. . . YIELD OF RADIOLOGIST RECOMMENDATION FOR HEPATOLOGY...

Tu1636. . . HYPOXIC HEPATITIS IS UNDERRECOGNIZED AND UNDERDIAGNOSED...

Tu1637. . . LONGITUDINAL HCV CARE OF PREGNANT PATIENTS...

Tu1638. . . USEFULNESS OF ANTILKM-1 ANTIBODY TESTING IN...

Tu1639. . . EPIDEMIOLOGY AND RISK FACTORS OF CHOLANGIOCARCINOMA...

Tu1640. . . OVEREXPRESSION OF FOXM1 PREDICTS POORER SORAFENIB...

Tu1641. . . OUTCOMES OF PATIENTS WITH HILAR CHOLANGIOCARCINOMA...

Tu1642. . . QUANTITATIVE HEPATIC FUNCTION PREDICTS TIME TO...

Tu1643. . . SEX, RACIAL AND ETHNIC DISPARITIES IN...

Tu1644. . . REVEALING THE MOLECULAR DRIVERS OF HEPATOBLASTOMA...

Tu1645. . . MIR-125B-5P CONFRS RESISTANCE TO SORAFENIB BY...

Tu1646. . . INCIDENCE AND MORTALITY TRENDS OF INTRAHEPATIC...

Tu1647. . . LONG TERM OUTCOMES OF SELF-EXPANDABLE METAL...

Tu1648. . . PROGNOSTIC IMPACT OF TYROSINE KINASE INHIBITOR...

Tu1649. . . MECHANISTIC STUDY OF COPPER-STIMULATED PROGRESSION OF...

Tu1650. . . EPIDEMIOLOGY AND PREVALENCE OF GALLBLADDER CANCER...

Tu1651. . . OUTCOMES OF PATIENTS WITH HEPATOCELLULAR CARCINOMA...

Tu1652. . . PREVALENCE AND MANAGEMENT OF GALLBLADDER CANCER...

Tu1653. . . THERAPEUTIC EFFICACY AND SAFETY OF LENVATINIB...

Tu1753. . . ASSOCIATIONS BETWEEN MOOD DISORDERS AND GASTRIC...

Tu1754. . . IMPAIRED DUODENAL MUCOSAL BARRIER FUNCTION CAUSES...

Tu1755. . . NATIONAL TRENDS IN READMISSION FOR CANNABINOID...

Tu1757. . . EFFECTS OF 4-WEEK CURCUMINOID ON CLINICAL...

Tu1758. . . EFFICACY OF TOPIRAMATE AS PROPHYLAXIS IN...

Tu1759. . . EFFECT OF PROTON PUMP INHIBITOR ON...

Tu1760. . . DUODENAL BILE SALTS AND MUCOSAL CHANGES...

Tu1761. . . DEVELOPMENT OF A MOTILITY FRAILTY INDEX...

Tu1762. . . IMPACT OF SLEEP IMPROVEMENT ON GASTROINTESTINAL...

Tu1763. . . A RECURRING COST OF CARE: EMERGENCY...

Tu1764. . . NATIONAL ESTIMATES OF 30-DAY READMISSIONS AMONG...

Tu1765. . . FUNCTIONAL DYSEPSA AND NON-CELIAC WHEAT SENSITIVITY...

Tu1766. . . DISCRIMINATION OF PATIENTS WITH CHRONIC NAUSEA...

Tu1768. . . EFFICACY OF SUMATRIPTAN AS ABORTIVE TREATMENT...

Tu1769. . . HALOPERIDOL USE IN THE EMERGENCY DEPARTMENT...

Tu1770. . . RUMINATION SYNDROME: ASSESSMENT OF VAGAL TONE...

Tu1771. . . FACTORS IN ESTABLISHMENT OF ENTERAL AUTONOMY...

Tu1772. . . NAUSEA AND VOMITING SEVERITY IS ASSOCIATED...

Tu1773. . . ANTRAL EXPRESSION OF PROSTAGLANDIN E SYNTHASE...

Tu1774. . . EVALUATION OF GASTRIC MOTOR FUNCTION IN...

**Abstract Funding Source Key**

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1834. . . . INCIDENCE AND ANATOMICAL DISTRIBUTION OF COLORECTAL... (5*)

Tu1835. . . . UTILITY OF FECAL IMMUNOCHEMICAL TEST (FIT)... (5*)

Tu1836. . . . TUMOR AREA AND MICROSCOPIC EXTENT OF... (3*) (GRAIL Inc)

Tu1837. . . . HIGH SEDATION REQUIREMENTS FOR PATIENTS AGES... (5*)

Tu1838. . . . COLORECTAL CANCER SCREENING: ADDING RISK PROFILING... (5*) (NIL)

Tu1839. . . . CLINICOPATHOLOGICAL CHARACTERIZATION AND SURVIVAL OUTCOME OF... (5*)

Tu1840. . . . THE EFFECT OF DIRECT-ACTING ORAL ANTIACOULANTS... (5*)

Tu1841. . . . FREQUENCY OF SIGNS AND SYMPTOMS PRECEDING... (5*)

Tu1842. . . . GEOGRAPHIC DISPATITIES OF YOUNG ONSET COLORECTAL... (5*)

Tu1843. . . . INCREASED RISK OF ADVANCED COLONIC ADENOMAS... (5*)

Tu1844. . . . CHANGING EPIDEMIOLOGY OF COLORECTAL CANCER RELATED... (5*)

Tu1845. . . . COMPARATIVE EFFECTIVENESS OF SURVEILLANCE COLONOSCOPY TIMING... (2*)

Tu1846. . . . PHASE 2A PROOF OF CONCEPT PLACEBO... (3*) (ABIVAX)

Tu1847. . . . THE IMPACT OF COGNITIVE BEHAVIORAL MINDFULNESS... (6*)

Tu1848. . . . EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS... (3*) (This study was funded by Janssen Research & Development, LLC)

Tu1849. . . . HISTOLOGIC REMISSION AND MUCOSAL HEALING IN... (3*) (The study was funded by Eli Lilly and Company.)

Tu1850. . . . DOSE ESCALATION OF UPADACITINIB IN CROHN'S... (3*) (AbBie, Inc)

Tu1851. . . . CORTICOSTEROID SPARING EFFECTS OF USTEKINUMAB THERAPY... (3*) (This study was funded by Janssen Research & Development, LLC)

Tu1852. . . . PHARMACOKINETICS AND PHARMACODYNAMICS OF OPL-002, A... (3*) (Oppilian Pharma)

Tu1853. . . . SUSTAINED REDUCTION OF IL-23 RELATED CYTOKINES... (3*) (The study was funded by Eli Lilly and Company.)

Tu1854. . . . MIRIKIZUMAB REGULATES GENES INVOLVED IN ANTI-TNF... (3*) (The study was funded by Eli Lilly and Company)

Tu1855. . . . EFFICACY AND SAFETY OF ESCALATION TO... (3*) (Pfizer Inc)

Tu1856. . . . THE EFFECT OF TOFACITINIB ON SERUM... (3*) (Pfizer Inc)

Tu1857. . . . TOFACITINIB, AN ORAL, SMALL MOLECULE JANUS... (3*) (Pfizer Inc)

Tu1858. . . . ASSESSMENT OF AGE AS A RISK... (3*) (Pfizer Inc)

Tu1859. . . . CLINICAL AND MOLECULAR CHARACTERIZATION OF PATIENTS... (3*) (This study was funded by Janssen Research & Development, LLC)

Tu1860. . . . ASSOCIATION OF HISTOLOGIC-ENDOSCOPIC MUCOSAL HEALING AFTER... (3*) (This study was funded by Janssen Research & Development, LLC)

Tu1861. . . . A RANDOMIZED, OBSERVER-BLINDED PHASE IB MULTIPLE,... (3*) (Sponsored by Genentech, Inc.)

Tu1862. . . . BI 695501 DEMONSTRATES SIMILAR EFFICACY AND... (3*) (Boehringer Ingelheim)

Tu1863. . . . TRANSCRIPTIONAL AND MICROBIAL BIOMARKERS OF RESPONSE... (3*) (Pfizer Inc)

Tu1864. . . . ENDOSCOPIC RESPONSE TO INDUCTION WITH USTEKINUMAB... (3*) (This study was supported by Janssen)

Tu1865. . . . VEDOLIZUMAB TREATMENT PERSISTENCE AND SAFETY IN... (3*) (Takeda)

Tu1866. . . . EFFICACY AND SAFETY OF AN ADDITIONAL... (3*) (Pfizer Inc)

Tu1867. . . . EFFICACY OF TOFACITINIB DOSE ESCALATION TO... (3*) (Pfizer Inc)

Tu1868. . . . THE EFFECT OF TOFACITINIB ON EXTRAINTESTINAL... (3*) (Pfizer Inc)

Tu1869. . . . TIME TO LOSS OF EFFICACY AMONG... (3*) (Pfizer Inc)

Tu1870. . . . C-REACTIVE PROTEIN LEVELS AND PARTIAL MAYO... (3*) (Pfizer Inc)

Tu1871. . . . THE CONCORDANCE OF SHORT FORM-36 HEALTH... (3*) (Pfizer Inc)

Tu1872. . . . IDENTIFICATION OF BIOMARKERS AND MECHANISTIC INSIGHT... (3*) (AbbVie, Inc.)

Tu1873. . . . LONG-TERM SAFETY AND EFFICACY OF RISANKIZUMAB... (3*) (AbbVie Inc)

Tu1874. . . . MAINTENANCE OF REMISSION WITH TOFACITINIB IN... (3*) (Pfizer Inc)

Tu1875. . . . IMPACT OF DISEASE DURATION ON TOFACITINIB... (3*) (Pfizer Inc)

Tu1876. . . . A PILOT DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL... (2*) (6) (Supported by grants from the CIHR Institute of Nutrition, Metabolism and Diabetes (INMD), the Canadian Association of Gastroenterology (CAG), AbbVie Canada and Crohn’s and Colitis Canada (CCC). Vitamin D was provided in kind by Euro-Pharm International)

Tu1877. . . . EVALUATION OF CLINICAL RELATIONSHIP BETWEEN FECAL... (3*) (Celltrion, Inc.)

Tu1878. . . . FILGOTINIB DECREASES MOLECULAR MARKERS OF JAK1... (3*) (Gilead Sciences, Inc.)

Tu1879. . . . EFFICACY AND SAFETY OF LONG-TERM TREATMENT... (3*) (This study was funded by Janssen Research & Development, LLC)

Tu1880. . . . EFFECTS OF THE JANUS KINASE (JAK1)-SELECTIVE... (3*) (Sponsored by Gilead Sciences, Inc)

Tu1881. . . . SAFETY, PHARMACOKINETICS AND IMMUNE MODULATORY PROPERTIES... (3*)

Tu1882. . . . GB004, A NOVEL PROLYL HYDROXYLASE... (3*) (Gossamer Bio, Inc)

Tu1883. . . . HIGHER TROUGH GOLIMUMAB LEVELS ARE ASSOCIATED... (3*) (GOAL-ARC is

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds   (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)   (3) = Industry or Commercial Entity   (4) = Institutional Funds
(5) = No Study Funding   (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)   (7) = Professional Organization (e.g. AGA, AASLD, etc.)
supported as an investigator initiated study by MSD and Thermo Fisher Scientific.)

Tu1884. . . . DIAGNOSTIC ACCURACY OF RECTAL BLEEDING AND... (3*)|(Pfizer Inc.)

Tu1885. . . . Efficacy of ustekinumab for ulcerative colitis... (3*)|(This study was funded by Janssen Research & Development, LLC.)

Tu1886. . . . dose adjustment in patients with moderate... (3*)|(This study was funded by Janssen Research & Development, LLC.)

Tu1887. . . . Impact of mirikizumab treatment on health-related... (3*)|(AbbVie, Inc.)

Tu1888. . . . Early and sustained improvement in stool... (3*)|(AbbVie)

Tu1889. . . . Upadacitinib was not associated with anaemia... (3*)|(AbbVie, Inc.)

Tu1890. . . . The efficacy and safety of adalimumab... (3*)|(Abbvie)

Tu1891. . . . risk of late post-operative recurrence of... (5*)

Tu1892. . . . tofacitinib for ulcerative colitis: results of... (1*)

Tu1893. . . . real world effectiveness of tofacitinib for... (5*)

Tu1894. . . . impact of discontinuing thiopurines at anti-TNF... (4*)|(Lantmännen Research Foundation)

Tu1895. . . . tofacitinib induces clinical and endoscopic remission... (5*)

Tu1896. . . . tofacitinib is safe and effective as... (5*)

Tu1897. . . . portal vein thrombosis is a risk... (5*)

Tu1898. . . . exclusive enteral nutrition with a polymeric... (5*)

Tu1899. . . . real-world effectiveness and safety of tofacitinib... (4*)|(7)

Tu1900. . . . a pharmacokinetic (PK) and safety study... (3*)|(Enterome)

Tu1901. . . . non-adherence to maintenance medications in pregnant... (2*)

Tu1902. . . . comprehensive registered dietician assessment in the... (4*)

Tu1903. . . . evaluation of potential mechanisms underlying the... (3*)|(Gilead Sciences, Inc.)

Tu1904. . . . use of mycophenolate moftelin in inflammatory... (5*)

Tu1905. . . . cannabis effect on inpatient disease outcomes... (4*)

Tu1906. . . . prevalence and association of cannabis use... (5*)

Tu1907. . . . efficacy including rapid response and... (4*)

Tu1908. . . . effect of fiber-based enteral feeds on... (2*)|(4)

Tu1909. . . . impact of fecal microbiota transplantation on... (3*)|(4)|[(This study was primarily funded as an investigator initiated study by Finch Therapeutics)]

Tu1910. . . . subjects on a gluten-free diet have... (6*)

Tu1911. . . . the effect of a plant-based diet... (2*)

Tu1912. . . . nutrient-dependent physiological and proteomic analysis of... (2*)

Tu1913. . . . role of dietary and non-digestible carbohydrates... (2*)

Tu1914. . . . the small intestinal microbiome in obesity... (6*)

Tu1915. . . . microbiota-mediated effects of dietary fiber on... (2*)|(4)

Tu1916. . . . curdlan feeding in mice improves DSS... (2*)

Tu1917. . . . prandial dietary zinc intake affects development... (2*)

Tu1918. . . . the influence of walnut consumption on... (6*)

Tu1919. . . . a novel integrated in vivo/ ex vivo... (2*)|(3)|(Lantmännen Research Foundation)

Tu1920. . . . association between dietary fat intake and... (6*)|(2)

Tu1921. . . . the interplay between gut microbiota and... (5*)

Tu1922. . . . diet significantly alters enterohepatic recirculation of... (4*)|(2)

Tu1923. . . . spirulina platensis alleviates chronic low-grade inflammatory... (5*)

Tu1924. . . . changes in the gut microbiota and... (4*)

Tu1925. . . . sex- and colorectal cancer-associated changes in... (4*)

Tu1926. . . . microbial digestion of xanthan gum in... (2*)

Tu1927. . . . the effects of carotenoid ingestion on... (2*)

Tu1928. . . . streptococcus sp. VT_162 MRNAS targets contributes... (2*)

Tu1929. . . . antimicrobial resistance gene burden decreases over... (2*)

Tu1930. . . . fecal lipidomics analysis of the neonatal... (2*)

Tu1931. . . . lactobacillus-containing probiotics are associated with changes... (6*)

Tu1932. . . . the dose-response relation between a fiber... (5*)|(Tsumura & Co.)

Tu1933. . . . the challenges in developing a faecal... (4*)

Tu1934. . . . salivary and stool microbiota differences are... (2*)

Tu1935. . . . does the use of angiotensin receptor... (5*)

Tu1936. . . . patient perspectives on the long-term management... (2*)

Tu1937. . . . patient willingness to participate in celiac... (5*)

Tu1938. . . . probiotics for celiac disease: a systematic... (5*)
Tu1939. . . . IS A MULTIVITAMIN
SUFFICIENT TO MEET... (5*)

Tu1940. . . . PREVALENCE OF OBESITY
IN PATIENTS WITH... (5*)

Tu1941. . . . SELF-REPORTED NON-
CELIAC GLUTEN SENSITIVITY IN
KOREAN... (5*)

Tu1942. . . . COMPARISON OF
PARENTAL GLUTEN-FREE DIET
KNOWLEDGE... (6*)

Tu1943. . . . REFFERAL FOR DIETARY
INTERVENTION FOR CELIA... (5*)

Tu1944. . . . A GASTROENTEROLOGIST
SUPERVISED BEHAVIORAL WEIGHT
MANAGEMENT... (5*)

Tu1945. . . . FREQUENCY OF OBESITY
COUNSELING BY PHYSICIANS... (5*)

Tu1946. . . . USE OF A NOVEL VIRTUAL
HEALTH... (5*)

Tu1947. . . . IMPACT OF A CHILDCARE
CENTER-BASED OBESITY... (2*)

Tu1948. . . . TRENDS IN OBESITY SELF-
AWARENESS AMONG OBESE... (5*)

Tu1949. . . . GLOBAL, REGIONAL AND
TIME-TREND PREVALENCE OF... (4*)

Tu1950. . . . OBESE MINORITIES HAVE
HIGHER HOSPITALIZATION RATES...
[5*]

Tu1951. . . . AUTOPHAGY
DYSFUNCTION THROUGH HEPATIC
BCL-2 OVEREXPRESSION...
[3*] (Tsumura & Co.)

Tu1952. . . . DEFINING THE ROLE OF
INTESTINE-SPECIFIC FF2... (4*)

Tu1954. . . . IMMEDIATE
POSTOPERATIVE COMPLICATION
REASON FOR READMISSION... (5*)

Tu1955. . . . CALCIUM-SENSING
RECEPTOR REGULATES INTESTINAL
DIPEPTIDE ABSORPTION...
[2*] (National Natural Science
Foundation of China [NSFC])

Tu1957. . . . ANOREXIA NERVOSA CARE
PATHWAY. THE ROAD... (5*)

Tu1958. . . . CONTINUOUS DECREASE
OF THE MYOBLAST DETERMINATION...
[3*]

Tu1959. . . . INTESTINAL ELECTRICAL
STIMULATION FOR TREATING
DIABETES... (2*)

Tu1960. . . . COST EFFECTIVENESS OF
OFFERING UNSEDATED
COLONOSCOPY... (5*)

Tu1961. . . . WHEN TO FORGO
ENDOSCOPY IN FAVOR... (5*)

Tu1962. . . . VISITATION WITH A
GASTROENTEROLOGIST AND
PATIENT... (4*)

Tu1963. . . . SINGLE-USE
DUODENOSCOPES FOR ERCP: A COST-
EFFECTIVE... (5*) (Boston Scientific
reimbursed funds to purchase a 1-year
license for the Treeage Decision analysis
software used to build and analyze the
economic model. The presenting author,
Ananya Das, MD is a teaching and
research consultant with Boston
Scientific.)

Tu1964. . . . USABILITY OF A NOVEL
DISPOSABLE ENDOSCOPE... (2*)

Tu1965. . . . GASTROINTESTINAL
ENDOSCOPY CAPACITY IN EAST
AFRICA... (5*)

Tu1966. . . . ANAESTHETIC SUPPORT
TO PERFORM COLONOSCOPY WHEN IS...
(5*)

Tu1967. . . . RATE OF
GASTROINTESTINAL ENDOSCOPY USE
AND... (2*)

Tu1968. . . . TO SCOPE OR NOT TO
SCOPE?... (4*)

Tu1969. . . . IMPROVING QUALITY OF
UPPER ENDOSCOPY AMONG...
(4*)

Tu1970. . . . MACHINE LEARNING
CAN IMPROVE ESTIMATION OF...
(5*)

Tu1971. . . . A NOVEL AND EFFICIENT
METHOD USING... (5*)

Tu1972. . . . POSITIVE MULTI-TARGET
STOOL DNA TEST AND...
(5*)

Tu1973. . . . AUTOMATED DIGITAL
PATIENT NAVIGATION PROGRAM
IMPROVES...
(5*)

Tu1974. . . . EVALUATING THE NUMBER
NEEDED TO SCREEN... (3*) (Guardant
Health)

Tu1975. . . . INCIDENCE OF
INADEQUATE ENDOSCOPIC
ASSESSMENT AND...
(5*)

Tu1976. . . . MISINFORMING THE
PUBLIC: PREDICTORS OF FACTUAL...
(5*)

Tu1977. . . . CHARACTERIZATION OF
UNPLANNED HOSPITAL VISITS
AFTER... (5*)

Tu1978. . . . WHERE DO WE GO FROM
HERE?... (5*)

Tu1979. . . . FACTORS ASSOCIATED
WITH DELAYS IN INPATIENT...
(5*)

Tu1980. . . . SHORT TERM
CARDIOVASCULAR COMPLICATIONS
RELATED TO...
(5*)

Tu1981. . . . ASSOCIATION MODELING
BETWEEN PATIENTS' AGE AND...
(5*)

Tu1982. . . . COMPARISON BETWEEN
SPLIT-DOSE AND SINGLE-DOSE
POLYETHYLENE... (5*)

Tu1983. . . . COMPARING THE IMPACT
OF MORTALITY DATA...
(5*)

Tu1984. . . . COMPARING THE REAL-
WORLD EFFECTIVENESS OF 4L...
(1*)

Tu1985. . . . A PATIENT-DRIVEN
APPROACH TO IMPROVING THE...
(4*)

Tu1986. . . . OPEN ACCESS
COLONOSCOPY: AN UNDERUTILIZED
PROGRAM... (5*)

Tu1987. . . . THE IMPACT OF A 2
LITER... (5*)

Tu1988. . . . TELEPHONE TRIAGE TO
'Straight to Test' (TSTT)... (5*)

Tu1989. . . . PRE-COLONOSCOPY
BOSTON BOWEL PREPARATION SCORE
ASSESSMENT...
(5*)

Tu1990. . . . MACHINE LEARNING
MODELS FOR PREDICTING NAFLD...
(5*)

Tu1991. . . . ANALYSIS OF ERCP IMAGE
USING ARTIFICAL-INTELLIGENCE...
(5*)

Tu1992. . . . NEEDLE-BASED CONFOCAL
LASER ENDOMICROSCOPY (NCLE)
FOR...
(5*)

Tu1993. . . . PERCUTANEOUS
TRANSPAPILLARY GALLBLADDER
DRAINAGE FACILITATES
TRANSPAPILLARY...
(5*)

Tu1994. . . . FACTORS RELATED TO THE
IMAGE CLEANLINESS...
(1*)

Tu1995. . . . PILOT STUDY TO IDENTIFY
PREDICTORS OF...
(1*)

Tu1996. . . . NON-INVASIVE BREATH
TEST SCREENING TO ASSESS...
(2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1997</td>
<td>UPPER GI TRACT BIOLOGY USING AN... (6*)</td>
</tr>
<tr>
<td>1998</td>
<td>PREDICTORS OF LOCATION, SIZE AND NUMBER... (5*)</td>
</tr>
<tr>
<td>1999</td>
<td>WIZARDY OF CHROMATIC HANDS- SAVING THE... (5*)</td>
</tr>
<tr>
<td>2000</td>
<td>RISK OF METACHRONOUS ADVANCED NEOPLASTIC LESIONS... (5*)</td>
</tr>
<tr>
<td>2001</td>
<td>A NOVEL PANEL OF 92 BLOOD-BASED... (4*),(6)</td>
</tr>
<tr>
<td>2002</td>
<td>DOES THE 330° VIEWING ANGLE COLONOSCOPE... (5*)</td>
</tr>
<tr>
<td>2003</td>
<td>ESTABLISHING NEED FOR SERRATED POLYP DETECTION... (0*)</td>
</tr>
<tr>
<td>2004</td>
<td>APPLICATION OF COMPUTATIONAL FLUID DYNAMICS TO... (4*)</td>
</tr>
<tr>
<td>2005</td>
<td>DUODENAL UNDERWATER ENDOSCOPIC MUCOSAL RESECTION IS... (5*)</td>
</tr>
<tr>
<td>2006</td>
<td>EVALUATION OF PERFORMANCE IN COLON CAPSULE... (5*)</td>
</tr>
<tr>
<td>2007</td>
<td>OUTCOMES OF PHARMACOLOGIC VENOUS THROMBOEMBOLISM PROPHYLAXIS... (5*)</td>
</tr>
<tr>
<td>2008</td>
<td>SYSTEMATIC REVIEW AND META-ANALYSIS OF DECOMPRESSION... (5*)</td>
</tr>
<tr>
<td>2009</td>
<td>IMMUNOHISTOCHEMISTRY EXPRESSION OF CYTOKINES FOR DIAGNOSING... (4*)</td>
</tr>
<tr>
<td>2010</td>
<td>HEALTH RELATED QUALITY OF LIFE AND... (5*)</td>
</tr>
<tr>
<td>2011</td>
<td>GASTRIC VERSUS ESOPHAGIAL BUTTON BATTERY INGESTIONS... (4*)</td>
</tr>
<tr>
<td>2012</td>
<td>CAREGIVERS KNOWLEDGE ATTITUDE AND PRACTICES ON... (5*)</td>
</tr>
<tr>
<td>2013</td>
<td>EOSINOPHTILIC ESOPHAGITIS IN NON-CAUCASIANS: A UNIQUE... (5*)</td>
</tr>
<tr>
<td>2014</td>
<td>LYMPHANGIOGRAPHY AS A DIAGNOSTIC AND THERAPEUTIC... (5*)</td>
</tr>
<tr>
<td>2015</td>
<td>GASTROINTESTINAL AND HEPATIC MANIFESTATIONS OF PTEN... (5*)</td>
</tr>
<tr>
<td>2016</td>
<td>HIRSCHSPRUNG’S DISEASE IN PATIENTS WITH CONGENITAL... (5*)</td>
</tr>
<tr>
<td>2060</td>
<td>LONG-TERM SAFETY OF THE SEQUENTIAL USE... (5*)</td>
</tr>
</tbody>
</table>

**Abstract Funding Source Key**

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)